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ABSTRACT
The need to find novel anticancer agents with better potency, efficacy and 
safety are highly demanded. Therefore, the first part of the study was aimed 
to synthesise new compounds based on stilbenes, indole-based isoxazoies 
and tricyclic anilides as potential antitumour agents, which later will be 
evaluated for their anticancer properties.
The syntheses of substituted stilbenes were achieved via catalyzed or 
uncatalyzed methods, yielding stilbene analogues in moderate to good 
yields. Preliminary antiproliferative studies on four cancer cell lines (prostate, 
non-small lung, colon and breast) demonstrated their antiproliferative 
potential in the micromolar range. Unfortunately, the stilbenes were unable to 
inhibit the Wnt-signaling pathway in colon cancer cells.
Next, the synthesis of indole-based isoxazole analogues was achieved via 
two different methods; affording the compounds in low to moderate yields. 
The compounds will later be tested for their anticancer properties.
The synthesis of 3289-8625 (tricyclic anilides) analogues, compounds which 
showed potent inhibitory activites on the PDZ domain of Dishevelled (PDZ- 
Dvl) as an important component in the Wnt signaling pathway was also 
carried out. The synthesis was achieved via various methods which gave rise 
to the formation of two analogues, which showed better binding affinities 
towards the PDZ-Dvl compared to the parent compounds.
Finally, the therapeutic potential of the stilbenes was expanded to the 
synthesis of stilbene-based analogues as novel positron emission 
tomography (PET) imaging probes especially for the detection of p-amyloid 
plaques in brain, which is a hallmark of Alzheimer’s disease. The syntheses 
of stilbenes were sought using fluorine-19, using methods that can later be 
adapted for 18F-PET radiochemistry. The syntheses of stilbenes attached to 
19F-linker were afforded in good yields. Stilbenes directly attached to 
potassium trifluoroborate were synthesised in moderate yield. Nevertheless, 
the attempt to synthesise stilbene derivatives attached to a potassium 
trifluoroborate linker using novel procedures failed.
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CHAPTER 1 
INTRODUCTION
“During the past century, human life expectancy has increased significantly 
due to improved health care, including the availability of vaccines and new 
pharmaceutical drugs. With the ageing population on the rise, complex 
diseases such as Alzheimer's disease, Parkinson’s disease and various 
types of cancers, combined with new diseases with debilitating 
consequences can reduce the general quality of life. This, together with the 
fact that the drug discovery and developmental process is competitive, 
lengthy, risky, and expensive with a high failure rate, posses challenging 
opportunities for the development of new drugs”
Chengalvala et at. 2005.
1.1 Cancer
Cancer is the name given to a range of specific diseases resulting from the 
body’s own cells which have become aberrant growing out of control 
(Reichert and Wenger 2008). The hallmarks of cancer have been reviewed 
extensively by Hanahan and Weinberg (2000). The review highlights the six 
essential criteria that distinguished cancer from normal cells: “self-sufficiency 
in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis”. In other words, 
cancer - which consists of abnormal cells with diverse oncogenic mutations, 
are able to proliferate without control and metastasize to other tissues, which 
later can harm the life of the living creature (Doucas et al. 2005; Ashkenazi
2008).
Cancer is a major cause of morbidity in the UK. In 2007 alone, 
297,991 people were diagnosed with cancer. The 20 most commonly 
diagnosed cancers in the UK is shown in figure 1.1 below (Office for National
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Figure 1.1: 20 most commonly diagnosed cancers (excluding non-melanoma 
skin cancer) in the UK and number of new cases (2007).
Statistics 2010; ISD online 2007). Cancer is also the second leading cause of 
death worldwide, where cancer has caused more death than heart disease 
for people under the age of 85. “In Europe, one of four deaths is attributable 
to cancer, and in those aged 45 to 64 that rate is almost double” (Albreht et 
al. 2008).
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The ‘War on Cancer’ which commenced in 1970 was initiated to boost 
the anti-cancer drug programme. Since then, anticancer drug development is 
still considered slow which is reflected by the low number of anticancer drugs 
entering the clinics (Collins and Workman 2006; Reichert and Wenger 2008, 
de Bono and Ashworth 2010).
1.2 Cancer drug development
The need to distinguish cancerous cells (which need to be eradicated) from 
normal cells is the factor that makes cancer drug development very 
challenging (Reichert and Wenger 2008). Other than surgery, the major goal 
of killing cancer cells is achieved by various methods: chemotherapy (using 
anticancer drugs), radiation or immunotherapy; where induction of apoptosis 
is a prominent feature in killing the tumour cells. Despite aggressive 
therapies, resistance of many tumours to current treatment protocols still 
constitutes a major problem in cancer therapy (Fulda and Debatin 2006). 
Most conventional cancer therapies are only able to extent life expectancy of 
patients for perhaps a few years, despite the serious side effects that are 
caused upon treatment (Amin et al. 2009).
Natural products, without any doubt have contributed an important 
role as chemotherapy and chemopreventive agents in various cancer 
malignancies. Whether natural compounds which are directly extracted from 
living creatures or synthetic compounds derived from the natural original 
structure, they are now widely used as anticancer and chemopreventative 
agents. One commonly used example is Paclitaxel, a microtubule disruptor 
which is isolated from the bark of Taxus brevifolia, and has been used for 
treatment of various cancers including leukemia and breast cancer (Amin et 
al. 2009). Another example is resveratrol, which belongs to a class of 
polyphenolic compounds called stilbenes. Resveratrol is considered as a 
natural compound which can be developed into potential drugs due to its 
striking biological activity, despite its simple structure which allow various 
modifications on the stilbene ring (Pezzuto 2008). On the other hand, small 
molecules possess numerous advantages in the drug discovery process as
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compared with peptides (such as higher metabolic stability and bioavailability) 
and even natural products (such as easier access to analogues with 
increased potency, easier synthesis, greater solubility, and support for 
structure-activity relationship studies). In addition, the methods for 
synthesising small molecule inhibitors are rapidly improving (Pagliaro et al. 
2004).
Heterocycles are the most important chemical entities in drug 
discovery. They can be found in the vast majority of drugs either synthetic or 
natural product derived, which reflects their importance in drug design. They 
can imitate and stabilize the binding of various functional groups such as 
natural ligand or substrate (Broughton and Watson 2005). One common 
example is indole, which is considered as a privileged structure in drug 
design due to its abundance in biologically active natural or synthetic 
products (de Sa Alves et al. 2009).
Conventional cancer discovery processes usually involves the 
synergistic processes between chemical syntheses and biological evaluation. 
In recent years, the drug discovery processes have gradually shifted from 
“cytotoxic, non-specific chemotherapies” to more “personalized” (“molecularly 
targeted, rationally designed”) medicine, where the agents target precisely 
on molecular pathology which is responsible for individual cancer 
progression (Collins and Workman 2006). As each cancer patient is not 
identical, this approach will allow a more personalized treatment and is 
anticipated to be a more reliable and effective for cancer treatment, which 
can cause less side-effects to the patient (de Bono and Ashworth 2010).
Traditionally, the classification of anticancer agents is based on the 
origin or mechanism of action of the drugs, for example as antitumour 
antibiotics (e.g. Doxorubicin), antimetabolites (e.g. 5-Fluorouracil), alkylating 
agents (e.g. Cisplatin) and plant alkaloids (e.g. Etoposide) (Figure 1.2). 
Nevertheless, the discovery of novel antitumour agents which exhibit various 
mechanism of actions in tumour cells due to their diverse “biochemical and 
pharmacological properties”, resulted in the dilemma to accurately classify
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the compounds based on the native classification method. This highlights the 
advancement that has been achieved in cancer drug development which 
makes it possible to develop drugs that showed multiple inhibitory activities 
in various cancer types (Carter et al. 1987; Schepartz 1995).
OH
hoOH Y ' Y w
HNv ^ k F
5-FluorouracilOH Q
OMe
c ,
cr >nh3
Cisplatin
OH
^ O OMe
Doxorubicin Etoposide
Figure 1.2: Examples of classic anticancer agents.
Protein kinase inhibitors have dominated cancer drug discovery over 
recent years. Protein kinases are enzymes that phosphorylate proteins, 
resulting in functional changes of target proteins (Gotlink and Verheul 2010). 
The ability of the small-molecule kinase inhibitors to selectively treat common 
malignancies such as breast and lung cancers have promoted the 
development of this series of inhibitors (Janne et al. 2009; Johnson 2009). 
However, their ability is limited to a subset of treated patients which limit its 
applicability in clinical settings (Janne et al. 2009). Tyrosine kinase inhibitors 
are probably the most well-studied protein kinase inhibitors, besides serine, 
threonine or lipid kinase inhibitors, due to the role of tyrosine kinases as 
important cellular signalling proteins which mediate various biological 
activities (Janne et al. 2009; Gotlink and Verheul 2010). Table 1.1 shows 
examples of small molecule kinase inhibitors already approved for the 
treatment of various cancers.
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Table 1.1: Examples of clinically approved kinase inhibitors (Janne et al. 
2009).
Structure Name Indication
N ^ ]
T
i iN " Y ^ i l  °
H U U U
Imatinib (Gleevec; 
Novartis)
CML, GIST, 
HES
N ^ i
T
c f 3
Nilotinib (Tasigna; 
Novartis)
Imatinib-
resistant
CML
^ N ' ^ ^ 0 ^ 0Me
Erlotinib (Tarceva; 
OSI
Pharmaceuticals/
Genentech/Roche)
NSCLC,
pancreas
cancer
FY ^ i
Gefitinib (Iressa; 
AstraZeneca)
NSCLC
NH2 CF3
°  tC 5t ' ° ' y ^ i °  A r cl 
‘U A na nJ ^ J
H H
Sorafenib
(Nexavar;
Bayer/Onyx)
Renal
cancer
y 0
H V n h  / —*/  O ^ N  
H
Sunitinib (Sutent; 
Pfizer)
Renal
cancer,
imatinib-
refractory
GIST
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^ ^ f n^ V ^ t 0 mmI HN-^ . _
\
Lapatinib (Tykerb; 
GlaxoSmithKline)
Breast
cancer
7  s b  < /
OH
Dasatinib (Sprycel;
Bristol-Mayers
Squibb).
Imatinib-
resistant
CML
CML=chronic myelogenous leukaemia; GIST=gastrointestinal stromal 
tumours; HES=hypereosinophilic syndrome; NSCLC=non-small cell lung 
cancer.
Another successful approach especially in the treatment of hormone 
related-cancers (such as breast cancer and prostate cancer) is antihormonal 
therapy. The therapy is based on the use of selective estrogen modulators 
(for breast cancer) and selective androgen modulators (for prostate cancer) 
to inhibit the hormone receptors on the hormone receptor-positive cancers 
(Rau et al. 2005; Jordan et al. 2008). The success of antihormonal therapy 
which could enhance the patient survival significantly had driven the 
progress of targeted therapy and individualized medicine strategies (Jordan
2009). Tamoxifen has become the most commonly used estrogen modulator, 
while Flutamide and Bicalutamide are potent anti-androgen agents (Figure 
1.3) (Rau et al. 2005; Jordan 2009). Nevertheless, the treatment option is 
restricted to those patients with hormone receptor-positive cancers (not 
effective to patients with receptor-negative cancers), and the susceptibility to 
drug-resistance or relapse upon antihormonal treatment (Jordan et al. 2008; 
Jordan 2009) is problematic.
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Tamoxifen Flutamide Bicalutamide
Figure 1.3: Structures of commonly used antihormonal agents.
1.3 Small molecule inhibitors targeting protein-protein interactions
in cancer drug development
Interactions between specific pairs or groups of proteins play a major role in 
the regulation of various processes in the cell. Abnormal protein-protein 
interaction is closely related to the initiation of many human diseases, either 
through the loss of crucial protein interaction or through the formation of a 
protein complex at an unsuitable time or location (Ryan and Matthews 2005; 
White et al. 2008).
Typically, the development of therapeutic agents is mostly dedicated 
to the inhibition of a single protein, usually a defined ligand-binding site on an 
enzyme or receptor, which is amenable for drug design. Nevertheless, the 
increasing knowledge on the importance of protein-protein interactions which 
are abundant in nature and their crucial role to mediate various biological 
processes, the development of small molecule inhibitors specifically targeting 
protein-protein interactions is seen as an emerging and important modality in 
cancer drug discovery (Vincent et al. 2007; White et al. 2008). Protein- 
protein interactions represent an enormous and diverse group of targets for 
therapeutic intervention (Arkin 2005). In most cases, the existence of “hot 
spots” on the surface of the protein which are responsible for protein-protein 
binding, and the presence of small and narrow pockets within the protein 
which is amenable to be manipulated to design inhibitors for that particular 
protein, make protein-protein interactions an interesting drug target (Arkin 
and Wells 2004; White et al. 2008).
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One important example in the search of inhibitors for protein-protein 
interaction is the inhibition of an intracellular receptor of the Wnt signalling 
pathway, the PDZ domain of Dishevelled. The inhibition of this protein is 
anticipated to subsequently inhibit the expression of (3-catenin level which is 
responsible for gene transcription (Zhang et al. 2009b). The potency of 
inhibiting this protein interaction is highlighted by the number of small- 
molecule antagonists which have been designed to inhibit this particular 
protein (Wang et al. 2008).
1.4 Non-invasive imaging techniques in medicine
Non-invasive imaging techniques are of particular importance in the health 
sector with the main goals being diagnosis, disease monitoring and staging. 
In order to cater for the needs for various parameters in imaging, a number 
of methods have been developed including “X-ray diffraction and CT, optical 
(fluorescence) methods, MRI, single photon emission computed tomography 
(SPECT) and positron emission tomography (PET)”. Of all the imaging 
methods, PET has become a popular method of choice for disease 
monitoring in drug discovery and development due to its high sensitivity and 
good resolution of radiolabelled compound in vivo (Daniels et al. 2010).
The advancement of PET imaging techniques for disease intervention 
emphasizes the needs for development of specific radiotracers. In view of 
this, radiolabelled compound attached to 18F as a positron emitting isotope is 
of interest due to its convenient half-life (110 minutes) to allow sufficient 
synthesis of radiotracers to GMP standard, ample time for distribution and 
minimal radioactive exposure to the patient. Among the PET radiotracers 
which are currently in clinical trial are stilbene-based compounds, which 
found excellent applicability for the detection of amyloid plaques in the brain 
of Alzheimer’s disease patients (Cai et al. 2008; Rowe et al. 2008; Daniels et 
al. 2010).
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1.5 General aims and objectives
This first few part of the study aimed to synthesis a range of small molecules 
which are intended to be developed as new anticancer agents. For this 
purpose, three different approaches to synthesise small molecule inhibitors 
for cancer have been sought:
• In chapter 2, the study was dedicated to the synthesis of resveratrol- 
based stilbene analogues as potential anticancer agents. The 
synthesis of stilbenes is achieved using various methods ranging from 
catalysed, uncatalysed or using microwave irradiation. The 
synthesised stilbenes were later screened for their ability to inhibit 
cancer cell proliferation on a panel of cancer cell lines (by Mr Huw 
Mottram, Welsh School of Pharmacy). At the same time, the stilbenes 
were further evaluated for their ability to inhibit Wnt signaling pathway 
in colon cancer stem cells (in collaboration with Prof. J. P. Medema, 
Academic Medical Centre, Amsterdam, the Netherland).
• Chapter 3 was dedicated to the synthesis of indole-based isoxazole 
compounds which are anticipated to possess interesting antitumour 
activities. The syntheses of the compounds were achieved via two 
approaches: either via cyclization of alkynyl ketones with 
hydroxylamine, or via dipolar cycloaddition between nitrile oxides and 
terminal alkynes to afford the title compounds. The compounds are 
yet to be tested for their antiproliferative activity on cancer cell lines.
• Chapter 4 is intended for the synthesis of compound 3289-8625 
derivatives (compound 6569188 and 7359885) which have been 
shown to target specifically on the PDZ domain of Dishevelled, one of 
the important protein-protein interactions in the Wnt signalling 
pathway. The synthesized compounds were later tested for their 
binding affinity to Dishevelled PDZ domain via NMR-based chemical 
perturbation experiments and fluorescence-binding affinity studies (by 
our project collaborator, Prof. Jie J. Zheng, St. Jude Children’s 
Research Hospital, Memphis, USA).
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The next part of the study was dedicated to establish methods for the 
synthesis of stilbene-based imaging agents specifically designed to act as 
PET imaging probes. This study was the extension of the initial study on the 
synthesis of stilbenes as potential anticancer agents. The aim is to 
synthesise two series of stilbene compounds; either attached to alkylfluoride 
chain or attached to a trifluoroborate moiety. The approach taken was to 
synthesis stilbenes attached to cold (19F) stilbene first, which upon 
successful incorporation will be expanded to the synthesis of radiolabelled 
18F compounds in the future.
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CHAPTER 2
STILBENE ANALOGUES AS POTENTIAL ANTICANCER AGENTS
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CHAPTER 2 
STILBENE ANALOGUES AS POTENTIAL ANTICANCER AGENTS
2.1 Resveratrol
Resveratrol (3,4\5-trihydroxy-frans-stilbene) (Figure 2.1) is a polyphenolic 
natural product, synthesised by a wide variety of plant species including 
grapes and peanuts during stressful situations and present at relatively high 
concentration in red wine (at concentrations between 5 to 13 pM) and grape 
juice. Its stilbene structure is related to the synthetic oestrogen 
diethylstilbestrol (Baur and Sinclair 2006; Zhang and Go 2007; Hope et al. 
2008; Jiang 2008). Resveratrol is a classic example of a stilbene, which is 
referred to a family of compound which consists of the alkene ethene, 
surrounded by benzene rings. In nature, it is also found as a glycoside or 
methoxide (Regev-Shoshani et al. 2004).
OH
HO
OH
Figure 2.1: Structure of resveratrol
Resveratrol was first discovered in the 1940s, but it was not until 1992 
when it attracted vast interest due to the finding that it was responsible for 
the cardioprotective constituent of red wine (Baur and Sinclair 2006). 
Therefore, is closely related to a phenomenon called “French Paradox”, due 
to the fact that the French population have a relatively low incidence of 
coronary heart diseases despite their relatively high saturated fat diet 
(Simoni et al. 2006; Yoo et al. 2006).
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Numerous biological activities have been ascribed to resveratrol, 
which may explain its anti-inflammatory, antioxidant, antimutagen, 
anticarcinogenic, anti-cancer, anti-fungal, antibacterial and cardioprotective 
properties (Baur and Sinclair 2006; Yoo et al. 2006; Zhang and Go 2007; 
Jiang 2008). Moderate consumption of red wine is also associated with a 
lower incidence of dementia and Alzheimer’s disease, which is closely 
related to its neuroprotective property and therapeutic potential (Vingtdeux et 
al. 2008).
Unfortunately, the clinical use of resveratrol may be limited by its poor 
oral bioavailability. The bioavailability of resveratrol is almost zero due to its 
fast and extensive metabolism (Regev-Shoshani et al. 2004), as it is rapidly 
inactivated by phase II conjugation enzymes (Gao et al. 2006; Zhang and Go 
2007). This resulted in resveratrol having a short initial half-life of around 8- 
14 minutes (Baur and Sinclair 2006). It has been found that resveratrol and 
its metabolites are lost mainly in the urine in the course of 72 hours (Walle et 
al. 2004). Upon absorption, resveratrol is metabolised in the liver by the 
phase-2 enzymes, to form water-soluble fra/is-resveratrol-3-O-glucuronide 
and the primary metabolite frans-resveratrol-3-O-sulfate, which indicated that 
most transformation occurred on the 3-OH position (Yu et al. 2002; Athar et 
al. 2007). These will make resveratrol substantially more hydrophilic, which 
results in decreased ability to enter cells. Albumin also has been found to 
bind to resveratrol to be distributed in the body only when the concentration 
is high (Jiang 2008). In conclusion, the available in-vivo studies indicate that 
resveratrol although absorbed to a high extent by the organism, has poor 
bioavailability and may be converted in vivo into compounds lacking anti­
proliferative activity (Wenzel and Somoza 2005).
2.2 Resveratrol in cancer
Resveratrol has gained considerable attention because of its potential cancer 
chemopreventive and anticancer properties. Resveratrol had been shown to 
have potent effects on a number of cancer cells, with properties involving 
inhibition of initiation, promotion and progression (Walle et al. 2004; Yoo et al.
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2006). Among its various actions, resveratrol has been demonstrated to 
inhibit cellular survival signalling. Resveratrol may interfere with apoptosis 
pathways both by directly triggering apoptosis-promoting signalling cascades 
and by blocking anti-apoptotic mechanisms. By blocking survival and anti- 
apoptotic pathways, resveratrol can sensitize cancer cells, which may result 
in synergistic antitumour activities (Fulda and Debatin 2006, Simoni et al. 
2006; Chan et al. 2008). In colon cancer cells, resveratrol is capable of 
inducing apoptosis via the death receptor and mitochondrial pathways, 
where caspase-6 activation is among a prominent feature for apoptosis 
induction (Chan et al. 2008).
Resveratrol has been shown to suppress angiogenesis and 
metastasis, through modulation of multiple pathways involved in cell growth, 
apoptosis and inflammation (Tseng et al. 2004). The anti-carcinogenic 
effects of resveratrol appear to be closely associated with its antioxidant 
activity, and it has been shown to inhibit cyclooxygenase, hydroperoxidase, 
protein kinase C, Bcl-2 phosphorylation and nuclear factor kappa-B (NF-kB) 
among many others (Athar et al. 2007). Extensive studies have revealed 
multiple molecular targets of resveratrol, which affect cell growth, 
inflammation, apoptosis, angiogenesis, invasion and metastasis, whether 
through anti-oxidant properties, or through pro-oxidant effects which can 
cause oxidative DNA damage that may lead to cell cycle arrest or apoptosis, 
as reviewed by Athar et al. (2009).
2.3 Stilbene derivatives as promising scaffolds for anticancer agents
Although resveratrol clearly exerts an effective anticancer influence, previous 
studies have shown that the bioavailability of this compound is quite low 
(Regev-Shoshani et al. 2004; Baur and Sinclair 2006). Therefore, in order to 
develop a resveratrol-based anticancer drug with potent anti-tumourigenic 
activity and better bioavailability, the free phenolic group on the stilbene 
backbone could be blocked, leaving only those groups which contribute to 
antitumour activity, thus preventing the rapid biotransformation associated 
with resveratrol itself (Yoo et al. 2006). A study done by Heynekamp et al.
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(2006) showed that resveratrol and its analogues induced markedly different 
apoptosis-inducing activities against sensitive and resistant leukaemia cells, 
suggesting that minor structural changes in these hydroxylated stilbenes 
have major effects on biological activity.
Other stilbene derivatives exhibit quite similar biological properties as 
reported for resveratrol (Gao et al. 2006; Simoni et al. 2006). The stilbene 
moiety is commonly encountered in natural products and many members are 
associated with therapeutically important pharmacological properties. 
Resveratrol is probably the best-known stilbenoid, although the c/s-stilbene 
combretastatin A4 is a related natural product that has been extensively 
tested as an anticancer agent (de Lima et al. 2009).
Novel stilbenoids based on the resveratrol structure may provide a 
solution to the bioavailability limitations exert by resveratrol. The 
methoxylation of hydroxyl groups results in an increase in lipophilicity. These 
changes will influence bioavailability, susceptibility to metabolism and the 
pharmacological profile of the resulting analogues, as the methoxylated 
stilbenes are metabolised more slowly. Methoxylated analogues of 
resveratrol provide a useful starting point for the rational design of 
chemopreventive and chemotherapy agents with improved pharmacological 
properties (Zhang and Go 2007; Wilson et al. 2008), as shown by the 3,5- 
dimethoxy moiety which is frequently associated with noticeable biological 
activity. Methoxylated stilbenes also undergo different metabolic conversion 
and have higher bioavailability with respect to resveratrol (Sale et al. 2004). 
A case in point is 3,4,5,4’-tetramethoxy-fra/7s-stilbene (DMU-212), a synthetic 
methoxylated analogue of resveratrol- which had an improved 
pharmacokinetic profile, selective growth inhibitory effects against cancer 
cells with almost no inhibitory effect on the growth of normal cells, and a 
unique mode of action compared to resveratrol (Simoni et al. 2006). A 3,4- 
dihydroxyl group is also important to enhance anticancer activity of trans- 
resveratrol analogues (Murias et al. 2004). Previous study also suggested 
that 2,3’,4,5’-tetramethoxy-fraA?s-stilbene other than DMU-212 are potent 
apoptosis-inducing agents with clinical potency. Another example is shown
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by analogue 2,3\4,4\5’-pentamethoxy-fra/7S-stilbene, which have been found 
to be a potent inducer of apoptosis in colon cancer cells via targeting 
microtubules (Li et al. 2009).
The introduction of fluorine atom into resveratrol analogues also has 
proven to improve the bioavailability of resveratrol. This growing interest is 
due to the unusual and unique chemical properties of fluorine as the most 
electronegative element in periodic table. The incorporation of fluorine into a 
drug increases its lipophilicity, thus enhancing its absorption into biological 
membranes (Alloatti et al. 2008). One example is by Moran et al. (2009) 
which reported the synthesis of fluorinated analogues of resveratrol still 
retaining the 3,4’,5-substitution pattern. From their study, one fluorinated 
analogue, (£)-3,5-difluoro-4’-acetoxy stilbene showed better potency 
compared to the parent compound resveratrol and had a broad spectrum of 
anticancer activity when tested on a panel of 60 cancer cell lines by the US 
National Cancer Institute.
Another study by Minutolo et al. (2005) suggested that some 
naphthalene-based resveratrol analogues were able to induce apoptosis in 
MDA-MB-231 human breast cancer cell line. Further study of this series of 
compounds by replacing the aromatic core of the initial naphthalene-based 
resveratrol analogues with pseudo-heterocyclic (salicylaldoxime) or 
heterocyclic (benzofuran, quinoline or benzothiazole) scaffolds resulted in 
some compounds with comparable antiproliferative activity to the previously 
active naphthalene-based compounds on MDA-MB-231 cells (Bertini et al.
2010).
The simplicity of resveratrol, associated with its interesting anti-cancer 
property, offers promise for the rational design of new chemotherapeutic 
agents and efforts have recently been devoted regarding a detailed study on 
the structure-activity relationship (SAR) of this type of substituted stilbene 
derivatives (Simoni et al. 2006). Several targets have been proposed for 
resveratrol and other trans-stilbene polyphenols, including p53/Bax pathway,
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CD95-CD95 ligand pathway, or the putative resveratrol-binding proteins 
(Gosslau et al. 2008).
2.4 Reported procedures for making stilbene derivatives.
A large number of stilbene derivatives have been isolated from various plant 
species. The naturally occurring stilbenoid compounds are attracting 
considerable attention because of their wide -range of biological properties 
and potential therapeutic values. As a result of their interesting activities and 
the simplicity of their structure, a large number of derivatives were 
synthesized using various synthetic procedures with the aim of extending the 
structure-activity relationship information of this class of molecule. Listed 
below are examples of synthetic methods reported for making stilbenes.
2.4.1 Ruthenium (Ru)-catalysed cross metathesis
OMe
OMe 2 mol% Ru-based Grubbs II catalysts 
CH2CI2
OMe 40 °C, 1.5 h 
chromatography
OMe
OMe
OMe
OMe
88%
5%
7%
OMe
Figure 2.2: Alkene cross-metathesis.
Alkene cross-metathesis can provide convenient access to stilbenoid 
compounds, as reported by Valder et al. (2006) (Figure 2.2) and Ferre- 
Filmon et al. (2005). This Ru-catalysed cross-metathesis employing the 
Grubbs-ll catalysts enables a straight forward synthetic access to a variety of 
unsymmetrical and symmetrical substituted trans-stilbenes. This protocol is
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particularly attractive because “readily available starting materials (styrenes) 
are reliably converted into valuable products in a single step” (Valder et al. 
2006) without even the need to protect sensitive hydroxyl functional groups 
(Ferre-Filmon et al. 2006). Although the reaction afforded only (E)-double 
bonds when styrenes were used as the substrates, it obviously lacks 
selectivity by giving a mixture of three different coupling products. This is 
probably due to their ability to either perform secondary metathesis on the 
newly formed C=C double bond of the stilbenoids compounds, or due to 
homocoupling. However, the selectivity issues in the formation of the 
coupling products can be improved by the use of one of the reaction partner 
in excess to the other (Ferre-Filmon et al. 2005).
2.4.2 The Wittig reaction
The Wittig reaction is the reaction of an a-phosphorous stabilised anion with 
a carbonyl derivative (Lawrence 1996). The Wittig reaction has been known 
for decades as a primary method for synthesising a stilbene block unit from 
two aromatic building blocks (Ferre-Filmon et al. 2005). The stilbene skeleton 
has been efficiently constructed by Wittig reaction between an aromatic 
aldehyde or ketone and an aromatic phosphonium ylide. A large number of 
starting materials (benzyl halides and aryl aldehydes) are commercially 
available (Husemoen et al. 2003). The reaction usually afforded the alkene in 
specific position and high yielding, and in many instances is stereoselective 
(Lawrence 2005). However, as the reactions are not catalytic, 
stereoselectivity issue still remain the main concern due to the formation of a 
mixture of E and Z alkenes, which is mainly due to the poor control over the 
configuration of the assembled C=C double bonds (Ferre-Filmon et al. 2005).
As showed by Roberti et al. (2003), preparation of stilbene derivatives 
was accomplished between the appropriate aromatic aldehydes and suitable 
aromatic ylides obtained from phosphonium salts (Figure 2.3). The reaction 
produced a mixture of E and Z isomers (7:3) which was purified and 
separated by flash chromatography. The same approach also utilized by 
Zhang and Go (2007), Alloatti et al. (2008) and Gosslau et al. (2008) to
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synthesise their stilbenes. Unfortunately, other than selectivity issue between 
the formation of E and Z isomer, these method also suffered of low yield of 
trans product, and the production of triphenylphosphine oxide as a byproduct 
which needs to be purified by chromatography (Lion et al. 2005).
P(Ph)3Br CHO
Figure 2.3: The Wittig reaction
2.4.3 Modified Wittig reaction (Horner-Wadsworth-Emmons reaction)
Ri-rb
o
^ ° Et +
''OEt R24f-
CHO DMF, MeONa
18-crown-6,120°C
Figure 2.4: The HWE reaction
The coupling of phosphonic acid esters with carbonyl compounds, also 
referred to as the Horner-Wadsworth-Emmons (HWE) reaction, represents 
another powerful carbonyl olefination reaction (Figure 2.4). In contrast to the 
related Wittig-type reaction, the HWE reaction opens a convenient synthesis 
route for C=C double bonds, exhibiting E-configurations exclusively 
(Wadsworth and Emmons 1961). This methodology possessing the key 
advantages of both (E)-specificity and easy removal of the water-soluble 
dialkylphosphoric acid byproduct (Lion et al. 2005). As described by Lion et 
al. (2005), Heynekamp et al. (2006) and Li et al. (2006), this reaction 
involved the coupling of substituted benzylphosphonic acid diethyl esters 
with substituted benzaldehydes to afford exclusively E-stilbenes. This 
method was shown to give high overall yield and purity and without 
necessitating chromatographic purification at any stage.
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In addition, Gester et al. (2007) also described the application of HWE 
reaction as novel labelling techniques in 18F chemistry for the convenient 
synthesis of E-configured stilbenes, as outlined in figure 2.5 below. The 
procedure basically involved the reaction of substituted phosphonic acid 
esters with a readily available 4-(18F)-fluorobenzaldehyde in the presence of 
potassium tert-butoxide in DMF at 60 °C for 15 min to give radiolabeled 
stilbene compounds. The procedure may be applied to the synthesis of 
polyphenolic compounds and aromatic amines bearing an E-configured 
stilbene backbone as pharmaceutically interesting compounds.
DM F, fBuOK
R = O M O M , N M e2
Figure 2.5: Synthesis of 18F-labelled stilbenes via HWE reaction 
2.4.4 Perkin reaction
The Perkin reaction is the pioneer method for the first chemical synthesis of 
resveratrol as reported by Spath and Kromp in 1941. This method was then 
re-investigated by Solladie et al. (2003) and employed by de Lima et al. 
(2009) for the synthesis of their stilbenes. This method first involved the 
condensation of substituted phenylacetic acid and substituted benzaldehyde 
(Figure 2.6). The decarboxylation was then carried out in the presence of 
copper chromite to afford the cis-trans mixture, where the cis isomer was 
always predominant. Cis-trans isomerisation of the mixtures in refluxing THF 
with phenyldisulfide led to the pure trans stilbenes in good yield. This method 
suffered from a long reaction time, tedious experimental work and harsh 
reaction conditions (Solladie et al. 2003). However, the need to use toxic 
quinoline-copper combination for decarboxylation of phenylacetic acid have 
represents a serious drawback especially when concerning the impact on 
the environment, which limits the synthetic utility of the Perkin type reaction 
to be further expanded for stilbene synthesis (Sinha et al. 2007)
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.0 Et3N, AC2O MeO.MeO. CHO
reflux, 15 hMeO' OMe
OMe OMe
CuCr204-BaCr204/Quinoline 
230 °C, 1 hOMe
MeO.MeO.
reflux, 4 h
OMe
OMeOMe
Figure 2.6: The Perkin reaction
2.4.5 Heck reaction (aryl halides as electrophiles)
The palladium-catalyzed C-C coupling between aryl halides or vinyl halides 
and activated alkenes (e.g. styrene, butyl acrylate) in the presence of a base 
is well-known now as a Heck reaction. “Industrial application of Heck 
reactions are rare because the reactivity of aryl halides decreases 
dramatically in order Arl>ArBr>ArCI, which means that the cheap chlorides 
and even some bromides do not afford sufficiently high yields, turnover 
numbers and selectivity” (Ferre-Filmon et al. 2004). As exemplified by Guiso 
et al. (2001) and Farina et al. (2007) who used traditional Heck reactions for 
the synthesis of their stilbenes, the reactions were carried out by coupling the 
substituted styrene with substituted aryl halides in the presence of palladium 
(II) acetate, triphenyl phosphine as ligand, triethyl amine as base and 
acetonitrile as solvent to afford the stilbenes in moderate to good yields 
(Figure 2.7).
OAc
Pd(OAc)2, PPh3l Et3N
OAc+
AcO'AcO‘ OAc AcO‘
Figure 2.7: The Heck reaction with aryl halides
C h a p t e r  2 : S t i l b e n e  a n a l o g u e s  a s  a n t i c a n c e r  a g e n t s  124
However, the traditional Heck reaction is often prone to unwanted 
oxidative degradation and other side reactions observed with phosphine 
ligands that are formed following a dissociation step in the catalytic cycle, 
hence highlighted the need for inert atmosphere conditions for efficient 
catalysis to occur. In certain condition, the addition of free ligand is needed to 
stabilise the palladium during the reaction, which later may afflict the final 
product purification (Eisnor et al. 2006). Therefore modified Heck reactions 
which use non-phosphine based complexes as catalyst precursors are more 
preferable. For example, nitrogen, oxygen and sulphur-containing 
palladacycles (Andrus and Song 2001) and palladium oxazoline complex 
(Eisnor et al. 2006) can provide excellent alternatives to their phosphorus- 
based counterparts.
2.4.6 Heck-Matsuda reaction (arydiazonium salt as electrophile)
This type of reaction comes from the synthetic advantages of using 
arenediazonium salts in Heck arylations. The reaction can be carried out 
under phosphine-free conditions, and are much easier than the traditional 
Heck protocol. Moreover, they are usually faster, less costly and greener. As 
reported by Moro et al. (2008), they managed to synthesise resveratrol, 
DMU-212 (3,4,5,4’-tetramethoxystilbene) and several analogues employing a 
very efficient palladium-catalyzed Heck-Matsuda arylation of styrenes with 
arenediazonium salts as the intermediates in a short, straightforward, regio- 
and stereoselective manner. The synthesis of resveratrol was achieved in 3 
steps with an overall yield of 72% and DMU-212 was synthesised in a single 
step in 93% yield (Figure 2.8).
OMe
MeO
Pd(dba)3 dba, NaOAc
 ►
PhCN, RT MeOOMe
OMe
Figure 2.8: The Heck reaction with aryldiazonium salt
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2.4.7 Heck reaction with ethene
2.4.7.1 Ethene gas as reagent
Ethene is the simplest form of acyclic alkene that can be found in nature. 
However, it has received relatively less attention in the Heck reaction 
(Kormos and Leadbeater 2008). One main reason which makes it less 
attractive to be used as a reagent in Heck reaction is that the difficulty in 
handling the ethene gas. “The over-reaction with the aryl halide coupling 
partner to give symmetrical stilbenes rather than monosubstituted alkene still 
remain as the major obstacle”. Therefore, the amount of gas used in the 
reaction needs to be monitored precisely using a complex experimental 
setup which is usually costly and time consuming (Ferre-Filmon et al. 2004).
As shown in Figure 2.9 below, Kormos & Leadbeater (2008) have 
successfully designed strategies for the preparation of nonsymmetrical 
stilbenes using a one-pot two-step double Heck strategy. First they 
developed a protocol for the synthesis of styrene using ethene as the alkene 
coupling partner with aryl halide under controlled conditions featuring 
microwave irradiation. The stilbene-forming step involved the coupling of the 
second aryl halide partner to the crude styrene-containing reaction mixture to 
give the desired stilbene. Both steps involved the use of palladium as 
catalyst. DMF was used as solvent with a mixture of potassium carbonate 
and tributylamine as bases. All the reactions were done using microwave 
apparatus as it offers a convenient method for safely, easily and accurately 
loading vessels with gaseous reagents and monitoring the progress of 
reactions, yielding the desired stilbenes in low to moderate yield.
C2H4i Pd, DMF, 
K2C 0 3( tributylamine
OMe 125 °C’ MW’ 50 W OMe Pd’ 175 °C’ MW’ 5 " 25 w  M e0”
Figure 2.9: The Heck reaction with ethene gas
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2.4.7.2 Substituted ethylenes as reagent
As a way to counteract the problem of using ethene gas in stilbene synthesis, 
liquid vinyltrialkylsilane and vinyltrialkoxysilane were used as a more 
convenient approach to handle ethylene substitutes. For example, Sengupta 
et al. (1998) described a double Heck reaction of aryldiazonium salts with 
vinyltriethoxysilane which led to symmetrical trans-stilbene derivatives in 
moderate to good yields (Figure 2.10). The reaction used readily available 
starting material, simple operational procedure, fast reaction times, and 
afforded stilbene products in good yields under mild condition and produced 
regioisomerically pure products.
2.4.8 Decarbonylative Heck reaction
This method was first utilised by Andrus et al. (2003) and then further refined 
by Andrus and Liu (2006) for the synthesis of phytoalexin resveratrol 
analogues. This method involved the coupling of acid chloride derived from 
inexpensive substituted benzoic acids with substituted styrenes in the 
presence of palladium acetate, A/-ethylmorpholine (NEM) as base and a 
carbene-type ligand. This approach takes only four steps and gives 
resveratrol in excellent 53% overall yield. The nature of the added base is 
critical for the success of the transformation, as shown by the use of NEM, a 
non-coordinating amine which proved optimal for the reaction.
r \  F
Pd(OAc)2, MeOH
OMe
(vinyltriethoxysilane) 60 °C, 1 h MeOx^ " ' ^
Figure 2.10: The Heck reaction with ethylene substitutes
Pd(OAc)2, A/-Ethylmorpholine
p-xylene, 120 °C
Figure 2.11: Decarbonylative Heck reaction
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2.4.9 Suzuki reaction
The Suzuki reaction is another alternative to synthesise stilbenes and 
naphthalene-based stilbene analogues under palladium catalysis, as shown 
by Eddarir et al. (2001), Andrus & Song (2001) and Minutolo et al. (2005). 
The method usually involves the palladium cross coupling of boranes or 
boronic acids and esters with organic halides or diazonium salts. This 
method showed high selectivity and good susceptibility to different functional 
groups on either coupling partners. Other advantages include easy 
preparation of reagents which are facile to handle due to their insensitive 
nature towards water (Ferre-Filmon et al. 2004).
As shown in Figure 2.12 (Andrus and Song 2001), the cross coupling 
of styrylboronic acid and aryldiazonium salts with the presence of palladium 
(II) acetate can lead to formation of various stilbene derivatives. The reaction 
proceeded in the absence of any added base under mild conditions and with 
high yields (68-87%).
^ B ( O H ) 2 Pd(OAc)2, THF
Figure 2.12: The Suzuki reaction 
2.4.10 The Stille reaction
The Stille reaction is one of the most powerful tools in C-C coupling 
processes, which involves the “palladium catalysed coupling of organotin 
reagents with organic electrophiles such as aryl and vinyl halides or triflate” 
(Ferre-Filmon 2004). Organotin derivatives offered various advantages as a 
useful reagent in Stille reaction; “air stability, resistance to hydrolysis, easy 
handling and storage, and tolerance to a wide variety of functional groups”. 
The C-C coupling reaction can be carried out under mild condition without
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the need for any additives such as base, which is susceptible for various 
sensitive functional groups. This makes the reaction to have diverse 
functionality whether “in general organic synthesis, polymer functionalisation 
and particularly in natural product syntheses”. Unfortunately, the formation of 
toxic tin byproducts which are harmful and can hamper later product 
purification is a major disadvantage of this procedure, which has driven many 
efforts to address this problem, mainly by the modification of the tin reagents 
(Carrera et al. 2008).
Nevertheless, the application of organostannanes intermediates in the 
syntheses of stilbene derivatives via Stille vinylation is extremely rare (Ferre- 
Filmon et al. 2004). One example described by Nishibayishi et al. (1996), 
involved the reaction of organic tellurides with various alkenes in the 
presence of palladium (II) salts to give corresponding substituted stilbenes 
(Figure 2.13).
jC X
PdCI2, AgOAc, Et3N 
MeOH, 25 °C, 20 h
X = H, Br, Me, OMe
Figure 2.13: The Stille reaction
2.4.11 The Negishi reaction
The new carbon-carbon double bond by the Negishi coupling reaction 
involved an organozinc compound, an organic halide and a nickel or 
palladium catalyst (King et al. 1977). Bosanac and Wilcox (2001) have 
showed that the Negishi reaction can be applied to the synthesis of stilbenes. 
In this palladium-catalysed reaction, an organozinc reagent was coupled with 
an organohalide to yield exclusively Z-isomers in 71% yield (Figure 2.14).
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Br 1) f-BuLi, -78 °C to 0 °C 
then ZnCI2, THF, O to 23 °C
2) Pd(PPh3)4, reflux
OTBS
Br
HO'
3) TBAF
Figure 2.14: The Negishi reaction
2.4.11 The McMurry coupling
The McMurry reaction is an organic reaction in which two ketone or aldehyde 
groups are coupled and undergo reductive dimerisation to yield alkenes upon 
treatment with low-valent titanium reagents such as titanium(lll) chloride and 
a reducing agent (McMurry and Fleming 1974). This carbonyl coupling 
reaction is able to provide symmetrical stilbenes from the correspending 
aldehydes and ketones which can be manipulated to the synthesis of various 
symmetrical chemical entities (Ferre-Filmon et al. 2004). Ali et al. (1992), 
obtained symmetrical polyalkoxy- and polysilyloxystilbenes by reductive 
coupling of alkoxy and silyloxybenzaldehydes, respectively, with zinc and 
titanium tetrachlorides (Figure 2.15). All products isolated under these 
reaction conditions possessed a trans stilbene structural motif. Nevertheless, 
the Z-isomers can still be synthesised if the orientation of the two carbonyl 
moieties is controlled by geometric constraints (Ferre-Filmon et al. 2004).
2) TiCI4> CH2CI2i refli 
1)Zn, THF, 0°C -ifOMe
Figure 2.15: The McMurry reaction
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2.5 Research objective
The aims of this study are to synthesise substituted stilbene analogues 
based on the resveratrol scaffold, and to evaluate their biological activities. 
The more lipophilic resveratrol derivatives are anticipated to have improved 
drug-like properties and potencies to be developed as potential anti-cancer 
agents. Substituted stilbene analogues were targeted to have better 
resistance towards metabolism and therefore increased bioavailability and 
drug-likeness.
The initial part of the study was to exploit traditional methods for parallel 
solution phase synthesis based on the reported Horner-Wadsworth-Emmons 
(HWE) reaction in order to synthesise a library of methoxylated, hydroxylated, 
fluorinated and pyridine-based stilbene analogues. The synthesis procedure 
was further expanded by using microwave irradiation and palladium- 
catalyzed based methods to compare various synthetic methods for stilbene 
synthesis. The synthesised stilbene analogues were further tested on a 
panel of cancer cell lines [prostate (PC3), non-small lung (A549), colon (Lovo) 
and breast cancer (MCF-7)] in order to evaluate their antiproliferative activity 
and to generate possible structure activity relationships. At the same time, 
the synthesised stilbenes were further evaluated for their ability to inhibit Wnt 
signaling pathway (discussed in chapter 4) in colon cancer stem cells, where 
the aberrant activation of this pathway is often implicated in driving the 
formation of various human cancers, particularly those of the digestive tract.
2.6 Synthesis of methoxylated, hydroxylated and fluorinated stilbene 
analogues via Horner-Wadsworth-Emmons (HWE) reaction.
There are a number of synthetic methods that had been developed towards 
the synthesis of stilbene analogues. Generally, the synthesis was achieved 
by combining two molecular fragments together via carbon-carbon double 
bond (C=C). The synthetic methods chosen will give exclusively trans 
isomers with no detectable cis isomers. Any methods that give mixtures of E 
and Z isomers which will necessitate chromatographic separation at the end
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were not considered in this study. Therefore, as the initial part of the study an 
efficient method for the synthesis of trans-stilbenes via HWE reaction as 
described by Lion et al. (2005) was chosen. This method involves the 
reaction of a phosphonate ester with a benzaidehyde to produce 
predominantly trans alkenes as shown below (Figure 2.16).
CHO DMF, MeONa
18-crown-6 ,120°C
Figure 2.16: The Horner-Wadsworth-Emmons reaction.
2.6.1 The Michaelis-Arbuzov rearrangement
The first step in the reaction is the formation of a phosphonate ester as an 
intermediate, via Michaelis-Arbuzov reaction. It is one of the most widely 
used and versatile methods for the synthesis of phosphonates (Bhattacharya 
and Thyagarajan 1981). The reaction for the formation of diethyl 
phosphonate ester is very straight-forward. In this case, the methoxybenzyl 
bromide is converted to the required substituted diethyl phosphonate esters 
by the reaction with an ester of trivalent phosphorus (e.g. triethyl phosphate). 
Figure 2.17 shows the reaction mechanism involved in the synthesis of the 
phosphonate esters.
,OEt
'•OEt©"O
Figure 2.17: Synthesis of phosphonate esters: Michaelis-Arbuzov reaction
The overall reaction conditions were monitored by TLC. The 
phosphonate esters were subjected to further synthesis procedure for 
stilbene synthesis. The Michaelis-Arbuzov reaction (Figure 2.18) proved to
C h a p t e r  2 : S t i l b e n e  a n a l o g u e s  a s  a n t i c a n c e r  a g e n t s  132
be an efficient method to synthesise phosphonate esters yielding the desired 
products in excellent yields (Table 2.1).
0 ^ 0
o/ v  >—v n^OEt
* f Y
Br + / - 0 . p,0 130°C -140°C  Ri T Y ^ OEt ♦ / /—Br
Compound 1, 2 and 3
Figure 2.18: The Michaelis-Arbuzof reaction
Table 2.1: Summary of the synthesis of the phosphonate esters.
Compound no. R Yield (%)
1 4-OMe 96
2 3-OMe 99
3 3,5-diOMe 98
2.6.2 The Horner-Wadsworth-Emmons (HWE) reaction.
Horner-Wadsworth-Emmons olefination chemistry as described by Lion et al. 
(2005) was chosen as the main reaction procedure for the synthesis of 
substituted trans-stilbene to ensure regioselectivity. Reaction of substituted 
benzylphosphonic acid diethyl ester with substituted benzaldehydes in DMF 
using sodium methoxide as the base in the presence of 18-crown-6 at 120 
°C afforded substituted stilbenes exclusively in the (£)-conformation. A slight 
excess of benzaldehyde was required to ensure complete reaction and the 
limiting factor is phosphonate ester. Excess benzaldehydes can easily be 
eliminated by using Girard’s reagent [(carboxymethyl) trimethylammonnium 
chloride hydrazide), forming a weakly basic nitrogen nucleophile and acetic 
acid, giving water-soluble benzaldehyde hydrazide derivatives which can 
simply removed by a wash with brine. The diethylphosphoric acid byproduct 
is water soluble and can easily be removed. The reaction mechanism 
involved in the synthesis of stilbenes via HWE reaction is summarised in 
Figure 2.19.
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OEt
NaOMe
18-crown-6
,OEt
120 °C EtO ^OEt
l f Ri
stabilised, erythro 
more favourable
oxaphosphetane
intermediate
t r a n s  isomer 
(organic layer)
Diethylphosphoric acid 
(aqueous layer)
Figure 2.19: Reaction mechanism of the HWE reaction
Unlike the Wittig reaction which uses the phenylphosphonium 
intermediate, the HWE reaction uses phosphonate stabilised carbanions 
which will react with the carbonyl group of the benzaldehyde. Deprotonation 
of the phosphonate ester by a strong base such as sodium methoxide 
resulted in the generation of phosphonate ion. The carbon atom of the 
carbonyl group bears a slight positive charge resulting from the difference in 
electronegativity between the carbon and the oxygen group and therefore will 
become the target for the nucleophilic phosphonate ion to attack. This 
nucleophilic addition will form oxaphosphetane, an unstable ring structure 
which can undergo rapid elimination to afford the corresponding trans- 
alkenes on heating (Bruckner 2002).
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18-crown-6 ether is used to improve the dissolution of sodium 
methoxide in DMF which results in the generation of greater nucleophilicity 
(Reichwein & Pagenkopf 2003). The trans product is favoured over the cis 
product as the trans pathway seems to be formed more quickly, and the c/s- 
oxaphosphetane will be gradually converted to the trans-oxaphosphetane 
(Bruckner 2002). The products obtained by this method showed no 
detectable Z isomer by 1H NMR analysis. This is confirmed by looking at the 
ethylenic protons which appeared as two distinct doublets with a coupling 
constant of 16-17 Hz (c/'s isomer would show a coupling constant of 9-10 
Hz).
2.6.3 Synthesis of methoxylated stilbene analogues
To begin, methoxylated stilbene analogues were chosen first for synthesis, 
as the starting materials are readily available and there is no need to protect 
any functional group. The reaction started with the making of substituted 
methoxy benzyl phosphonate esters (1), (2) or (3) (refer 2.6.1) which were 
then coupled with differently substituted methoxy benzaldehydes to afford 
the methoxylated stilbenes (Figure 2.20 and Table 2.2).
CHO DMF MeONa
18-crown-6,120 °C
1,2 or 3 R2 = OMe
Figure 2.20: Synthesis of methoxylated stilbenes
Table 2.2: Summary of the synthesis of methoxylated stilbenes.
Compound no. Ri r2 Yield (%)
4 4-OMe 4-OMe 91
5 3-OMe 4-OMe 84
6 3-OMe 3-OMe 57
7 3-OMe 3,5-diOMe 16
8 4-OMe 3.5-diOMe 18
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9 4-OMe 3,4-diOMe 68
10 4-OMe 2,4-diOMe 57
11 4-OMe 2,5-diOMe 45
12 3,5-diOMe 3,4-diOMe 40
13 3,5-diOMe 2,4-diOMe 19
14 4-OMe 3,4,5-triOMe 21
16 3,5-diOMe 3,5-diOMe 18
17 3,5-diOMe 2,5-diOMe 22
18 3,5-diOMe 3,4,5-triOMe 74
The attempt to synthesise compound 15 using compound 1 and 3- 
methoxy 4-hydroxy benzaldehyde, without protection of the hydroxyl group 
was unsuccessful, due to the nature of the unprotected hydroxyl group which 
was unstable under these reaction conditions as it can undergo other side 
reactions. This highlighted the need to find a suitable protecting group in 
order to synthesise stilbene analogues with hydroxylated substitution which 
should be stable under the reaction condition and can easily be cleaved 
without affecting the stilbene double bond. Further study by Paola Casule, an 
Erasmus student (February 2010 to July 2010) in our lab identified 
methoxyethoxymethyl ether (MEM) group as a suitable protecting group to 
synthesise hydroxylated stilbenes via HWE reaction, where deprotection 
method using pyridinium p-toluene sulfonate in refluxing methanol managed 
to give the desired hydroxylated compound without necessitating column 
chromatographic purification at any stage.
Traces of DMF can still be detected in most of the reaction products 
even after extraction with ether, which is largely immiscible with DMF. This 
made the purification steps harder, as the DMF cannot be easily eliminated 
even after prolonged evaporation due to its high boiling point. Nevertheless, 
keeping the impure compound which had undergone work-up at room 
temperature for several days increased the probability of the compounds to 
precipitate thus making the final purification step easier. The Girard’s reagent 
was able to remove excess benzaldehyde from most of the compounds,
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except for compounds 7, 8, 13, 14, 16 and 17 which could not be eliminated 
fully from the reaction mixture even after the addition of more Girard’s 
reagent and prolonged stirring for more than 24 hours. These make it 
necessary to use column chromatography to separate the excess 
benzaldehydes, thus contributing to lowering the yield of the final 
compounds.
The overall yield obtained from the HWE reaction varied greatly 
between different substitutions. Formation of compounds 4, 5 and 18 
proceeded smoothly and gave clean precipitate after quenching with water 
with no need for further purification, giving the pure compounds in excellent 
yields. Compounds 6 and 9 were obtained in moderate yield after 
recrystallization using ethanol/ethanol-water. Compounds number 10, 11, 13 
and 17 were prepared in low to moderate yield maybe due to the steric 
hindrance by the 2-methoxy substituents which prolonged the reaction times. 
Even after 24 hours of heating the starting material can still be detected and 
the reaction did not go to completion.
Compounds with a 3,5-dimethoxy substitution at the phosphonate 
ester were found to be harder to synthesize (compound 12, 13, 16 and 17, 
with exception of compound 18). A few attempts had to be made before 
obtaining the desired compounds. These compounds also suffered from the 
presence of unreacted phosphonate esters even after 24 hours of reaction 
and the need for column chromatography purification. It was also not 
surprising to get compound 14 in low yield (21%), due to the inductive effect 
of three methoxy groups as electron donating groups on the benzaldehyde 
ring and the para-methoxy group at the phosphonate ester ring which will 
make the reaction slower, thus contributing to lower yields.
The hardest compounds to make were compounds 7 and 8. Attempts 
to synthesise the compounds using compound 3 as the intermediate and 
their 3-methoxy and 4-methoxy benzaldehydes as their counterpart failed to 
give the desired compounds. Nevertheless, when compound 1 and 
compound 2 were used as the intermediates, with 3,5-dimethoxy
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benzaldehyde as their counterpart, the desired compounds 8 and 7, 
respectively were obtained at low yields after purification using column 
chromatography to remove unreacted starting materials.
2.6.4 Synthesis of methoxylated stilbenes with other substitution 
(fluorine, bromine or nitro groups).
Following the successful approach to the synthesis of methoxylated 
analogues of stilbenes via HWE reaction, the same protocols were chosen to 
synthesise methoxylated stilbenes with other substitution patterns, where 
substitution with fluorine was chosen first. The same phosphonate esters 
were used (compound 1 or 2) and 3- and 4-fluorobenzaldehyde as their 
counterpart (Figure 2.21). Using this procedure, a few stilbene analogues 
bearing methoxy and fluoro substitution have been successfully synthesized 
as outlined in table 2.3 below:
CHO DMF, MeONaP -°B + r" "OEt R 2 f -
18-crown-6, 120 °C
1 or 2 Compound 20, 28, 29
Figure 2.21: Synthesis of compound 20, 28 and 29.
Table 2.3: Summary of the synthesis of fluorinated stilbenes via HWE
reaction.
Compound no. Ri r2 Yield (%)
20 3-OMe 3-F 48
28 3-OMe 4-F 7
29 4-OMe 4-F 79
Compound 20 and 29 proceeded smoothly giving the compounds in 
moderate to good yields after recrystalisation using ethanol. Recrystalisation 
of compound 28 using ethanol and ethanol/water gave mixtures of 2 types of
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crystals. The recrystallisation was then repeated using different solvent pairs: 
methanol-water and acetone-water, but both procedures still did not give any 
difference to the formed crystals. The next attempt involves the separation of 
the crystals using column chromatography (hexane:ethyl acetate = 5:1), 
where two separable crystals were obtained, the desired product in 7% yield 
and the unexpected product in around 8% yield. The yields of the two 
crystals were very low, maybe due to the loss of the compounds after several 
attempts of recrystalisation and separation by column chromatography.
The unexpected compound was then subjected to identification using 
NMR for proton, carbon and fluorine and mass spectrometry. The 1H-NMR 
result showed two peaks at 6 3.88 and 3.86 ppm indicative of two methoxyl 
groups. The proton signal also lacking any indication of proton-to-fluorine 
coupling which usually showed as complex coupling, especially when the 
protons are adjacent to the expected fluorine atom. Although the decoupled 
fluorine NMR also showed a single peak at 5 -114.11 ppm, the high noise to 
signal ratio suggested that the fluorine peak detected might just be a slight 
impurities which still remain within the product. The ethylenic bond with the 
coupling constant (J value) of 16.5 ppm can be detected from the proton 
NMR suggesting the formation of a trans stilbene isomer. The compound 
was subjected to further analysis with mass spectrometry, which indicated 
the rise of a major peak at m/z 240.10 which is different to the parent 
compound (compound 28 had calculated molecular weight of 228.28). At this 
point, the structure of the unexpected compound was expected to be a 3,4’- 
dimethoxystilbene (as previously synthesised compound 5). This was proved 
to the fact that compound 5 and the unexpected compound both have 
identical 1H- and 13C-NMR, and identical molecular weight (compound 5 
had calculated molecular weight of 240.12). Nevertheless, the unexpected 
compound is expected to be less pure indicated by a slight decrease in 
melting point compared to the purer compound 5 (compound 5 = 106-108 °C; 
unexpected compound = 101-104 °C).
The reason for this unusual observation is expected to be due to the 
displacement of the fluorine atom with methoxyl group from the base used
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(sodium methoxide). This displacement is expected to take place before the 
formation of the stilbene, due to the electron withdrawing nature of the 
carbonyl group of the 4-fluorobenzaldehyde (Figure 2.22). The displacement 
of fluorine is harder to occur after the formation of stilbene due to the lack of 
electron withdrawing effect to drive the fluorine substitution. Since methoxy is 
a better nucleophile than fluorine, the formation of the unexpected compound 
is slightly higher (8%) compared to compound 28 (7%). The factor which 
determines this kind of condition to occur is unknown. Repeated attempt to 
synthesis compound 28 still resulted in the same observation.
MeO'
OMe
OMe
OMe
DMF, MeONa, 
18-crown-6, 120 °C
OMe
OMeOMe
Compound 28 Compound 5
Figure 2.22: Attempt to synthesis compound 28 which gave rise to the 
formation of the unexpected compound 5.
The next attempts were dedicated to the synthesis of other stilbene 
derivatives containing nitro and bromo substitution, in order to further expand 
the applicability of the HWE method (Figure 2.23). Four compounds have 
been synthesised as outlined in the table 2.4 below:
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R17T
jLoE t ^ s ^ C H O  DMF. MeONa 
  (| ____________
° E‘ R 2 ^
18-crown-6,120 °C
Ri-n-
R-i = 3-OMe, 4-OMe R2 = Br, N02 33, 34, 35, 36
Figure 2.23: Synthesis of methoxylated stilbenes with bromo and nitro
substitution.
Table 2.4: Summary of the synthesis of nitrated and brominated stilbene.
Compound no. Ri r2 Yield (%)
33 3-OMe 4-N02 52
34 4-OMe 4 -NO 2 41
35 3-OMe 4-Br 30
36 4-OMe 4-Br 69
These compounds suffered from incomplete reaction, with traces of the 
phosphonic acid diethyl esters still detected even after 30 hours of heating. 
Upon quenching with water, all the reactions formed precipitates which were 
collected and further recrystallised in hot ethanol to afford the pure title 
compounds in moderate yields.
The synthesis procedure was also expanded to test the applicability of 
the HWE reaction by making some styryl pyridines. The same approach was 
applied using 6-chloropyridine 3-carboxaldehyde with compound 1 or 2 as 
the starting materials (Figure 2.24).
CHO DMF, MeONa
18-crown-6,120 °C
R-, =  3-OMe, 4-OMe 37,38
Figure 2.24: Synthesis of styrylpyridines.
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Table 2.5: Synthesis of styrylpyridines.
Compound no. Ri r2
37 3-OMe 6-chloropyridine
38 4-OMe 6-chloropyridine
The TLC suggested that the reactions did not go to completion, as the 
phosphonate esters can still be detected even after 48 hours of heating. 
Compound 37 formed oily residue after quenching with water, and the 
removal of excess of benzaldehydes via Girard’s reagent was successful. 
The crude compound was obtained as a solid which was further purified by 
recrystallization in ethanol.
The synthesis of compound 38 was more straightforward as the 
reaction formed precipitate after quenching with water, which was further 
recrystallized in ethanol to afford white solid. But after recrystallization, the 
purity of both compounds were not satisfactory as indicated by the proton 
NMR. The number of proton under the peak at the aromatic region showed 
more than 9 expected protons. There was even an unidentified peak at 
around 5 5.43 ppm indicating the possibility of a side reaction, although 
carbon-carbon double bond peaks, indicating a trans stilbene (J = 16.5 Hz) 
were detected. The same case was seen in both compounds even after 
repeated attempts to recrystallise them. These findings suggested the 
possibility of side reactions that interfere with the formation of the desired 
compounds. This may be due to the lone pair of the pyridine ring which was 
able to further react and the harsh reaction condition that make the HWE 
procedure less suitable for the synthesis of styryl pyridine.
At this stage, HWE reaction was found as an efficient method for 
making methoxylated, fluorinated and other substituted stilbene analogues. 
The next effort was focused in making hydroxylated stilbenes by finding a 
suitable protecting group to protect the phenol, as the initial attempt to make 
hydroxylated stilbene without protection of the hydroxyl group was 
unsuccessful. A method by Sinha et al. (2007) describing the synthesis of
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hydroxystilbene with trans selectivity under microwave irradiation without the 
need for protection of the hydroxyl group was found to be attractive. This 
method was chosen for the next stage of the synthesis due to its mild, simple 
and environmentally benign reaction condition.
2.7 Synthesis of hydroxylated stilbenes under microwave activation
According to Sinha et al. (2007), the synthesis of hydroxylated (E)-stilbenes 
via modified Perkin reaction between substituted benzaldehydes and 
phenylacetic acids bearing 4-hydroxy substitution at the aromatic ring, in the 
presence of piperidine-methylimidazole and polyethylene glycol under 
microwave irradiation is an unusual, mild but convenient one-pot two-step 
synthesis of hydroxylated stilbenes with trans selectivity. The developed 
protocol provides a green alternative to the classical Perkin reaction method 
employing a toxic decarboxylating agent in the form of quinoline-copper salt, 
and the requirement for harsh protection-deprotection steps. The 
microwaves can effectively bring out the simultaneous condensation- 
decarboxylation reaction, especially in view of the fact that all the 
intermediates proposed in the mechanism are more polar than the starting 
material. Figure 2.25 showed the hypothesised reaction mechanism involved 
in the formation of hydroxylated stilbenes under microwave irradiation.
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CHO MeO.
Piperidine/Methyl imidazole (Mim)
H0‘
OH
OMe
COO'MimH
OH
Microwaves 
support the 
transient polar 
intermediates
OMe
< r “OMe
C=0
OMe
HO
Figure 2.25: Hypothesis of the reaction mechanism involved in the synthesis 
of hydroxylated stilbenes under microwave irradiation (Sinha et al. 2007).
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Synthesis of this series of compounds was started by the synthesis of 
compound 22 (3-methoxy 4’-hydroxy stilbene) by irradiating a mixture of 4- 
hydroxy benzaldehyde with 3-methoxy phenyl acetic acid in the presence of 
piperidine-methyl imidazole as the base and poly-ethylene glycol (PEG; 
average molecular weight: 200) as the solvent at 160 °C for 10 minutes 
(Figure 2.26). After acidification, extraction and column chromatography, the 
pure compound was obtained in 22% yield (as opposed to the 44% reported 
yield).
1? Plperidin®. N-methyl»mi<lazole
r V  h + ( X  B ---------------------------- - a j  ■V ' PEG. Microwavz 160°C HO
OMe
Figure 2.26: Synthesis of compound 22 via microwave irradiation
At this stage the reason for the lower yield was unknown. 
Nevertheless, further attempts to synthesise compounds 23 to 27 using the 
same method were carried out as outlined in table 2.6:
Table 2.6: Attempts to the synthesis of other hydroxylated stilbenes 
via microwave irradiation.
Compound no. Substituted
benzaldehyde
Substituted phenyl 
acetic acid
23 4-OH, 3-OMe 4-OH
24 3,4-diOMe 4-OH
25 3,5-diOMe 4-OH
26 4-OH, 3-OMe 3-OMe
27 3F 4-OH
All of the experiments were carried out under the same chemical condition as 
compound 22 and irradiated for 10 minutes. But after the work-up, none of 
the reaction mixture showed sign of desired compound formation even 
though the TLC showed the limiting reagent (substituted phenyl acetic acid)
C h a p t e r  2:  S t i l b e n e  a n a l o g u e s  as a n t i c a n c e r  a g e n t s  145
were fully consumed. The TLC also showed the formation of many Impurities 
indicating the possibility of side reactions. Purification by column 
chromatography only managed to get the starting benzaldehydes as the 
main product. The synthesis procedure was repeated by prolonging the 
reaction time from 10 to 20 minutes. The increased reaction time did not 
improve the result and only added to the formation of more impurities. At this 
stage, this synthetic procedure was considered as not efficient for the 
synthesis of hydroxylated stilbene with limited susceptibility to various ring 
substitution.
Nevertheless, in order to ascertain the specific role of microwave 
irradiation in this type of synthesis, the reaction of compound 22, 26 and 27 
were carried out using the same chemical condition but under conventional 
heating at reflux temperature (160 °C). After heating for 24 hours, the TLC 
showed spots of the unreacted starting material with many impurities and no 
product formation can be detected after the work-up. This finding confirmed 
the applicability of the said method for microwave irradiation, but not using 
conventional heating.
2.8 Synthesis of fluorinated stilbenes via palladium-catalyzed Heck 
reaction.
The Heck reaction is an established method for formation of the carbon- 
carbon bond. It is widely used in the synthesis of stilbenes because of its 
applicability, flexibility and adaptability. The synthesis of fluorinated stillbenes 
by using palladium-catalyzed Heck reaction was intended to compare its 
applicability and reproducibility with the HWE reaction for the synthesis of 
stilbene analogues.
2.8.1 Decarbonylative Heck reaction
The first approach chosen to synthesise fluorinated stilbenes via Heck 
reaction was by a method described by Andrus and Liu (2006) which was 
reported to be efficient in synthesising fluorinated stilbenes giving the
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products in good overall yield (74% to 88%). The procedure involved the 
reaction of substituted benzoyl chloride and substituted styrene in the 
presence of palladium (II) acetate, A/-ethyl morpholine as base in p-xylene at 
120 °C as outlined in figure 2.27 below:
To begin the synthesis, 3,5-difluorobenzoyl chloride (1 equiv.) was reacted 
with 4-methoxy styrene (1 equiv.) under the reaction conditions described 
above. Even after heating for 48 hours, the reaction did not go to completion. 
However, the reaction was stopped and after the work-up with ethyl acetate 
and brine, the NMR showed no product formation. Although most of the 
xylene had been eliminated, some still remained and could be detected from 
1H-NMR. The TLC also showed the formation of many impurities. Then the 
reaction was repeated using the same procedure but under nitrogen, but the 
inert condition seemed not to give any difference in the reaction condition 
and the product formation. So, in our hands, this method was not successful 
to synthesise fluorinated stilbene analogues.
2.8.2 Heck-Matsuda coupling reaction
Next attention was focused on the synthesis of fluorinated stilbene 
analogues by using Heck-Matsuda reaction, which involved the Heck 
arylation of styrene with arenediazonium salt (Moro et al. 2008). This 
reaction can be carried out in the absence of ligand (phosphine-free 
condition) and reported to be much easier to handle, faster, less costly and 
greener than the traditional Heck protocol. The diazonium salt should be an 
efficient leaving group giving nitrogen gas as the by-product.
PdfOAtfe, N-elhylmcrpholine
F
Figure 2.27: Decarbonylative Heck reaction
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The reaction was started by preparing the diazonium salt following the 
method described by Doyle and Bryker (1979). Boron trifluoride diethyl 
etherate was added to para-methoxy aniline in cooled dry dichloromethane in 
the presence of terf-butyl nitrite. The resulting crystalline precipitate showed 
to be the pure compound with no need for further purification and giving the 
product in excellent yield (97% to 99%). The reaction involved is outlined in 
figure 2.28:
NgBF*
^  f  /?  anhydrous CHaCb. pentane .•"’' W
F^ F * I J  --------------- — *---------   I  J
T  ^bulylnitriie.-15  °C
O C H , cx: h 3
Figure 2.28: Synthesis of para-methoxy diazonium tetrafluoroborate salt
The afforded diazonium salt was used straight away in the next reaction. In 
order to test the applicability of this method, the synthesis of 4-fluoro 4’- 
methoxy stilbene (compound 29) was chosen to compare the result of the 
same compound synthesized using HWE reaction. The synthesis of another 
analogue, 2-fluoro 4,-methoxy stilbene (compound 30) was carried out to 
check the reproducibility of this synthetic procedure. The synthetic procedure 
is outlined in figure 2.29 below:
Pd(dba)2, NaOAc, PhCN
OMe R = 2-F or 4-F (29), (30)
Figure 2.29: Heck-Matsuda reaction
The synthesis of compound 29 via this method was shown to be 
unsuccessful. The reaction was completed within 3 hours as determined by 
TLC, where the limiting reagent (4-fluoro styrene) can no longer be detected. 
Unfortunately, the work-up of the reaction was not as easy as expected. The
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high boiling point solvent benzonitrile was very hard to evaporate in vacuo. 
The extraction of the reaction mixture using water and common organic 
solvents failed as the mixture formed an emulsion and was not immiscible 
with both water and common organic solvents. The crude product showed no 
methoxy peak and no fluorine peak which indicated the failure of the reaction. 
It was anticipated that the starting materials had undergone degradation 
during the reaction. Repetition of the same reaction under inert atmosphere 
did not improve the reaction outcome. The synthesis of compound 30 using 
the same approach, under normal condition and under nitrogen was also 
unsuccessful. No product formation can be detected even after 72 hours of 
reaction. The crude product only showed the possible formation of side 
product polystyrene (with 32 equivalent protons detected by 1H-NMR at the 
aromatic region).
2.8.3 Heck reaction via palladium-oxazoline complex and Heck 
reaction in water as solvent.
The failure of the previous attempts prompted the need to find a more 
reliable Heck reaction procedure for stilbene synthesis. Therefore, another 
Heck reaction procedure was sought, this time using method described by 
Eisnor et al. (2006) which described the synthesis of stilbenes by a palladium 
(Pd)- oxazoline complex (compound 29a). Unlike other palladium catalysts 
which are air sensitive and prone to further oxidation, necessitating inert 
atmosphere and in some cases necessary for addition of ligands which will 
hamper later product purification, this Pd-oxazoline complex can efficiently 
operate in open air and does not require additional ligand. The synthesis of 
compound 29a is outlined in figure 2.30 below (Gossage et al. 2004):
Me OH
LiiPdCUxMiC
Figure 2.30: Synthesis of palladium-oxazoline complex (29a).
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The synthesis of the complex 29a involved the treatment of 
methanolic lithium tetrachloropallade (II) hydrate with 2-ethyl-2-oxazoline, 
which is a cheap and commercially available polymer precursor, giving the 
pure title compound in moderate yield (65% to 70%) without the need for 
further purification. The complex is reported to be stable in open air and can 
be stored at -20 °C until required for next synthesis, without losing its 
catalytic activity.
The next step was the synthesis of the fluorinated stilbene as 
described by Eisnor et al. (2006). The synthesis involved the addition of 1 
equivalent of substituted aryl halides (in this case 4-fluoroiodobenzene), 1.2 
equivalent of substituted styrene (e.g. 4-methoxy, 4-fluoro) in DMF, 1.2 
equivalent sodium acetate as base and 10 mol% of the complex 29a. The 
reaction procedure is outlined in Figure 2.31 below:
.£: X
Ri1 29a. NaOAc, DMF X'. 7
4  J  + R- t J     Ktf ]i4a-iso v140 150 °C V.-S*
R =4-F,4-OH. R,= 4-F. 4-OMe 29 S1 32
4-OAc
Figure 2.31: Synthesis of stilbenes via Heck reaction.
The synthesis was started by making compound 29 (4-fluoro 4’- 
methoxy stilbene). The reaction ran smoothly and completed within 5 hours. 
The reaction mixture was quenched with water to get precipitate which was 
then subjected to column chromatography to get the pure compound in 55% 
yield. The reduction of palladium-oxazoline complex loading from 10 to 2 mol% 
did not change the reaction time, but only reduced the yield to nearly quarter 
(14%) even though the TLC showed full consumption of the starting 
materials. In order to test the reproducibility of the method, the synthesis of 
compound 31 (4,4,-difluorostilbene) under the same reaction condition was 
carried out. The reaction also ran smoothly but needed longer reaction time
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(48 hours) to afford the compound after column chromatography in 55% yield. 
At this stage, this method was considered to be reliable for stilbene synthesis.
Further studies were dedicated to the synthesis of hydroxylated 
stilbenes via this method. Therefore, the synthesis of compound 32 (4-fluoro 
4’-hydroxystilbene) was carried out without any protection of the hydroxyl 
group by reacting 4-iodophenol with 4-fluorostyrene under the same reaction 
condition. The reaction suffered from incomplete consumption of starting 
materials even after 48 hours of heating, and following the work-up and 
column chromatography purification the compound was obtained in low yield 
(13%) with a slight trace of impurities. The attempt to recystalise the 
compound using ethanol/ethanol water failed to give a purer compound.
The finding highlighted the need to protect 4-iodophenol in order to 
increase the yield and to improve the purity of the hydroxylated stilbene. 
Acetoxy group was chosen as the protecting group due to its stability and 
extensive used as the protecting group for stilbene synthesis under Heck 
reaction [e.g. Moro et al. (2008), Farina et al. (2007), Andrus and Liu (2006)]. 
The protection of para-iodophenol was achieved following the procedure 
described by Adamski-Wemer et al. (2004) as outlined in figure 2.32 below:
AC2O, pyridine
(| T  ---------------- ► f Y ° Y CH3
, A A  RT. 24h JA A  0
(32a)
Figure 2.32: Protection of 4-iodophenol
The synthesis of acetic acid 4-iodophenol ester (compound 32a) was 
achieved by addition of 4-iodophenol with acetic anhydride and pyridine at 
room temperature for 24 hours. The pure compound was afforded after 
column chromatography in good yield (88%). The protected iodophenol was 
then subjected to the synthesis of protected stilbene under the same reaction 
condition where the reaction completed within 24 hours. After the work-up 
and column chromatography, pure compound 32 was obtained in 87% yield
Ch a pt e r  2: S t i l be n e  ana l ogues  as a n t i c a n c e r  agents 151
without the need for deprotection of the acetoxy group. In fact, the acetoxy 
group was readily cleaved during the reaction where the addition of 
deuterium oxide (deuterium exchange) in the NMR tube of compound 32 
showed the disappearance of the OH peak at 9.5 ppm.
On the other hand, another effort to synthesise stilbene analogues via 
Heck reaction was reported by Lipshutz and Taft (2008) who described a 
Heck coupling reaction at room temperature in water as the only solvent. 
Attracted to the mild and environmentally attractive reaction condition, the 
synthesis of compound 29 was sought using the reported procedure. The 
reaction involved the coupling of 4-fluoroiodobenzene with 4-methoxy 
styrene in the presence of Johnson-Mattey catalyst [(dtbpfJPdCh], 
triethylamine as base and a nonionic, Vitamin E-based amphiphile ‘PTS’ (15 
wt % in water) (Figure 2.33). The PTS (Figure 2.34) forms nanomicelles in 
water which allows cross-coupling to take place. The reaction was carried 
out for up to 30 hours at room temperature, but the traces of the limiting 
reagent (4-fluoroiodobenzene) can still be detected. Nevertheless, the 
reaction stopped and the product isolated by filtration through a pad of silica 
gel. The recrystallization in ethanol of the crude product afforded the pure 
compound in 35% yield.
1 PT S. 2 mo\% {dtbpfpdCI? x [. if
J  JF x-:" + J J ------------------*■H.iCO" EtaN.RT.30h . 0  
F ' 25
Figure 2.33: Heck coupling in PTS at RT
Figure 2.34: Structure of ‘PTS’
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The overall results for the synthesis of fluorinated stilbenes via Heck 
reaction are summarised in table 2.7 below:
Table 2.7: Summary of the synthesis of stilbenes via Heck coupling
Compound no R Ri Method used Yield (%)
29 4-F 4-OMe 10 mol% Pd- 
oxazoline
55
2 mol% Pd-oxazoline 14
In ‘PTS’ at RT 35
31 4-F 4-F 10 mol% Pd- 
oxazoline
55
32 (unprotected) 4-OH 4-F 10 mol% Pd- 
oxazoline
13
32 (protected)
(it was obtained as 
deprotected)
32a 4-F 10 mol% Pd- 
oxazoline
87
In conclusion, Heck reaction promoted by catalyst 29a is a reliable method 
for synthesising stilbenes with different substitution. The synthesis of 
compound 29 using the HWE and Heck reaction suggested that the HWE 
method is superior to the Heck reaction in terms of compound yields.
Following the success in synthesis of protected hydroxylated stilbene 
via Heck reaction, the same approach was applied to the synthesis of 
hydroxylated stilbene via HWE reaction. The synthesis of protected aldehyde 
was employed as described by Banerjee et al. (2006) (Figure 2.35). This 
method involved the protection of vanillin (3-methoxy-4- 
hydroxybenzaldehyde) with acetic anhydride in the presence of sodium 
hydroxide as base and in ice-cold water and ether as the solvents. The 
method proved to be very efficient, mild and afforded the protected vanillin as 
white solid in 92% yield.
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CHO
CHO AC2O, NaOH, Et3N, H2Q
HO' 0 °C to RT, 30 min OMe
(15a)OMe
Figure 2.35: Synthesis of protected vanillin (15a)
The protected vanillin (4-formyl-2-methoxyphenyl acetate; compound 
15a) can be used straight away in the next reaction without the need for any 
purification, and was subjected to HWE reaction with compound 2 to make 
compound 15. Upon heating of the reaction, the reaction mixture turned from 
light yellow to dark red. Following three hours of heating, the TLC showed 
the formation of many impurities with no fluorescence spot indicating the 
formation of stilbene. At this stage, this approach was considered to be 
unsuccessful. It was suggested that the acetoxy protecting group cannot 
survive the HWE reaction condition due to the strong base used which then 
caused the ester bond to break and released the free phenolic group to 
further react.
2.9 Biological study
2.9.1 Antiproliferative activity of stilbene analogues
A number of stilbene analogues based on the resveratrol pharmacophore 
which were synthesised using various methods were subjected to preliminary 
antiproliferative study, carried out in collaboration with the Tenovus Cancer 
Research Group, Welsh School of Pharmacy, Cardiff University by Mr Huw 
Mottram. The antitumour screening which involved four cancer cell lines, 
namely PC3 (prostate), A549 (non-small lung), Lovo (colon) and MCF-7 
(breast), were able to provide useful knowledge on the ability of the stilbenes 
to inhibit cancer cell’s growth and to induce cancer cell death over a range of 
compound concentrations. The MTT assay was used to detect the viability of 
the cells after incubation with the stilbenes which will later determine the 
cytotoxicity of the test compounds. The principal of the assay lies on the 
ability of the test compounds to induce the reduction of yellow MTT to a
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water soluble purple formazan which is largely impermeable in living cells. 
The compounds were prepared as 100mM solutions in DMSO and stored at - 
20 °C until used. Decimal dilutions of compounds were prepared in cell 
growth medium immediately prior to each assay (PC3 and Lovo in DMEM 
+10% FCS, A549 and MCF7 in RPMI +10% heat inactivated FCS), with final 
concentrations of 0.1 -  100 pM per well. Eight treatment replicates were 
made for each compound concentration. Cells were seeded into 96-well 
microtiter plates at a density of 5x103 (MCF-7 and Lovo) and 3x103 cells per 
well (PC3 and A549), and allowed 24 hours to adhere. The viability of the 
cells is measured as the number of active cells after the treatment with the 
test compounds, and is proportional to the level of purple formazan where 
the colour can be quantified using a spectrophotometer. The results obtained 
were plotted as a dose-response curve using OriginPro® Software and IC5o 
values calculated. Table 2.8 summarizes the results of the MTT assay:
Table 2.8: IC 5 0  values of four human cancer cell lines after incubation with 
selected stilbenes.
Compounds IC50 (MM)
PC3 A549 Lovo MCF-7
4 >100 >100 >100 >100
5 >100 >100 >100 >100
6 >100 >100 100 >100
7 >100 >100 100 >100
8 >100 >100 40 >100
9 40 40 5 40
10 >100 >100 60 100
11 >100 >100 >100 >100
12 50 100 50 50
13 50 >100 50 >100
14 50 >100 >100 0.1
16 >100 >100 >100 >100
17 >100 1 >100 >100
18 >100 >100 >100 100
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20 >100 >100 100 >100
22 50 50 20 50
28 >100 >100 >100 >100
29 >100 >100 >100 >100
32(1) >100 >100 >100 >100
32 (2) 50 50 30 50
From the table, It can be concluded that some of the stilbenes may have the 
ability to inhibit the growth of certain cancer cell lines in the pM range. 
Unfortunately, no structure activity relationship can be generated from the 
results. The most striking results were shown by compound 14 which can 
inhibit the MCF-7 breast cancer cell line at less than 0.1 pM, and compound 
17 which can inhibit the A549 cell line at 1 pM. Compound 9 also showed 
good antiproliferative activity on Lovo cell line at 5 pM. Figure 2.36 
summaries the structures of compounds exhibiting the best antiproliferative 
potential from the assay. One common feature from the compounds which 
showed promising antiproliferative activity is the existence of at least one 
methoxyl group in both sides of the stilbene benzene rings. This is in 
accordance with the previous study which showed that the methoxyl group 
on the stilbene skeleton is responsible for the apoptosis (programmed cell 
death) inducing activity of the stilbenes on cancer cells (Li et al. 2009). 
Nevertheless, a more detailed and comprehensive study should be carried 
out in order to test the inhibitory activity of this compounds in a wider range 
of concentrations and to further test the cytotoxicity activity of the stilbenes 
whether via apoptosis- or necrosis-based cell death.
OMe OMe
OMeOMe
MeO.
OMe OMeOMe
MeO'MeO'
(14)
Figure 2.36: Structures of compounds showing the best antiproliferative
activity from the MTT assay.
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2.9.2 Testing of stilbene analogues in Wnt signaling assay
Resveratrol and other stilbene analogues have the ability to inhibit cancer 
cells growth through multiple pathways; one of them is by inhibiting the Wnt 
signalling pathway (discussed in chapter 4). A study by Hope et al. (2008) 
highlighted the ability of resveratrol to inhibit the Wnt signaling pathway in 
colon-derived (NCM460) and colon cancer (RKO) cell lines, both lacking 
intrinsic activation of Wnt pathway. They suggested that the Wnt inhibitory 
effect may be at least partially due to inhibition of p-catenin nuclear 
translocation. However, other anti-Wnt mechanisms must be operative, as 
Wnt inhibition was seen in NCM460 cells in the absence of demonstrable 
effects on p-catenin quantity or intracellular localization. Therefore, based on 
their findings, the next study was dedicated to test the ability of the 
synthesised substituted stilbenes to inhibit the Wnt signalling pathway. The 
study was done on colon cancer stem cells (CSC) that was lentivirally 
transduced with TOP-GFP [TCF (T-cell-specific transcription factor)/LEF 
(lymphoid enhancer binding factor) reporter driving expression of GFP (green 
fluorescence protein)] construct, with mutant APC (adenomatous polyposis 
coli) (Vermeulen et al. 2010). The principal of the assay relies on the use of 
the TCF/LEF reporter that directs the expression of enhanced GFP upon 
activation of the pathway, where a positive inhibitory activity of the stilbene 
analogues will be shown as the ability of the stilbenes to reduce the 
expression of the GFP construct on CSC after up to two days of incubation 
with the stilbene compounds. This kind of assay enables primary screening 
of the tested stilbenes for their ability to inhibit the Wnt signalling pathway, 
especially at the downstream level of p-catenin where the transcription of 
Wnt-responsive genes mediated by the complexation of p-catenin to 
TCF/LEF occurred (refer Figure 4.1). The compounds were tested in a broad 
range of concentration: 2 mM, 10 pM and 50 nM. This study was done in the 
laboratory of Prof. J. P. Medema, Academic Medical Centre, Amsterdam, the 
Netherlands.
Unfortunately, neither of the parent compound resveratrol nor the 
tested stilbene analogues (together with other series of compounds which
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have been designed as inhibitors of Wnt signalling pathway, tested at the 
same time in the assay) showed significant ability to inhibit the GFP 
construct expression compared to control. Both the resveratrol and the 
stilbene analogues were not able to reduce the intensity of the GFP 
expression and were not able to reduce the number of cells upon treatment 
in CSC transduced cells. This might be due to the inability of the compound 
to inhibit the GFP expression at the downstream level of Wnt signalling 
pathway especially at the TCF/LEF transcription level. Nevertheless, this 
observation suggested that the stilbene analogues might be able to inhibit 
the Wnt signalling at other level of the pathway such as at the p-catenin level 
or at the upstream/receptor level of the Wnt pathway, thus highlighted the 
need for further testing of the compounds using a suitable assay protocol 
targeting various levels of Wnt signalling pathway.
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CHAPTER 3
SYNTHESIS AND EVALUATION OF INDOLE-CONTAINING 3,5-DIARYL 
ISOXAZOLES AS POTENTIAL ANTITUMOUR AGENTS
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SYNTHESIS AND EVALUATION OF INDOLE-CONTAINING 3,5-DIARYL 
ISOXAZOLES AS POTENTIAL ANTITUMOUR AGENTS. 
3.1 Introduction
3.1.1 Indole as a privileged structure in drug discovery
A number of oxygen and nitrogen heterocyclic derivatives have shown 
interesting biological activities and are of synthetic interest as they represent 
important classes of natural and non-natural products (Duchet et al. 2010). 
One of the most prominent structures found is the indole scaffold, which can 
be considered as a privileged structural motif found in various synthetic 
compounds and which can be found abundantly in natural products. There 
are a huge number of substituted indoles that have shown interesting 
pharmaceutical properties in a variety of therapeutic areas which explains 
the vast number of drugs containing the indole moiety, such as the analgesic 
Pravodoline, antiemetic Ramosetron and anti-inflammatory Indomethacin 
(Figure 3.1), among many others (Yeung et al. 2002; de Sa Alves et al. 
2009). As further reviewed by de Sa Alves et al. (2009), the chemistry of 
indole synthesis have attracted many chemists due to the evidence that 
showed many alkaloids containing the indole nucleus, as well as the 
essential amino acid tryptophan and the discovery of plant hormones, which 
all possess striking importance especially in drug discovery.
CHAPTER 3
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Pravacoline RamGSHslrGn IncomBthacin
Figure 3.1: Example of indole-based drugs
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3.1.2 3,5-Diaryl substituted azole as a promising scaffold for new
anticancer agents
On the other hand, a number of 3,5-diaryl-substituted azoles have been 
reported as promising new antitumour agents. Among those, 3,5-diaryl-1,2,4- 
oxadiazoles have shown striking importance as promising pro-apoptotic and 
antitumour agents, being identified using caspase- and cell-based high- 
throughput screening assays, as exemplified by compound 1d (Figure 3.2) 
(Jessen et al. 2005; Zhang et al. 2005). Compound 1d was found to be able 
to trigger apoptosis, interestingly, through arrest at Gi phase of the cell cycle. 
This distinguishes compound 1d from other anticancer agents including 
commonly used vinca alkaloids and taxanes that causes cell cycle arrest at 
the M phase. Importantly, compound 1d is able to selectively induce 
apoptosis only in certain cancer cell types, such as human breast cancer 
cells T47D and ZR75-1, and is also not active against primary normal cells 
such as HUVEC. This highlights its selectivity which can provide better 
toxicity profiles for this kind of apoptosis inducer.
Their data suggested that the 3,5-diaryl-1,2,4-oxadiazoles might be a 
new class of anticancer agents that are tumour-selective. Further extension 
of these work lead to another series of more water-soluble derivatives 
(compound 2a-b), Figure 3.2) that showed better efficacy in cancer xenograft 
model in vivo (Kemnitzer et al. 2009). Further recent work done by Ziedan et 
al. (2010) demonstrated that a number of indole-based 3,5-diaryl substituted 
oxadiazoles (compound 3a-b) have the ability to posses antiproliferative 
activity in the low micromolar IC5o range (using COLO 320 and MIA PaCa-2 
human cancer cell lines) and were able to induce apoptosis in sensitive cell 
lines through caspase activation (Figure 3.2).
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3a (R=N02 R-CI) 
3b(R=CI, R-OMe)
2a (X=C) 
2 b (X=N)
Figure 3.2: Structures of biologically active 3,5-diaryM ,2,4-oxadiazoles
Interestingly, further recent work done by Ziedan (2010) suggested 
another series of indole-based 3,5-diaryl substituted isoxazoles, which is 
another subset of substituted azole compounds, showed interesting 
antiproliferative activity in two human cancer cell lines; namely MDA-MB-231 
(breast cancer) and HeLa (cervical cancer) cell lines. Several compounds in 
this series possess low micromolar IC50 activities; compound 4a was found 
to be the most active, although not as potent as the clinically used anticancer 
agent Doxorubicin, while 3 compounds (compound 5a, 6a and 6b) were also 
found to be active in both cancer cell lines (Figure 3.3).
OMe OMe 6a (R = N02)
6b (R = COOCH3)
4a
Figure 3.3: Structures of biologically active 3,5-diaryl substituted isoxazoles
3.1.3 Aims of study
In view of the potential of the indole-based 3,5-diaryl-1,2,4-oxadiazoles and
3.5-diaryl isoxazoles as promising antitumour agents, this study is aimed to 
extend the recent work to further synthesise indole-based 3,5-diaryl 
substituted isoxazoles, and later on to evaluate their antiproliferative activity. 
This work would provide a substantial comparison to previously described
3.5-diaryl oxadiazole and isoxazole compounds and so to generate 
consequential structure activity relationship from the afforded structures.
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3.2 Synthesis of 3-(1A-/-indol-2-yl)-5-phenylisoxazoles and 3-(1- 
methyl-1/y-indol-2-yl)-5-phenylisoxazoles via condensation or 
cyclisation of alkynyl ketones and hydroxylamine.
The first part of the study focused on the synthesis of a 3-indolylisoxazole 
series. The syntheses were achieved following three chemical steps:
i) Synthesis of acyl chloride from corresponding indole-2 carboxylic 
acid
ii) Synthesis of alkynyl ketones from the reaction between indol-2- 
carbonyl chloride and phenylacetylenes
iii) Cyclisation of alkynylketones with hydroxylamine to give 3,5- 
disubstituted isoxazoles.
The overall reaction is outlined in Figure 3.4 below:
oxa lyl chloride
0.9  msl% PdCI*(PPhjl2
3 m olSCul, 1.25 equiv. EtyM. 
dry THF, RT, 30 - 45 min
□H dry CH^CIj. RT. 24 h
pyridine: B O H  (1:3), 
reflux, 5h
OCH3 ^ 3-F (4-regIoisomer)
H  C H S 4 - O C H j
H  C H 3  3 - F
H  C H 3  3 - O C H $ ( +  n e g io is o m e r )
Figure 3.4: Overall reaction scheme for synthesis of 3-indolylisoxazoles 
3.2.1 Synthesis of acid chlorides
To start the synthesis, different substituted indole carboxylic acids were used 
as the starting material in order to synthesise the corresponding acid chloride. 
This transformation will permit further coupling with acetylene in the next step. 
Although thionyl chloride whether neat or in non-polar solvents such as 
toluene is commonly used as the chlorinating agent, the need for reflux at
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high temperature made it less attractive for this kind of reaction. Therefore, 
the milder and more selective oxalyl chloride was chosen. The reaction was 
done in dichloromethane (or tetrahydrofuran) at room temperature with 
stirring for 24 hours. /V,A/-dimethylformamide (DMF) was used as a catalyst 
to accelerate the reaction (Figure 3.5). The overall yield of the reaction was 
more than 96% and upon evaporation of the solvents, the crude compound 
was used straight away in the next reaction without further purification.
oxalyl chloride, DMF (catalytic)
OH dry CH2CI2, RT, 24 h
61a: R = OCH3; R' = H 
63a: R = H; R' = CH3
Figure 3.5: Synthesis of acid chloride
3.2.2 Synthesis of alkynyl ketones
There are a number of ways to synthesise alkynyl ketones that have been 
reported previously; these include reaction of acetylene with acid chloride 
(e.g. Bernini et al. 2009) and by reaction of acetylenic Grignard reagent 
intermediates with aldehydes followed by oxidation (Tangdenpaisal et al. 
2009). Nevertheless, palladium and/or copper-catalysed cross couplings of 
terminal acetylenic derivatives with acid chlorides are usually considered as 
the method of choice. Increased functional group tolerance together with 
better yields makes the method attractive despite the instability of acid 
chlorides which needs to be considered.
Therefore, to proceed with the synthesis, the method described by 
Cox et al. (2005) was chosen for the alkylnyl ketones synthesis. The reaction 
involved the coupling between indole-2-carbonyl chloride and substituted 
phenylacetylenes using 0.9 mol% PdCl2(PPh3)2, 3 mol% copper iodide and 
1.25 mmol triethylamine as base in anhydrous tetrahydrofuran at room 
temperature, under nitrogen atmosphere. The reaction was very rapid, and
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was complete after 30-45 minutes by TLC analysis. The isolated crude 
products needed further purification by column chromatography (Figure 3.6). 
Nevertheless, variable and inconsistent yields were achieved after every 
reaction. For example, 3-(3-methoxy-phenyl)-1-(1-methyl-1 H-indol-2-yl)- 
propynone (65c) was achieved in 95% yield but the yield of 1 -(5-methoxy- 
1/-/-indol-2-yl)-3-(3-methoxy-phenyl)-propynone (61c) was quite low (23%). 
The need for really anhydrous conditions resulted in variable yields of each 
alkylnyl ketone, where sometimes the major product was the Glaser 
oxidation adduct from self-condensation of the terminal alkyne.
One attempt to synthesise alkynylketones from 5-methoxy-1/-/-indole-
2-carbonyl chloride (61a) and 4-methoxyphenyl-acetylene was unsuccessful, 
where only the product of Glaser dimerisation was afforded as the main 
product together with unreacted 61a, even after repeated attempts under 
carefully controlled anhydrous conditions (Figure 3.7). Another attempt to 
react compound 61a with 1-ethynyl-4-nitrobenzene was also unsuccessful 
(Figure 3.8). The reason for the selectivity which determined the successful 
coupling of compound 61a to different kinds of phenyl acetylene is unknown. 
The structure of the alkynyl ketones was confirmed by the disappearance of 
the acetylenic proton in 1H-NMR and the appearance of two quaternary 
alkynyl carbons C2 and C3 at around 6 85 to 92 ppm in 13C-NMR.
0.9mal% PdClz(PPh3fc 
3 mol% Cul 1.25 equiv. BUN. 
dry THF, RT. 30 -4 5  min
‘ * N
G laR ^CCH * R‘ = H 
63z l  R = H: R'= CH3 CCH3 H 3-OCHs
CCHj H 3-F
CH
Figure 3.6: Synthesis of alkynyl ketones 61c to 65c
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coci
H3c° - { ~ ^ =  =  Q-OCH3
product of Glaser dimerisation as the main sideproduct 
(dimer of terminal alkyne formed through Glaser coupling)
H3CCV ^ r ^U C V c o c ,
H
unreacted acyl chloride
3-(5-methoxy-1 H-indol-2-yl)-5-(4- 
methoxyphenyl)isoxazole
Figure 3.7: Attempt to synthesise 3-(5-methoxy-1H-indol-2-yl)-5-(4-
methoxyphenyl)isoxazole.
0.9 mol% PdCI2(PPh3)2 
3 mol% Cul, 1.25 equiv. Et3N, 
dry THF, RT, 30 - 45 min
Figure 3.8: Unsuccessful coupling of compound 61a to 1-ethynyl-4-
nitrobenzene
3.2.3 Synthesis of 3,5-diaryl isoxazoles.
The final procedure to synthesise 3,5-diaryl isoxazoles was achieved using 
the method described by Johnston and Shorter (1968), which mentioned the 
formation of isoxazoles via cyclisation of alkynyl ketones. The method 
involved the formation of two intermediates: the first one is the formation of 
an oxime intermediate via condensation reaction between carbonyl group of 
alkynyl ketones and hydroxylamine, followed by the reaction with the alkyne 
moiety to give the desired product (Figure 3.9).
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Base
R-C-i :-R2
Figure 3.9: Reaction mechanism for the formation of isoxazoles.
This procedure was initially reported to give only one isomer. Nevertheless, 
Adlington et al. (2000) also mentioned that the formation of other regioisomer 
in a mixture with the initial isomer is possible (Figure 3.10) via an alternative 
mechanism pathway (Figure 3.11). To date, no papers have mentioned the 
criteria which determine the formation of a certain isomer; however, the 
formation of the initial isomer (A) is more favorable in most cases.
$  N-o. N-o.
R-C —C=C-Rj * NHjOH -----
R'
Regioisomer A R egioi’somGr B
Figure 3.10: Formation of regioisomer A and B.
Ease
NHjOH
Figure 3.11: Alternative pathway for the formation of regioisomer B
For this reaction, hydroxylamine hydrochloride together with 1-(1H- 
indol-2-yl)-3-(substituted phenyl)-prop-2-yn-1-one or 1-(1-methyl-indol-2-yl)-
3-(substituted phenyl)-prop-2-yn-1-one were dissolved in a mixture of 
ethanol/pyridine (3:1) and refluxed for 5 hours or until the completion of the 
reaction. After the work-up, the crude products were purified using column 
chromatography to afford the compound in a fairly low yield (from 56% to as
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low as 2% for regioisomers). Out of 5 reactions, 2 of them gave formation of 
regioisomers: 62c to form regioisomers 62 and 62b, and 65c to form 
regioisomers 65 and 65b; both of them which needed further column 
chromatography separation (as shown in Figure 3.12 for the formation of 
regioisomers 62 and 62b). Another 3 reactions gave only single isomer 
(isomer A -  compounds 61, 63 and 64).
EtOH, pyridine (1:3) H3c a
(62)
(62b)
Figure 3.12: Synthesis of compound 62 which gave rise to regioisomer 62b.
3.2.4 Determination of regioisomers
In order to distinguish the characteristics between different formed 
regioisomers, the method described by Stephens and Arafa (2006) was 
employed. The determination of the regioisomers can be achieved by either 
using 13C-NMR spectra or by using mass spectrometry analysis. For 3,5- 
diphenyl isoxazoles, the chemical shift of C4 of isoxazoles can be calculated 
using the following equation:
6(C4) = 98.1 + 4(a5ph) + 0.66 (a3Ph) (1)
where:
5(C4): is the chemical shift of the C4 of isoxazole
98.1 : is the chemical shift of the C4 of unsubstituted 3,5-diphenylisoxazole 
(standard value)
asph : is the Hammet constant for the substitution on the 5-phenyl group 
a3ph : is the Hammet constant for the substitution on the 3-phenyl group
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If the equation is applied to compound 62 and 62b, where the Hammet 
constant for 3-fluorophenyl is +0.337 (Hammet 1937), while indole as an 
electron donating group would have a negative value for Hammet constant, 
therefore:
Compound 62 : 6(C4) = 98.1 + 4(0.337) + 0.66 ([-]aindole)
Compound 62b: 6(C4) = 98.1 + 4([-]aindole) + 0.66 (0.337)
It is clearly shown that compound 62 will have higher C4 value than 
compound 62b. This showed that the compound which have a higher C4 
value (6 98.2 ppm) is compound 62 while another regioisomer with a lower 
C4 value (5 97.07 ppm) is compound 62b. But in contrast to previous 
discussion, compound 62b was found to be more favourable in terms of 
formation than its regioisomer counterpart (compound 62) which is indicated 
by a slightly higher yield obtained (5% and 2%, respectively). The very low 
yield obtained also resulted from uncyclised alkynylketones even after 
prolonged reaction. On the other hand, compound 65 and its regioisomer 
65b followed the usual pattern of regioisomer formation, where compound 65 
has a much higher yield (20%) after column chromatography separation 
compared to their 5-indolylisoxazole counterpart (4% yield).
Another method that can be used to distinguish between different 
regioisomer is the fragmentation pattern from mass spectroscopy (electron 
impac*).
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h3co .
N-0
cleavage
minor fragmentation
Figure 3.13: Fragmentation pattern of compound 62
WESTWELL
PHARMY_SFM62 214 (3.567) Cm (214-32:40)
100~i
TOF MS EI+
308.10
123.02
293.08188.06
265.08
173.03
142.05157-04
237.08115.04 280.09209.06 342.06
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380
Figure 3.14: The mass spectrometry of compound 62
The mass spectrometry of compound 62 showed a fragmentation of acylium 
ion signal at m/z 123 together with the signal of the isoxazoles (m/z 308), 
that correspond well with the expected fragmentation pattern.
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N-0
cleavage
MeO.
~ V
minor fragmentation
acylium ion 
M/ZMZ
Figure 3.15: Fragmentation pattern of compound 62b
WESTWELL
PHARMY.SFM626160 (2.667) Cm (160-13) 
100- “ j96
TOP MS EI+ 
3.5164
308.10173.05
158.02
219.09121.03
265.08 293.071130.0395.0375.02
. il j |l.i |i,l, | i |..l
20703188.06 237.08
Figure 3.16: The mass spectrometry of compound 62b.
In compound 62b spectrum, the signal of the acylium ion was detected at 
m/z 173 together with the signal of the isoxazole at m/z 308, also agreeing 
well with the expected fragmentation pattern of 5-indolylisoxazoles.
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In conclusion, verification of regioisomers formed was confirmed by 
careful characterisation of 13C-NMR data and assignment of acylium ion of 
electron impact mass spectrometry fragmentation.
3.3 Synthesis of 5-(1-methyl-indol-2-yl)-3-substituted
phenyl isoxazoles via 1,3-dipolar cycloaddition
The first pathway to synthesise 5-indolylisoxazole compounds seemed quite 
complicated, especially due to the unspecific nature of the reaction to afford 
mixed regioisomers in certain compounds. Therefore, another method was 
sought which was expected to be more regioselective to produce 5-indolyl 
isoxazoles. The synthesis was chosen following the method as described by 
Lee (1982). The method basically involved the synthesis of isoxazoles by 
dipolar cycloaddition between aldoximes and terminal alkyenes using sodium 
hypochlorite. Specifically, for the synthesis of 5-(1-methyl-indol-2-yl)-3- 
substituted phenylisoxazoles the following methods were employed:
i) Formation of 2-ethynyl-1-methyl-1 H-indole from 1 -methyl-1 H- 
indole-2-carbaldehyde
ii) Formation of aldoxime from the reaction of various 
carboxaldehydes and hydroxylamine hydrochloride.
iii) Formation of isoxazoles by dipolar cycloaddition between the
aldoxime and terminal alkyne using sodium hypochlorite.
3.3.1 Synthesis of 2-ethynyl-1-methyl-indole
The synthesis of 2-ethynyl-1-methyl-indole (compound 66b) was achieved
following the method described by Roth et al. (2004). In this reaction,
Bestmann-Ohira reagent (or dimethyl-1 -diazo-2-oxopropylphosphonate) was
formed from the reaction between p-toluenesulfonylazide (66a), dimethyl-2-
oxopropylphosphonate and potassium carbonate, which in the presence of
methanol leads to the in situ generation of dimethyl
(diazomethyl)phosphonate. This latter reagent leads to the formation of the
desired terminal alkyne, in this case 2-ethynyl-1-methyl-indole, from its
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corresponding aldehyde (Figure 3.17). The mechanism of the reaction 
includes a Homer-Wadsworth-Emmons reaction, loss of nitrogen and 
rearrangement of the resulting alkenylidenecarbene into the alkyne. 
However, the reaction did not go to completion even after prolonged reaction 
time, thus affording the desired acetylene in moderate yield (55%). This is in 
line with the original paper, which reported that if the aldehydes bearing 
electron donating group was used, the reactions would not go to completion 
resulting in low yield, as was the case in the afforded compound.
(66a)
1. Dimethyl-2-oxopropylphosphonate 
K2C 03> CH3CN, RT, 2 h
CHO, MeOH CH:
(66b)
Figure 3.17: Synthesis of 2-ethynyl-1-methyl-indole (66b)
3.3.2 Synthesis of aldoximes
The next part of the synthesis was the formation of aldoximes. Aldoximes, 
are synthesised via a straightforward condensation reaction between 
aldehyde and hydroxylamine. The synthesis involved the reaction between 
substituted benzaldehydes with hydroxylamine hydrochloride in the presence 
of sodium carbonate as base in an aqueous methanolic solution 
(Me0H/H20=3:1) (Figure 3.18).
Upon the completion of the reaction, the aldoxime precipitates out of 
the reaction mixture, where the powder was collected by filtration and used 
without further purification in the next reaction. The pure products were 
afforded in good yields; 78% for compound 68b and 86% for compound 69b.
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N-OH
NH2OH.HCI, NaHC03 (6 8  b) ;R = 4-OCH3 
(69b); R = 4-F
MeOH, H20, RT
Figure 3.18: Synthesis of aldoximes 68b and 69b.
3.3.3 Synthesis of 5-(1-methyl-indol-2-yl)-3-phenylisoxazoles
The next part of the synthesis is the formation of 5-indolylisoxazoles. The 
reaction should be regioselective in order to avoid the problem of nonspecific 
regioisomer formation. The selected procedure followed the method by Lee 
(1982) involving dipolar cycloaddition reaction. For the reaction, terminal 
alkyne solution was dissolved in dichloromethane followed by addition with 
triethylamine as base and 2 equivalent of 13% sodium hypochlorite solution. 
Next, aldoxime solution in dichloromethane was added dropwise at 0 °C and 
the mixture was left to stir at room temperature under nitrogen atmosphere 
for 24 hours or until the completion of the reaction as indicated by TLC 
(Figure 3.19). Upon work up, the crude product was subjected to column 
chromatography purification to afford pure compound in low yield (23% for 
compound 66 and 29% for compound 67).
CHa
N-OH
- P ' 1"
NaOCI, E-feN. CH2CI2
C r v < i  ..
CHj
0 °C.-I:hen RT. 24 h
Compound no: R1
66
67
4-OCH3
4-F
Figure 3.19: Synthesis of compound 66 and 67.
The reaction mechanism follows the 1,3-dipolar cycloaddition of nitrile oxide 
(synthesized in situ during the reaction) with alkynes to afford 5-(1-methyl- 
1 /-/-indol-2-yl)-5-(substituted phenyl)isoxazoles (Figure 3.20), without
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formation of any regioisomer. This showed that this method was 
regioselective although the overall yield was low. Addition of catalyst is 
expected to give a better yield, as reported by Vieira et al. (2009) which 
showed the increase in yield of isoxazoles with the addition of copper(l) 
iodide. Compound 66 and 67 will provide useful structure activity relationship 
insight in comparison to their 3-indolylisoxazoles counterparts.
-NaOH
NaONaOCI
l-Ov
R = 4-OMe/ 4-F
Figure 3.20: Reaction mechanism for the synthesis of isoxazoles via 1,3-
dipolar cycloaddition.
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3.4 Synthesis of 5-(1Af-indol-5-yl)-3-substitued phenyl isoxazoles via 
1,3-dipolar cycloaddition
Following the success of the synthesis of 5-indolylisoxazoles giving specific 
isomers, another series of 5-indolyl isoxazoles based on 5-ethynylindoles 
moiety was sought to provide useful comparison for structure activity 
relationship study. The following procedure was employed to synthesise 
compounds of this series:
i) Synthesis of 5-ethynylindole from 5-iodoindole via Sonogashira 
coupling.
ii) Synthesis of substituted benzaldoximes from substituted 
benzaldehydes.
iii) Synthesis of isoxazoles via dipolar cycloaddition
3.4.1 Synthesis of 5-ethynylindole
The chosen method for the synthesis of 5-ethynylindole was by Sonogashira 
coupling using 5-iodoindole as the starting material. Following the procedure 
by Henon et al. (2006), to start the synthesis, 5-iodoindole was coupled with 
triethylsilylacetylene in the presence of triethylamine as base, Pd(PPh3)4 in 
combination with copper iodide as catalysts, in acetonitrile with heating at 
reflux for 5 hours to afford intermediate 5-triethylsilylethynylindole [68a(i)]. 
After the work-up, the reaction was used straight away in the next reaction 
without further purification.
The next step involved the removal of the triethylsilyl group from the 
intermediate. The chosen method was following the procedure described by 
Mathieu et al. (2006), where 1M tetrabutylammonium fluoride was used in 
tetrahydrofuran, and the reaction was left for 24 hours at room temperature 
for complete conversion to terminal alkyne, 5-ethynylindole (68a). Following 
the work-up, the crude product needed more purification by column 
chromatography. The overall yield of the reaction over two steps was 69%.
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/
 -------------------------- ( "  Pd(PFh,KCul. EtjN. y - 'Y  '  Bu+IF/HF
*  1 J ♦ " " j 1^  — . .. * N - V 1 - ^ 1 7 T * V J' VCH^CN. reflux. 5 h H RT.24h HN „
H x eBd(i) 6Ba
Figure 3.21: Synthesis of 5-ethynylindole 68a
3.4.2 Synthesis of substituted benzaldoxime
The synthesis of substituted benzaldoxime was achieved by using the same 
procedure as described at 3.3.2. The same benzaldoximes from 3.3.2; 
compounds 68b and 69b were further used for this series of 5- 
indolylisoxazoles. Another oxime, 3,4,5-trimethoxybenzaldoxime (70b) was 
synthesised in excellent yield, 90%.
3.4.3 Synthesis of 5-(1H-indol-5-yI)-3-pheny I isoxazoles
For these series of isoxazoles, the same procedure was employed as 
described in 3.3.3. The reaction mechanism involved 1,3-dipolar 
cycloaddition which started with the formation of nitrile oxides from 
substituted benzimidoyl chlorides intermediate which later underwent 
cycloaddition with 5-ethynylindole. The reactions however suffered from 
incomplete conversion of unreacted starting materials even after prolonged 
reaction times. Upon termination of the reactions, the afforded crude 
products needed further purification by column chromatography to afford the 
pure isoxazoles in low yield (7% yield for compound 68, 36% for compound 
69 and 29% for compound 70).
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N-OH
. ^  ^  ^  Jl
< n  f  4 l t  H
H Ki
NaOCI. B 3N. CH2CI2
---------------------------------- ► O-N
0 ®C.-lh€ n RT. 24 h
t  If T
* 4/X#cn. J
H
Compound no: R1
68 4-OCH*
68 4-F
70 34.5-tnOCHa
Figure 3.22: Synthesis of compound 68, 69 and 70.
3.5 Failed experiments:
3.5.1 Synthesis of indole-3-yl-isoxazole series via 1,3-dipolar 
cycloaddition using 1//-indole-3-carbaldehyde oxime
The synthesis of this series of isoxazoles was intended to provide useful 
structure activity relationship to previously synthesised indole-2-yl-isoxazoles 
series. The method of choice was via 1,3-dipolar cycloaddition due to its 
regioselectivity showed in the previous experiments. Unfortunately, the 
synthesis of this series of compounds was not as reproducible as expected. 
The first part of the synthesis involved the formation of compound 71a (1H- 
indole-3-carbaldehyde oxime) followed by 1,3-dipolar cycloaddition with 
substituted phenylacetylene to afford the proposed compounds 71, 72, 73 
and 74 (Figure 3.23).
NaOCI. EtjN. CH2CI;
0 cC. then FIT, 24 h
71: R = 3-OMo 
72: R = 4-OMe 
73: R = 4 -C F j 
74: R -  3 F
R  -  3 -O W p /4 -O M €/
3-F/4-CF3
Figure 3.23: Proposed synthetic procedure for compounds 71,  72,  73 and 74.
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3.5.1.1 Synthesis of (£)-1 H-indole-3-carbaldehyde oxime.
The synthesis of indole-3-oxime (71a) was achieved by the same reaction 
procedure described in 3.3.2 to synthesis benzaldoxime from indole-3- 
carboxaldehyde. The indol-3-oxime was afforded in good yield (73%) and in 
good purity with no need for further purification (Figure 3.24).
NH2OH.HCI, NaHC03
MeOH, H20, RT
(71a)
OH
Figure 3.24: Synthesis of 1 /-/-indole-3-carbaldehyde oxime (71a)
3.5.1.2 Synthesis of 3-(1 H-indol-3-yl)-5-phenylisoxazoles
The next part of the synthesis involved the synthesis of isoxazoles via 1,3- 
dipolar cycloaddition with substituted phenyl acetylene (summarized in 
Figure 3.25). For the first attempt, 3-methoxyphenyl acetylene was used as 
the starting material for the first compound of this series. The same method 
was employed as was previously described (refer 3.3.3 and 3.4.2). 
Unfortunately, even after repeated attempts, the starting material had not 
reacted indicated by no product formation even after prolonged stirring. 
Addition of different substituted phenyl acetylene (either 4-methoxy or 3- 
fluoro substituted) did not give any difference in the observation. Further 
substitution of dichloromethane with different solvents [THF, DMF, ethyl 
acetate, dimethylsulfoxide (DMSO) or te/7-butanol:THF (3:1)] also did not 
improve the outcome of the reaction.
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Figure 3.25: Summary for the attempted methods to synthesise indole-3-yl-
isoxazole series
Nevertheless, one interesting observation was detected when the 
reaction was done in solvents other than dichloromethane and DMSO: the 
formation of an insoluble precipitate which was not the desired compound, it 
was predicted that the precipitate was an intermediate of the reaction, whose 
NMR analysis showed that the precipitate still retained the compound 71a 
core structure, only missing one hydrogen peak at around 5 8.1 ppm which 
belongs to the proton of the oxime. This indicated that the precipitate was
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probably A/-hydroxy-1H-lndole-3-carbimldoyl chloride (compound 71b), which 
should be the first intermediate formed following the reaction with sodium 
hypochlorite before the attack of the base to form nitrile oxide species. 
Whereas in dichloromethane there was no reaction detected, the reaction in 
DMSO showed the possibility of nearly full consumption of compound 71a to 
another compound/intermediate, but still without any desired product 
formation indicated by TLC and following NMR determination of precipitate 
formed upon quenching with water.
Another attempt was also sought by changing the reagent for 
chlorination of oxime from sodium hypochlorite to A/-chlorosuccinimide in 
THF with triethylamine as base. The reaction was again found to be 
unsuccessful. A further attempt to change the base to potassium carbonate 
in ethyl acetate/water as solvent with heating at reflux for up to 36 hours also 
did not change the fate of the reaction. At this stage, the insolubility of the 
intermediate 71b was seen as the biggest obstacle that made all the 
attempted reactions fail. Although the intermediate dissolved in DMSO, this 
was apparently not a suitable solvent for the reaction to occur.
In order to test this hypothesis, compound 71b was independently 
synthesised using A/-chlorosuccinimide in DMF from compound 71a. After 3 
hours of stirring at room temperature, compound 71b precipitated out of the 
reaction mixture and was collected. The NMR of the collected precipitate, 
which only dissolved in DMSO, showed the same spectrum as was 
previously seen which gave enough evidence to support the initial hypothesis. 
The precipitate was used straight away in the next cycloaddition reaction in 
THF and triethylamine, but even after up to 48 hours of stirring no reaction 
occurred, most probably due to its insolubility in THF.
Another attempt was made to synthesise 3-ethynyl-1H-indole 
following the method in 3.3.1 as an alternative reagent to synthesise the 
regioisomer, 5-(1/-/-indol-3-yl)-3-phenylisoxazoles also failed to give the 
desired product, where no reaction occurred even after prolonged stirring for 
up to 48 hours (Figure 3.26). This highlights the failure of previously
C h a p t e r  3 :  I n d o l e  b a s e d  3 , 5 - d i a r y l  i s o x a z o l e s  181
successful method to synthesise indole-3-yl isoxazoles series, thus 
emphasising the need to find alternative pathways in order to synthesise this 
kind of isoxazole series.
1 DirrethyJ-2-oxoprapylpho*phonaiB. CHjCN. pHoluenesulfonyiaeide. RT. 2h:
X "S , .J-
 *  -'jj MeOH. RT. 24 h ^  fl
Figure 3.26: Attempt to synthesise 3-ethynyl-1 /-/-indole.
3.5.2 Attempt to synthesis 3-(5-methoxy-1tf-indol-2-yl)-5-(4- 
(trifluoromethyl)phenyl)isoxazole (and regioisomer).
Synthesis of this compound via the formation of alkyknyl ketone and 
cyclisation using hydroxylamine hydrochloride (pathway 1) suffered from low 
yields of alkynyl ketone intermediate [1-(5-methoxy-1/-/-indol-2-yl)-3-(4- 
(trifluoromethyl)phenyl)prop-2-yn-1-one; 12% yield] and product (together 
with the formation of regioisomer). Attempts to separate the isomers using 
column chromatography [hexane:ethyl acetate (10:1)] only resulted in 
separation of around 20% of the compound mixtures, where the rest remain 
as mixed isomers. The separated regioisomers were obtained in a very low 
yield and were very hard to purify due to the presence of lots of impurities 
(Figure 3.27).
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1 2 % yield
0.9 mol% PdCI2(PPh3 )2 
3 mol% Cul, 1.25 equiv. R 3N, 
dry THF, RT, 30 - 45 min EtOH, pyridine (1:3) NH2OH.HCI, 
refiux, 5 h
Figure 3.27: Attempt to synthesise 3-(5-methoxy-1H-indol-2-yl)-5-(4- 
(trifluoromethyl)phenyl)isoxazole (and regioisomer)
3.6 Future study: Biological evaluation.
The synthesised isoxazoles will be further evaluated for their biological 
activity in human cancer cell lines. The initial screening will involve the 
determination of their antiproliferative activity. The result is anticipated to 
generate useful structure-activity relationship for the identification of lead 
compounds which will provide further encouragement for the development of 
this series of compounds.
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CHAPTER 4
SYNTHESIS AND EVALUATION OF SPECIFIC INHIBITORS TARGETING 
THE DISHEVELLED-PDZ DOMAIN OF THE WNT SIGNALLING
PATHWAY
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CHAPTER 4 
SYNTHESIS AND EVALUATION OF SPECIFIC INHIBITORS TARGETING 
THE DISHEVELLED-PDZ DOMAIN OF THE WNT SIGNALLING 
PATHWAY 
4.1 Introduction
4.1.1 Wnt signalling pathway
Wnts are secreted cysteine-rich glycoproteins that act as short-range ligands 
to locally activate receptor-mediated signalling pathways (Moon et al. 2004). 
The Wnt signalling pathway is one of the most evolutionary conserved 
biochemical signalling pathways. It is involved in a vast array of processes 
including embryonic development, adult tissue homeostasis (Staal and 
Clevers 2003; Bryja et al. 2007), cell tissue polarity, tissue patterning, control 
of cellular proliferation and development of neoplasia, in which cells respond 
to Wnts in a context-dependent manner through changes in survival and 
proliferation, cell fate and movement (Moon et al. 2004, Shan et al. 2005).
The pathway is initially activated by a Wnt ligand binding to a Frizzled 
(Frz) receptor and a low-density lipoprotein receptor related protein (LRP) 5 
or LRP6, which subsequently transduces a signal through one of at least 
three distinct intracellular signalling pathways: the “Wnt/Ca2+” pathway, the 
“Wnt/polarity” pathway (Horvath et al. 2007) and the classical and the best 
understood which is the highly conserved “Wnt/p-catenin” canonical pathway 
(Horvath et al. 2007; Leonard and Ettensohn 2007) (Figure 4.1). In all these 
pathways, the 7 transmembrane domain Frz proteins are bound by the 
secreted molecule Wnt and transduce the signal to the cytoplasmic protein 
Dishevelled (Dvl), the component at which these signalling pathways diverge 
(Wong et al. 2003; Moon et al. 2004).
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Figure 4.1: The Wnt signalling pathway (A: Wnt off; B: Wnt on)
The binding of W nt ligand to Frz and LRP 5/6 will result in the 
recruitment of axin to the LRP proteins and the cytoplasmic protein Dvl to the 
Frz receptor by an unknown mechanism that may include phosphorylation 
(Sen 2005; Shan 2005; Smalley et al. 2005; Leonard and Ettensohn 2007; 
Polakis 2007). Upon Wnt stimulation, Dvl is phosphorylated and the 
degradation complex formed by Axin, APC (adenomatous polyposis coli), 
CK1 (casein kinase 1) and GSK3(3 (glycogen synthase kinase-3 beta) is 
inhibited leading to the stabilization of p-catenin. p-catenin can then act in
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the cytosol, or In the nucleus, by binding to TCF (T-cell-specific transcription 
factor)/LEF (lymphoid enhancer binding factor) and regulating transcription 
(Sen 2005; Shan 2005; Smalley et al. 2005; Bryja et al. 2007). The cellular 
effect of Wnt and p-catenin depends on the functions of Dvl, the pivotal 
intracellular player in the pathway (Zhong et al. 2006; Polakis 2007).
The Wnt pathway has clinical relevance, which lies in its potential first 
for predicting the clinical outcome and second as a target for therapeutic 
agents. Importantly, in some cancers, the aberrant expression of 
components of the Wnt pathway correlates with advanced tumours, the 
probability of metastasis and survival rate (Doucas et al. 2005). Aberrant 
activation of the Wnt signalling pathway is implicated in the development of a 
broad spectrum of tumours, particularly those of the digestive tract (Barker 
and Clevers 2006) and colorectal cancer, which is the third most common 
cancer in the world (Chen et al. 2010). There are many ways to activate Wnt 
signalling in cancers. Up-regulation of Wnt-associated genes has been 
shown to play a role in the development of human cancers (Polakis 2007). 
However, although many Wnt genes (Wnt 1, Wnt 3a and Wnt 16) are thought 
to have oncogenic potential, others (Wnt 5a and Wnt 7a) have the 
characteristics of tumor suppressor genes (Moon et al. 2004). Taken 
together, the evidence suggests that Wnt pathway activation may have 
opposing functions that depend on the specific ligand/receptor combination. 
Because of the multiple functions of the Wnt family, inhibition of all Wnt 
signalling may not be a perfect strategy for tumour therapy. One solution 
would be to target only Wnt signalling molecules that contribute significantly 
to tumourigenesis (Fujii et al. 2007).
It appears that Wnt signalling is a key regulator in stem cell renewal 
(Wong et al. 2003). Wnt proteins are major components of mesenchymal 
stem cells, stromal cells, and a heterogenous population of fibroblast-like 
cells that support the growth, differentiation and survival of different cell 
lineages and cell types by providing cytokines/chemokines, adhesion 
molecules and extracellular matrix molecules (Moon et al. 2004). Targeted 
disruption of Wnt signalling by “loss-of-function mutations” is linked to
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dramatic phenotypes, ranging from embryonic lethality to severe central 
nervous system, limb, lung and kidney defects (Sen 2005) and various 
human cancers (Barker and Clevers 2007). For example, eighty percent of 
colorectal cancers alone reveal activation of this pathway by either 
inactivation of the tumour-suppressor gene adenomatous polyposis coli 
(APC) or mutation of the proto-oncogene p-catenin (Herbs and Kolligs 2007).
Dvl was one of the first components of the Wnt signalling pathway to 
be defined; yet its biochemical function remains poorly understood. Dvl 
family members are 500 to 600 amino acids in length and have been found 
in animals ranging from Drosophila to humans (Leonard and Ettensohn 
2007). Dvl family proteins (Dsh in Drosophila; XDsh in Xenopous; Dvl-1 to 3 
in mammals) are key intracellular mediators of the Wnt signalling pathway, 
where the Wnt signal is passed from the membrane Wnt receptor Fz to Dvl, 
which then relays the signal to downstream components (Lee et al. 2009; 
Zhang et al. 2009b). In addition to playing a role in the canonical Wnt 
signalling pathway, Dvl proteins are also involved in the planar cell polarity 
(PCP) pathway and the calcium-signalling pathway (Wharton 2003; Smalley 
et al. 2005; Leonard and Ettensohn 2007). Dvl is hypothesised to serve as 
the branch point at which the two pathways diverge, making its regulation of 
particular importance (Leonard and Ettensohn 2007). Some ectopically 
expressed Frz family members can recruit Dvl to the plasma membrane, and 
RNA interference studies have shown that Dvl is required for the Frz activity 
in Frz/LRP receptor complex but not for LRP function. Dvl is required to 
recruit axin to the Frz/LRP complex in a signal dependent manner (Smalley 
et al. 2005). The regulation of Dvl on Wnt signalling pathway is crucial in 
normal development and its aberrant activation is implicated in many 
tumours (Zhang et al. 2009b)
All Dvl family members contain three highly conserved domains 
(Figure 4.2): an N-terminal DIX (for Dishevelled and aXin proteins) domain 
contains -80 amino acids, a central PDZ (for Post Synaptic Density-95, 
Discs-large and Zonula occludens-1 proteins) domain contains -90 amino 
acids, and a DEP (for Dishevelled, EGL-10 and Pleckstrin proteins) domain
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as the most C-terminal conserved domain contains ~90 amino acids 
(Wharton 2003; Wong et al. 2003). The DIX domain is thought to be required 
for the canonical (p-catenin pathway), multimerisation and interaction with 
axin. The DEP domain is required for the PCP pathway signalling. The PDZ 
domain, on the other hand, may function in both pathways, by mediating the 
interaction of Dvl with a variety of binding partners, including the Frz 
receptor. PDZ domain plays an important role in both the canonical and non 
canonical Wnt pathways, and is involved in distinguishing between the two 
pathways (Wharton 2003; Wong et al. 2003; Smalley et al. 2005; Leonard 
and Ettensohn 2007). Wong et al. (2003) demonstrated that there is a direct 
interaction between Frz and Dvl. Specifically, the key interaction in the 
pathway is the direct recognition of PDZ domain of Dvl with the Frz 
conserved sequence (KTXXXW) that is C-terminal to the seventh 
transmembrane domain (Fujii et al. 2007; Lee et al. 2009; Zhang et al. 
2009b). The interaction is essential in the transduction of the Wnt signal from 
Frz to the downstream components of the pathway. Thus, the findings shed 
light on the mechanism by which the receptor Frz communicates with the 
downstream component Dvl (Wang et al. 2008).
Dishevelled Protein
DIX Basic PDZ DEP
Figure 4.2: The Dishevelled Protein (adapted from Nusse 2008).
The special role of the Dvl PDZ domain in the Wnt pathway makes it 
an ideal pharmaceutical target (Fujii et al. 2007). The PDZ domain is a 
common protein-protein interaction module that are characterised by the 
ability to recognise the extreme COOH-terminus of important drug target 
proteins or internal peptides (Sheng and Sala 2001; Wang et al. 2008; Zhang 
et al. 2009b, Lee and Zheng 2010). PDZ domain mediates crucial protein- 
protein interactions that enforce localisation and organisation of proteins in a
6716
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variety of submembranous complexes associated with G protein-coupled 
receptors, ceil signal mediators including ion channels, transmembrane 
receptors and regulatory enzymes (Harris and Lim 2001; Wang et al. 2008; 
Lee and Zheng 2010). Small molecule inhibitors of the PDZ domain in Dvl 
might be useful in dissecting molecular mechanisms and formulating 
pharmaceutical agents that target cancers or other diseases in which Wnt 
signalling is involved (Wang et al. 2008). A study carried out by Shan et al. 
(2005) showed that there is a direct interaction between Frz and Dvl and 
revealed a previously unknown connection between the membrane-bound 
receptor and downstream components of the Wnt signalling pathways. 
Therefore an inhibitor of the Dvl PDZ domain is likely to effectively block the 
Wnt signalling pathway at the Dvl level (Shan et al. 2005; Zhang et al. 
2009b).
Frizzled-7 (Frz-7), which is 1 of 10 members of Frz family, is reported 
to be over expressed in colon cancer cells, as well as in other cancer types 
such as melanoma, lung cancer and lymphoblastic leukaemia (Ueno et al. 
2009). In normal cells, its expression is very limited. Ueno et al. (2008) had 
revealed that the Frz 7 played a pivotal role as a receptor for canonical Wnt 
signalling pathway and may be important for the invasion and metastasis of 
cancer cells. Later, their data showed that Frz 7 may be a potential 
therapeutic target for cancers associated with aberrant activation of the Wnt 
signalling pathway. Since Frz 7 interacts directly with a PDZ protein 
interaction domain of the Dvl family, disrupting the Frz7-Dvl protein-protein 
interaction represents a promising strategy for cancer therapy (Fujii et al. 
2007).
4.1.2 Small molecule inhibitors of the Wnt signalling pathway.
The development of therapeutics specifically targeting the aberrant Wnt 
pathway in cancer cells is still largely in its infancy. The discovery of the role 
of Wnt signalling pathway as one of the fundamental molecular mechanisms 
in colon cancer has stimulated the search for small molecule inhibitors of the 
Wnt pathway proteins. To date, despite the prevalence of colon cancer in the
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adult population, there is no small molecule approved by the FDA for 
targeted therapy for colon cancers (Chen et al. 2010).
Several approaches are currently being explored in pursuit of these 
selective Wnt pathway inhibitors, such as antibody-based therapeutics (He et 
al. 2004) and viral-based therapies targeting Wnt-addicted cancers (Lipinski 
et al. 2004). However, a number of existing drugs, including NSAIDS (non­
steroidal anti-inflammatory drugs) and Vitamin A/D derivatives also show 
promise in treating Wnt addicted cancers and have the advantage of already 
being in the clinical use for other disorders (Barker & Clevers 2006). Table
4.1 shows some examples of potential small molecule inhibitors of the Wnt 
signaling pathway.
Table 4.1: Small-molecule inhibitors of the Wnt signalling pathway (Barker 
and Clevers 2007).
Name Structure Screening
method
IC50
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*
Integration
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250000
drug-like
compounds
Concentration required to reduce Tcf- p-catenin activilty in 501% colon
cancer cells. CBP, cAMP-responsive element binding protein (CREB) 
binding protein; ELISA, enzyme-linked immunosorbent assay; HTS, high- 
throughput screening; ND, not determined; Tcf, T-cell factor.
Fujii et al. (2007) have showed that inhibiting the PDZ domain of Dvl is 
a potential strategy for the treatment of Wnt-related cancer, as indicated by a 
small molecule inhibitor, FJ9, which is among the first non-peptide inhibitor to 
show therapeutic efficacy through disruption of Dishevelled-PDZ protein- 
protein interactions and currently a lead compound in drug development 
(Figure 4.3).
Figure 4.3: Structure of FJ9, a Frz-Dvl inhibitor (Fujii et al. 2007).
Further initiatives to manipulate the PDZ domain of Dvl for the development 
of novel therapeutic agents of Wnt signalling pathway was later reviewed by 
Wang et al. (2008), where a number of compounds that showed potent 
antagonistic activity on the PDZ domain are outlined below (Table 4.2).
Table 4.2: Antagonists of PDZ protein-protein interactions (Wang et al. 2008).
Target Antagonist Phase of 
development
Roles/Functions
PSD-95 
PDZ2/NMD 
A or nNOS
NA-1 Phase 1 
(Ending 
March 2007)
Treatment of ischemic brain 
damage; in animal toxicity 
studies, NA-1 showed safety 
and tolerability after 
intravenous administration.
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PSD-95 
PDZ2/NMD 
A or nNOS
Flavonoids Lead Flavonoids bind to the PSD-95 
PDZ2 domain.
Dishevelled
PDZ/Frz7
Wnt
receptor
Frz7 peptide 
(GSKTLQSWRR 
YH) 
Dapper peptide 
(SGSLKLMTTV)
Biological
study
In Xenopus embryos, Frz7 (or 
Dapper) peptide attenuates 
Wnt3A-induced canonical Wnt 
signaling
Dishevelled
PDZ/Frz7
Wnt
receptor
NSC-668036 Biological 
study HIT
In Xenopus embryos, NSC- 
668036 inhibits the canonical 
Wnt signaling induced by Wnt- 
3A.
Dishevelled 
PDZ/Frz 7 
Wnt 
receptor
FJ9 Lead Induction of apoptosis in 
human cancer cell lines and 
tumour growth inhibition in a 
mouse xenograft model.
NMDA: A/-methyl-D-aspartate; nNOS: neuronal nitrie oxide synthase.
Recently, Chen et al. (2010) also had listed some of the more current efforts 
for anti-Wnt compounds, as shown in table 4.3 below:
Table 4.3: Recent Wnt signalling active compounds:
Target Agent Activity Structure
Anti­
diabetic
Thiazolidinediones,
harmine
Wnt target 
genes
H /
Harmine
Axin XAV939, IWR Axin
stabilisation, 
tankyrasel and 
2 inhibition.
OH
XAV939
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Blocks Axin 
degradation
IWR-1
c-Met
kinase
Caspase
activation
NSAIDS,
celecoxib,
resveratrol
Suppression of 
Tcf gene 
expression 
B-catenin 
localization
HO—
OH
Resveratrol
p3CV \ _ / = V _
§
o ^ 'O
nh2
Celecoxib
DKK-1 (1-(4-
(naphthalene-2-
yl)pyrimidin-2-
yl)piperidin-4-
yl)methanamine
(NPPM)
Dkk-1 inhibitor
J X
NPPM
Dishevelled Niclosamide 
compound: 3289- 
8625, 3289-5066
Dishevelled 
downregulation. 
Dishevelled 
PDZ domain
3289-5066
Structure of 3289-8925 is 
reported in Figure 4.7.
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Cl OH
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On the other hand, Ewan et al. (2010) have discovered potent small 
molecule inhibitors which showed good activity in their cell-based ass
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(compound CCT031374, CCT036477 and CCT070535) (Figure 4.4). Their 
study is based on the ability of the tested compounds to inhibit their reporter 
cell lines that had an inactive basal TCF-reporter, which could be induced 
later through the activation of Dvl-estrogen receptor fusion protein following 
addition of estrogen. Compound CCT036477 showed the best activity in vivo 
which could present a useful template for further study of compounds 
targeting Wnt signalling pathway.
HN
Me
CCT031374 CCT036477 CCT070535
Figure 4.4: Structures of compounds CCT031374, CCT036477 and
CCT070535.
The ability of NSAIDS to act as potential Wnt signalling inhibitors has 
gained much interest over the past few years. A quite recent study was done 
by Lee et al. (2009), who found sulindac (Clinoril) and its metabolite, sulindac 
sulfone (Figure 4.5) can interact with the PDZ domain of Dvl and suppresses 
Wnt3A induced p-catenin signalling at the Dvl level. Their data suggest that 
sulindac and its metabolite have a potential anticancer property not only by 
their ability to inhibit cyclooxygenase (COX) 1/2 but also by their ability to 
inhibit aberrant canonical Wnt signalling by suppression of the Dvl PDZ 
domain.
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Sulindac
COOH
Sulindac Sulfone
COOH
Figure 4.5: Structure of Sulindac and Sulindac Sulfone
The most recent studies in the area of Wnt signalling inhibitors 
suggested another two series of compounds with potent activities on the Wnt 
signalling pathway. Zhang et al. (2011) have reported a series of fluorinated 
A/,A/-dialkylaminostilbenes as potential Wnt inhibitors. In their study, 
compound 4r (Figure 4.6) showed the best inhibitory activity at nanomolar 
level in the colorectal cancer cell line (LS174) especially at the transcription 
level downstream of p-catenin, and is able to inhibit the growth of human 
colorectal cancer cell xenografts in athymic nude mice. At the same time, 
Waaler et al. (2011) reported another two small molecules, namely JW67 
and JW74 (Figure 4.6) which showed striking inhibitory activities as 
antagonists of the canonical Wnt signalling pathway specifically at the level 
of the destruction complex in colorectal cancer cell line SW480. The 
compounds which were identified from a high-throughput screening on 
reporter cell lines with TCF-responsive promoter were able to reduce the 
level of p-catenin with subsequent downregulation of Wnt target genes 
especially Axin2. Compound JW74 also showed good inhibitory activity in 
vivo by inhibiting the growth of tumour cells in a mouse xenograft model of 
colorectal cancer and inhibited tumour formation and growth in small 
intestine and colon of ApcMin mice which is prone to develop polyposis and 
colon adenocarcinoma due to mutation in one allele of the Ape tumour 
suppressor gene.
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Figure 4.6: Structure of compounds 4r, JW67 and JW74.
4.1.3 Derivatives of 3289-8625 as specific small molecule inhibitors of 
the PDZ domain of Dvl.
Inhibition of Wnt signalling pathway is one of the various approaches used 
nowadays for developing novel cancer drugs. Targeting the PDZ domain of 
Dishevelled (Dvl) is an attractive strategy due to the role of this domain to 
transduce Wnt signals from the membrane receptor Frizzled to downstream 
components. A previous study done by Grandy et al. (2009) has identified 
small drug-like molecule through structure-based ligand screening and NMR 
spectroscopy and showed the compound to interact at low micromolar affinity 
with the PDZ domain of Dvl. This compound (3289-8625) (Figure 4.7) was 
obtained from screening of commercially available databases for its binding 
to Dvl-PDZ domain. The compound was docked to the Dapper peptide 
binding site of Dvl PDZ domain (Protein Data Bank code: IL60) and was 
chosen as one of the potential hits. Further validation of the docking results 
using a 1H-15N correlation NMR study showed that compound 3289-8625 
displayed the most significant chemical shift perturbation when titrated with 
15N-labelled Dvl-PDZ domain that indicated the strong binding affinity of the 
compound towards the protein. At the same time, a Xenopus testing system 
revealed that the compound could inhibit the Wnt signalling pathway by its 
permeability to the cell membrane, and ablity to retard the Wnt signalling 
pathway in the Hyaloid vessel system of the mouse eye that clearly showed 
the compound’s ability to penetrate the membrane of vascular endolthelial 
cells in vivo. The compound is also able to suppress the growth of prostate 
cancer PC-3 cells. All this data highlights the promising therapeutic potential
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of compound 3289-8625, which will provide a useful pharmacophore for 
further modification and structure-activity relationship study of future Wnt 
pathway inhibitors.
Recent studies in Prof. Jie J. Zheng’s laboratory, St Jude Children’s 
Research Hospital, Memphis USA revealed that when the two derivatives of 
3289-8625 (6569188 and 7359885) (Figure 4.8) were subjected to 
fluorescence spectroscopy measurement to measure their binding affinity 
towards the Dvl PDZ domain, the two derivatives showed better binding 
affinity towards the PDZ domain of Dvl compared to the parent compound 
(unpublished data) (Figure 4.9). This finding clearly provides a good basis for 
structure activity relationship studies to further improve the target compound 
specific to inhibit this particular protein.
Figure 4.7: Structure of 3289-8625
6569188 7359885
Figure 4.8: Structures of compound 6569188 and 7359885.
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Figure 4.9: Binding study of compounds 3289-8625, 6569188 and 7359885  
towards the Dvl PDZ domain characterised by fluoresence spectroscopy. 
Graph showing the changing of anisotropy of fluorescence label 2-((5(6)- 
tetramethylrhodamine)carboxyamino)ethyl methanethiosulfonate (TMR)- 
labelled PDZ domain with the increasing concentration of compounds 3289- 
8625, 6569188 and 7359885. (y axis= the fluorescence anisotropy; x axis=
compounds concentrations)
4.1.4 Aim of study
The discovery of 3289-8625 as a potential inhibitor of the PDZ domain of Dvl 
opens opportunities to further manipulate structure activity relationship 
studies towards the development of more potent inhibitors of this series. 
Therefore, this study is aimed to synthesis analogues of 3289-8625, 
especially the one which will combine both compounds 6569188 and 
7359885, and any possible analogues which arise during the synthesis, 
which is anticipated to have better affinity towards the Dvl-PDZ domain and 
to provide useful templates for further chemical optimisation. This work was 
carried out in collaboration with Prof. Jie J. Zheng (St. Judes Children’s 
Research Hospital, Memphis), an expert in Wnt signalling who provided the
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background work and the inspiration for the present studies through 
discussions with our group.
4.2 Synthesis of 3289-8625 analogues: first attempt.
4.2.1 Synthesis of the core benzoic acid derivative containing 5-amino- 
2-chloro-4-methyl substitution and possible analogues
The most crucial step in the synthesis of the target derivatives was the 
synthesis of the middle core benzene ring structure of the target compound, 
which consists of substitution with 5-amino, 2-chlorine and 4-methyl groups 
(compound 51 and 52). The syntheses of the key compounds were achieved 
following three main steps as outlined in Figure 4.10 below:
i) Esterification of the benzoic acid using methanol
ii) reduction of methyl 2-methyl-5-nitrobenzoate to 5-amino-2-methyl- 
benzoic acid methyl ester
iii) chlorination of the benzoate with /V-chlorosuccinimide (NCS)
(51): R1 = H;R 2  = CI
(52): R-| = Cl; R2  = H
H2N OCH3  N-Chlorosuccinimide
OH
CH3 CN/DMF, reflux, 48 h h3C
MeOH, TMSCI
relux, 5 h
(50a)
(50b)
Figure 4.10: Synthesis of methyl 3-amino-4-methylbenzoate chlorinated 
analogues (compound 51 and 52).
To start the synthesis, commercially available 4-methyl-3-nitro- 
benzoic acid was chosen as the starting material on a small scale (1g). The
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aim was to synthesise the correct key compound first, which later can be 
expanded to synthesise of the desired compound on a larger scale.
The first step involved the esterification of 4-methyl-3-nitro-benzoic 
acid to methyl 4-methyl-3-nitrobenzoate (50a) in order to protect the hydroxyl 
group of the benzoic acid, using chlorotrimethylsilane (TMSCI) in methanol at 
reflux for 5 hours. After the workup, crude brown solid was formed. 
Purification of the product was achieved by using acid-base extraction to 
remove traces of unreacted benzoic acid gave the pure compound in good 
yield (71%). The appearance of a singlet on 1H-NMR spectra at 5 3.98 ppm 
provides evidence for the formation of the methyl ester.
The next step involved the reduction of (50a) to 3-amino-4-methyl- 
benzoic acid methyl ester (50b) under hydrogen (atmospheric pressure) in 
the presence of palladium on carbon [Pd(C)] in ethyl acetate at RT. The 
reaction was carried out for 24 hours. After the workup, the purification of the 
crude mixture using column chromatography gave the pure compound 50b in 
good yield (86%). The reaction using this method proved to give a clean 
reaction indicated by TLC with only a slight trace of unreacted starting 
materials detected. The target compound is evidenced by the appearance of 
a broad singlet at around 5 4.2 ppm for the amino group, and most 
importantly, by an up-field shift of all the aromatic protons (from 6 7.45-7.63 
ppm of the nitro-precursor to 5 7.13-7.43 ppm of the amino product).
The third step that was the most important step involved the 
chlorination of the benzoate 50b with A/-chlorosuccinimide (NCS), which is a 
more convenient reagent for aromatic chlorination compared to chlorine or 
sulfuryl chloride. The first attempt involved the reaction of the benzoate 50b 
with 1.5 equivalents of NCS in /V,/V-dimethylformamide (DMF) following the 
method described by Altenbach et al. (2004). After heating at reflux for up to 
60 hours and following standard work-up of extraction with ethyl acetate and 
washing with brine, further purification using column chromatography only 
gave starting material as the main compound with only slight traces of 
compound 51 (methyl 5-amino-2-chloro-4-methyl benzoate) which cannot be
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easily separated from the starting material, while compound 52 (methyl 3- 
amino-2-chloro-4-methyl benzoate) which was eluted first was afforded in 42% 
yield. This attempt highlights the failure of this method, where the desired 
compound 51 could not be isolated in pure form.
A further attempt was sought, this time by using the method described 
by Davis (2009) that uses acetonitrile as the solvent of choice. Compound 
50b was heated in acetonitrile at reflux using 1.05 equivalents of NCS for 48 
hours, giving crude compound which needed further purification using 
column chromatography (hexane: ethyl acetate = 7:1). Compound 52 was 
eluted first in 43% yield, followed by mixtures of mostly compound 52 and a 
slight traces of starting material 50b in around 32% yield. This was closely 
followed by the elution of unreacted starting material 50b in 4% yield, before 
the elution of the last desired compound 51 in 20% yield. These entire 
compounds were confirmed by looking at 1H-NMR. For compound 51, the 
appearances of 2 distinct singlets at the aromatic region were evidence of 
the structure of the desired compound. Compound 52 showed two doublets 
with the coupling constant value (J value = 8.0 Hz) which clearly indicate the 
position of the protons which are ortho to each other.
The results clearly showed that the most favourable position for 
chlorination was the ortho position to amine and ester groups giving 
compound 52 in moderate yield. Nevertheless, the desired compound 51 
was successfully obtained in low yield. At this stage, the chlorination method 
of 50b using 1.05 equivalents NCS in acetonitrile was chosen as a suitable 
method for this reaction, giving compound 51 and 52 in low to moderate yield 
which will be used for further coupling reactions. The results of the 
chlorination procedure is summarised in Table 5.4.
Table 5.4: Summary of chlorination procedure of compound 50b using NCS.
Reaction condition Compounds afforded Yield (%)
NCS (1.5 equivalent), 
DMF RT, 60 h
52 42
Mostly starting material mixed with 56
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minor traces of 51
NCS (1.05 equivalent), 
MeCN, reflux, 48 h
52 43
Mixtures of mostly compound (52) 
with minor traces of 50b
32
Unreacted starting material (50b) 4
51 20
The next part of the synthesis was dedicated to the synthesis of desired 
compound 54 and its analogues 55 using the previously afforded compounds 
51 and 52. The main work involved the formation of amide bond between 
different benzene and aniline building blocks. The overall strategy for the 
synthesis of compounds 54 and 55 is outlined in Figure 4.11 below:
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cnc
(54b): Ri = H, R2 = Cl 
(55b): Ri = Cl, R2 = H
Pathway (A)
Zn (dust),
OCH3 THF, 70°C H3CO
+
h2n
Ri O
y V ' o c h3
H3C ^ i^ R 2
(51): R1 = H, R2 = CI
(52): Ri = Cl, R2 = H
e r f
Et3N, CH2CI2 
RT
OCH-j
(51a): Ri = H, R2 = Cl 
(52a): Ri = Cl, R2 = H
Pathway (B) 
oxalyl chloride, CH2CI2 OHCl
DMF (cat)., 18 h
H3CO (51b): Ri = H, R2 = Cl 
(52b): Ri = Cl, R2 = H
(51c): Ri = H, R2 = Cl 
(52c): Ri = Cl, R2 = H
Et3N, CH2CI2 
RT
Pathway (C) 
CDI, DMF, RT
(54b): Ri = H, R2 = Cl 
(55b): Ri = Cl, R2 = H
LiOH 
THF/H20  
72 h
(54): Ri = H, R2 = Cl
(55): Ri = Cl, R2 = H
Figure 4.11: Strategy to synthesise compound 54 and 55.
4.2.2 Synthesis of compound 51a (methyl 2-chloro-4-methyl-5-[2- 
phenylacetamidojbenzoate and its analogues 52a via amide bond 
formation
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The next step involved amide bond formation between the amino group of 
the benzoate and phenyl acetyl chloride as the benzene counterpart. The 
reaction is quite straightforward due to readily activated nature of the acyl 
chloride group on phenyl acetyl chloride which can be readily reacted with 
the amino group to form amide bond. Compounds 51 and 52 were subjected 
to reaction in triethylamine as the base and dichloromethane as the solvent 
at room temperature for 18 hours. Purification of compound 51b was quite 
straightforward, as recrystallisation of the crude solid (in methanol/water) 
afforded the pure compound in 50% yield. Compound 52b needed to be 
purified by column chromatography and was difficult to separate, as many 
spots of impurities/side products were seen under TLC. The crude 
compound needed further purification using column chromatography 
(dichloromethane: methanol). Further recrystallisation of the product in 
hexane:ethyl acetate afforded the pure compound 52b in 33% yield. The 
overall reaction procedure manages to give compound 51b and 52b in 
moderate yield. This may be due to the base used (triethylamine) which 
could have unselective attack at the benzoate 51 and 52, or the reaction of 
compound 51 and 52 with themselves which could raise the formation of side 
products.
4.2.3 Attempts to synthesise of compound 54 [2-(2-chloro-4-methyl-5- 
(2-phenylacetamido)benzamido)benzoic acid] and its analogues 
(55)
The next step involved the formation of another amide bond between the 
methyl ester (51b and 52b) and methyl anthranilate. The reaction between 
the ‘inactive’ methyl ester with aniline was tested first before any attempt to 
‘activate’ the methyl ester. There was only very few methods that reported 
the formation of amide bond via these pathway, among them are the use of 
zinc dust (Arora et al. 2005) and the formation of bislithium amide (Ooi et al. 
1999). But as the reactivity of the bislithium amide is unknown, the method 
that involved the formation of amide bond between aniline and ‘inactive’ 
methyl ester in the presence of zinc (dust) at 70 °C was chosen as it was 
shown to be convenient and had great synthetic utility (Pathway A) (Figure
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4.12). Unfortunately, even after 48 hours of heating, only starting material 
can be detected in the reaction mixture without any sign of product formation. 
At this stage, the method failed to give any product formation, which gave no 
option rather than to proceed with the activation of methyl ester.
Pathway (A)
Figure 4.12: Attempts to synthesise 54b and 55b via pathway A.
A more straightforward approach was to hydrolyse the methyl ester 
group to carboxylic acid. A few approaches were tested using mild 
alkali/bases; (a) lithium hydroxide in methanol:water, (b) lithium hydroxide in 
THF:water and (c) sodium hydroxide in methanol:water but all showed only 
traces of more polar product formation even after 24 hours of stirring at RT. 
But by prolonging the reaction procedure of method (b) for up to 72 hours at 
RT finally showed the formation of the desired compound by TLC (Figure
4.13). This may be due to the methyl esters only dissolving in organic phase 
but not/partially dissolved in aqueous phase and that slowing down the 
formation of the benzoic acid. Upon completion of the reaction, the reaction 
was evaporated to remove methanol, followed by extraction of the aqueous 
layer with dichloromethane to remove possible unreacted methyl ester. 
Further acidification of the aqueous layer with 1N hydrochloric acid and 
extraction with dichloromethane, afforded the pure hydrolysed product in 
good yield (82% and 78% for compound 51b and 52b respectively). The 
formation of compound 51b and 52b was confirmed by 1H-NMR, where the 
disappearance of methoxy peak and the rise of a single broad hydroxyl peak 
at around 513.0 to 13.5 ppm are indicative of the correct compounds.
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H X
H
i T Y ^ i r NY ^ i  0CH3
LiOH, THF/H20
f i3C ' ' ' ^ ^ R 2 72 h, RT
(51a): R, = H, R2 = Cl (51b): Ri = H, R2 = Cl
(52a): Ri = Cl, R2 = H (52b): Ri = Cl, R2 = H
Figure 4.13: Hydrolysis procedure of compounds 51a and 52a.
The next step involved the formation of amide bond between 
compound 51 b and 52b with methyl anthranilate (methyl 2-aminobenzoate). 
There are a number of strategies have been reported for amide bond 
formation, as extensively reviewed by Montalbetti and Falque (2005). The 
most popular and easiest one is the formation of acyl halides to activate the 
acid, or the use of coupling reagents such as carbonyl diimidazole (CDI) and 
carbodiimide. But since the aniline (methyl anthranilate) that is going to be 
used in the next step was predicted to be less reactive due to the presence 
of a methyl ester substitution at the ortho position of the aniline, the 
conversion of the benzoic acid to acyl chloride was chosen as the preferred 
method for coupling to amine. Methyl anthranilate was considered a low 
reactivity aniline due to the lone pair of the amino group which can be 
delocalized in the benzene ring, and most importantly, due to the existence 
of the electron withdrawing group at the ortho position of the amine, which 
can direct the lone pair of amine group towards itself, thus will dramatically 
reduce the nucleophilicity of the methyl anthranilate to efficiently react.
Due to restriction of the available amounts of compound 51 b (around 
0.18 mmol/0.05 g) and 52b (around 0.19 mmol/0.06 g), the next approach of 
amide bond formation via acyl chloride intermediate formation was tested 
first on compound 51b (Pathway B) (Figure 4.14). The chlorinating agent 
chosen for this particular reaction is oxalyl chloride, where anhydrous 
tetrahydrofuran (THF) was used as the solvent under inert atmosphere 
together with a catalytic amount of DMF to accelerate the reaction. Thionyl 
chloride was not chosen for this reaction due to the need for heating which 
might be incompatible to other functionalities in 51b, especially the 
previously formed amide bond. After 18 hours, the TLC of the reaction
C h a p t e r  4 : I n h i b i t o r s  o f  D i s h e v e l l e d - P D Z  d o m a i n  1109
indicated the formation of various spots, with possibly no detectable 51b 
trace, thus indicated that the reaction might have gone to completion with the 
formation of side products. Nevertheless, the reaction was stopped and the 
solvent evaporated. The reaction mixture was used straight away in the next 
step, which involves the formation of amide bond. This time, potassium 
carbonate was chosen as base in anhydrous THF at RT. After 18 hours of 
stirring, the TLC again showed formation of various spots. As at this stage it 
was unknown whether the correct acyl chloride had been synthesised 
previously due to the uncertain 1H-NMR of the acyl chloride, and the 
formation of the side products which might be due to the degradation of the 
starting material was already predicted. The use of a small quantity of 
starting material (0.18 mmol) for a reaction which might not run to completion 
and would lead to potential side products was also seen as a big challenge. 
An attempt to separate the pure compound in hexane:ethyl acetate was 
unsuccessful, as the characterisation of the afforded fractions were very hard 
to make and none of them indicated the possibility of the formation of 
compound 54b. At this stage, the conclusion whether the method is 
applicable to synthesis of compound 54b cannot be made, and the question 
whether the right acyl chloride intermediate have been synthesised also 
need to be considered thus highlighting the need to find better conditions to 
synthesise the acyl chloride intermediates.
Pathway (B)
OH oxalyl chloride, THF
DMF (cat)., 18 h H3CO
(51c): Ri = H, R2 = Cl(51b): Ri = H, R2 = Cl
(54b): Ri = H, R2 = Cl
Figure 4.14: The formation of 54b from 51b via 51c (Pathway B).
C h a p t e r  4 :  I n h i b i t o r s  o f  D i s h e v e l l e d - P D Z  d o m a i n  1110
Therefore, due to the uncertainty of the methods in Pathways A and B, 
another method was sought which used carbonyl diimidazole (CDI) as a 
coupling reagent for compound 52b with methyl anthranilate (Pathway C) 
(Figure 4.15). CDI was chosen as it allowed one-pot amide formation; 
without requiring the activation of any base. The reaction was done by simply 
adding CDI to compound 52b in anhydrous DMF. The reaction was stirred 
for at least 1 hour, to allow the formation of acylimidazole intermediate, 
before the addition of amine. As expected, reaction with methyl anthranilate 
was quite slow due to the inactive nature of the aniline itself, and even at the 
termination of reaction at 96 hours, the starting material can still be detected 
in the TLC. The crude reaction mixture was further purified using column 
chromatography, and the target compound was obtained and confirmed by 
1H-NMR in less than 3 mg and in poor purity. At this stage, amide bond 
formation via Pathway C with methyl anthranilate was seen as less 
successful due to formation of compound 55b in a very low yield (8% of 
impure compound) and poor purity, thus requiring further purification. At this 
stage, Pathway C was seen as a less attractive method for amide bond 
formation for this particular compound. This highlights the need to find a 
better method which can give a higher yield and better purity. Unfortunately, 
no starting material (compound 51b and 52b) was left to further test other 
method.
Pathway (C) 
CDI, DMF, RTOH NB
(52b): R-i = Cl, R2 = H (55b): Ri = Cl, R2 = H
Figure 4.15: Amide bond formation via pathway C.
As a conclusion, the synthesis of all target compounds at this stage 
failed. It was anticipated that a larger quantity of starting materials and some 
modification of the synthesis strategy would improve the overall reaction 
procedure and accessibility of the final compounds.
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4.3 Synthesis of 3289-8625 analogues: Second attempt.
The first attempt towards the synthesis of analogues 3289-8625 highlighted a 
few problems. The most obvious one is the problem with the reactivity of 
methyl anthranilate which requires good activating intermediates at the 
carboxylic acid counterpart to force the reaction to completion in a 
reasonable yield and good purity. At this stage, the formation of acyl 
chlorides intermediates was still seen as the best approach provided that the 
right acyl chloride is obtained. In view of this, the second attempt to 
synthesise these analogues was dedicated towards another pathway which 
involves the formation of the core benzene ring primarily attached with acyl 
chloride before being coupled with methyl anthranilate. This approach will 
provide greater possibility to synthesise the correct acyl chloride to ensure a 
more efficient method for amide bond formation with unreactive methyl 
anthranilate. The acyl chloride is also expected to be inert and stable enough 
to give a similar result as the methyl benzoate in the chlorination step using 
NCS. The synthesised amide bond between methyl anthranilate and the 
benzoyl chloride should also withstand the reduction reaction of nitro to 
amine using hydrogen gas and palladium on carbon as showed by Shen et 
al. (2007). The advantage of this approach would be to reduce the number of 
steps required to synthesise the final compound. The proposed reaction 
strategy is outlined in Figure 4.16 below:
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h3c ^ ^ x i
(50d)
H3CO^O
Et3N, CH2CI2 
RT
0 2N
h3c
i3c  ^  ci c r  'o c h 3
(54b)
LiOH 
THF/H20  
72 h
Et3N, CH2CI2 
RT OT *:
v?
Cl o ^ o c h 3
H2i Pd(C) 
EtOAc, RT
V5?
Cl o ^ o c h 3
Figure 4.16: Proposed reaction procedure for second attempt
In order to achieve this, the starting material used (4-methyl-3-nitro- 
benzoic acid) would need to undergo acyl chloride formation first, using the 
same method to synthesis compound 51c using oxalyl chloride in 
dichloromethane with the addition of catalytic DMF (Figure 4.17) to produce 
compound 50c (4-methyl-3-nitro-benzoyl chloride. Compound 50c was 
obtained in good yield (93%).
OH
oxalyl chloride, CH2CI2 0 2N
DMF (cat.), 0 °C to RT H3C'
50c
AFchlorosuccinimide 0 2N
CH3CN, reflux, 48 h
50d
Figure 4.17: Attempt to synthesise compound 50d via compound 50c.
Compound 50c was straight away subjected to the chlorination 
reaction using NCS in refluxing acetonitrile as previously mentioned for 
compound 51 and 52. Unfortunately, after 48 hours of heating, no product 
formation can be detected by TLC. This indicated that no chlorination
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reaction has occurred, where the benzoyl chloride might simply not react 
under these reaction conditions or might have undergone degradation due to 
its instability in the reaction condition. Increasing the load of the NCS used 
(from 1.05 to 2 equivalents) and prolonging the reaction time to 70 hours did 
not improve the reaction outcome.
This finding indicating the failure of the proposed method to give the 
desired compound thus highlights the need to find a better method to 
synthesise 3289-8625 analogues. This finding also suggested that the 
protection of benzoic acid starting material by esterification is still the best 
option which will allow further manipulation of reaction condition.
4.4 Synthesis of 3289-8625 analogues: Third attempt.
The third attempt of the synthesis of this analogues follow exactly the 
previous route described to synthesise compound 51 and 52 (in first attempt), 
with a few modifications made for the following amide bond reaction 
condition to improve the reaction outcomes. Compound 51 and 52 were 
synthesised first and afforded in a similar yield to previous attempts. This 
shows that the chlorination reaction is reproducible for this kind of compound. 
The overall proposed reaction conditions for the third attempt are outlined in 
Figure 4.18.
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Ri O
H2^ ° ch 3 +
h 3c r2 cnr” KaPQ4
51: R-t= H; R2= Cl 
52: R1= Cl; R2= H
54b: R-,= H; R2= Cl 
55b: R-|= Cl; R2= H
LiOH
MeOH/H20
reflux
THF, RT
OCH3
51a: R-|= H; R2= Cl 
52a: R-,= Cl; R2= H
LiOH
MeOH/H20
reflux
OH
(a), (b)or(c)
51b: R-,= H; R2= Cl 
52b: R-,= Cl; R2= H
54: R-,= H; R2= Cl 
55: Ri= Cl; R2= H
(a) (i) (COCI)2, THF, DMF (cat.), RT; or (ii) SOCI2, toluene, DMF (cat.), RT; 
or (iii) SOCI2, reflux; or (iv) (COCI)2 , 1,2-dichloroethane, DMF (cat.), RT; 
then K3 PO4 , THF, RT
(b) PPh3, DDQ, CH2 CI2, RT
(c) CH3 S 0 2 CI, Et3 N, THF, RT
Figure 4.18: Proposed reaction condition for third attempt.
After the successful reaction to synthesise compounds 51 and 52, 
both isomers were subjected to amide bond formation using a method 
described by Zhang et al. (2009), utilizing potassium phosphate (1.25 
equivalents) as base in anhydrous THF under inert atmosphere. The method 
was described as simple, mild and highly efficient giving the desired 
compound in good to excellent yield. Potassium phosphate as a cheap and 
simple inorganic base is superior to other commonly used base, such as 
triethylamine and sodium hydroxide as it greatly minimizes unwanted side
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reactions such as hydrolysis and racemisation which usually occur during 
amide formation with acyl chlorides. Both amide bond formations using 
compound 51 and 52 were completed within 18 hours of stirring at room 
temperature. This method proved to be mild, high yielding and showed only 
slight traces of impurities by TLC, which allowed the crude product 51a and 
52a to be used straight away in the next hydrolysis reaction without the need 
for further purification.
The previous method described for hydrolysis of the methyl benzoate 
51a and 52a involves the reaction using lithium hydroxide in methanol/water 
for 70 hours at room temperature. Nevertheless, some modification was 
made to the previously described method where this time heating at reflux is 
applied, where lithium hydroxide was still used as a mild base/alkali in 
methanol/water solution. Delightfully, the desired carboxylic acid was 
detected within 3 hours by TLC. It showed that the heat helped the 
dissolution of the methyl esters in the solvent system which helped to 
accelerate the overall reaction. Upon completion of the reaction, the solvent 
was evaporated to remove methanol, followed by extraction of the aqueous 
layer with dichloromethane to remove possible unreacted methyl ester. 
Further acidification of the aqueous layer with 1N hydrochloric acid and 
extraction with dichloromethane, the pure hydrolyse product was afforded in 
good yield (71% and 69% for compound 51b and 52b respectively). So far, 
the modifications applied to improve the reaction outcome of amide bond 
formation and hydrolysis were successful.
The last and the most crucial part of the third attempt is the formation 
of another amide bond between the methyl anthranilate and compound 51b 
and 52b. For the first approach, formation of acyl chloride intermediate was 
sought (Figure 4.19). For this purpose, four different reaction conditions were 
tested:
i) Oxalyl chloride in anhydrous THF with catalytic DMF at room 
temperature
ii) Thionyl chloride in anhydrous toluene with catalytic DMF at room 
temperature.
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iii) Thionyl chloride at reflux
iv) Oxalyl chlorides in anhydrous 1,2-dichloroethane with catalytic 
DMF at room temperature
i) (COCI)2l dry THF, DMF (cat.), RT
ii) SOCI2, dry toluene, DMF (cat.), RT
iii) SOCI2, reflux
iv) (COCI)2, dry 1,2-dichloroethane, 
DMF (cat.), RT OH
51b: R-|= H; R2= Cl 
52b: R-)= Cl; R2= H
51c: R-j= H; R2= Cl 
52c: R,= Cl; R2= H
K3 P O 4  V
THF, RT
54b: R-,= H; R2= Cl 
55b: R-|= Cl; R2= H
Figure 4.19: Attempts to synthesise compounds 54b and 55b via acyl
chloride intermediate.
Although theoretically, all the methods should be able to generate the same 
acyl chlorides, the findings showed that the method (i) and (iii) failed to give 
the desired intermediates by 1H-NMR determination and TLC. These may 
indicated that THF is a less effective solvent for this reaction and heating 
causes deleterious effect to the previously synthesized compound 51b and 
52b. Where else, the use of toluene or 1,2-dichloroethane as solvents either 
with thionyl chlorides or oxalyl chlorides at room temperature gave better 
formation of acyl chlorides 51c and 52c with define and clearly interpreted 
1H-NMR spectra, as proved by the disappearance of the hydroxyl group of 
51b and 52b. Compound 51c and 52c were used straight away in the next 
amide bond formation with potassium phosphate and THF at room 
temperature. Unfortunately, even after prolonged stirring for up to 50 hours 
no reaction had occurred. This indicated that the reaction had failed to give
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any product, and formation of acyl chlorides intermediate was not sufficient 
to activate the methyl anthranilate for successful reaction.
Due to the failure of the acyl chlorides approaches to allow the amide 
bond formation with methyl anthranilate, another method was sought using 
triphenyl phosphine (PPh3) and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) 
which act as an excellent dehydration system due to their ability to eliminate 
water from the reacting molecule, in dichloromethane at room temperature, 
as described by Iranpoor et al. (2009) (Figure 4.20). The use of DDQ is 
preferred due to its high reactivity and good selectivity towards desired 
product. The method was claimed to be very rapid, neutral and mild without 
the need for any base, giving the amide bond in excellent yield. The method 
is said to be applicable to use in aromatic amine and aromatic or non- 
aromatic carboxylic acid. Nevertheless, when compound 52b was subjected 
to reaction using this method, no product formation can be detected even 
after 48 hours of stirring at room temperature. This may be due to the less 
reactive nature of the methyl anthranilate which was very difficult to activate 
using this particular method.
h 2n
OH
51b: R-,= H; R2= Cl 
52b: R-|= Cl; R2= H
54b: R i= H; R2= Cl 
55b: R-,= Cl; R2= H
Figure 4.20: Attempt to synthesise compounds 54b and 55b via activation
using PPh3 and DDQ.
Following the failure of attempted methods either using the acyl 
chloride intermediate or using PPh3 and DDQ to make the second amide 
bond formation, another method was sought, this time using a procedure 
described by Shen et al. (2007), which used 3 equivalents of
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methanesulfonyl chloride (MsCI) as a reagent in the presence of 
triethylamine (3 equivalents) as base in anhydrous THF (Figure 4.21). 
Theoretically, the mesylate intermediate is commonly used to activate an 
alcohol instead of carboxylic acid. The proposed reaction mechanism for this 
particular reaction is by the production of mesylate intermediate which can 
act as a good leaving group for further coupling reaction to occur (Figure 
4.22).
OH
51b: R-i= H; R2= Cl 
52b: R-|= Cl; R2= H
54b: R-|= H; R2= Cl 
55b: R-!= Cl; R2= H
Figure 4.21: Synthesis of compounds 54b and 55b using MsCI.
Organic layerAqueous layer
Figure 4.22: The proposed reaction mechanism for the formation of amide 
bond via the formation of mesylate intermediate from carboxylic acid.
Surprisingly, after 20 hours of stirring at room temperature for 
reactions containing compound 51 b and 52b, TLC analysis showed the 
formation of an additional spot which might indicate the formation of the
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desired products, together with appreciable spots of starting materials which 
still can be detected. Prolonged stirring of the reaction mixtures for up to 72 
hours did not improve the outcomes. Nevertheless, the reactions were 
stopped and upon aqueous work-up, the crude products still needed to 
undergo purification procedure using column chromatography in 
dichloromethane: methanol (98:2) to afford the desired products in good 
identical yield and purity (73% for both compounds 54b and 55b 
respectively). The findings indicated that the formation of mesylate 
intermediates were able to activate the less reactive methyl anthranilate 
which can drive the amide bond formation reaction to completion and in good 
yield.
The last step involved the hydrolysis reaction of compound 54b and 
55b to afford the carboxylic acid derivatives of final compound 54 and 55. As 
described earlier for the synthesis of compound 51b and 52b, both the 
methyl ester 54b and 55b were reacted with lithium hydroxide in refluxing 
methanol/water for 3 hours. Upon the work-up, the final compounds were 
afforded in good yields (72% for compound 54 and 74% for compound 55). 
The afforded compounds were further evaluated for their binding affinity with 
the PDZ Dvl binding affinity using the NMR perturbation method.
4.5 Characterization of binding and inhibitory ability of compounds
54b, 55b, 54 and 55 towards Dvl PDZ domain
The next part of the study was dedicated to test the ability of compounds 54 
and 55 and their methyl ester counterparts (compound 54b and 55b) for their 
ability to bind to the PDZ domain of Dvl. The study was carried out by the 
group of Prof. Jie J. Zheng, St. Jude Children Research Hospital, Memphis, 
USA, as part of an ongoing research collaboration. The first part of the test 
was dedicated to evaluate the binding affinity of the compounds towards the 
Dvl PDZ domain by using NMR spectroscopy via a chemical shift 
perturbation experiment. The results of the experimants are shown in Figure 
4.23. In order to do these, 15N-labelled Dvl-PDZ domain (residues 247-341 of
C h a p t e r  4 : I n h i b i t o r s  o f  D i s h e v e l l e d - P D Z  cl o m a i n 1120
mouse Dvl1) were used as ligand. Compound 54 and 55 were titrated 
individually in various concentrations into samples of the liqand and the
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Figure 4.23: (Top) Interaction betweeen compound 54 and 55 with the Dvl 
PDZ domain. The data showed the 15N-HSQC spectra of free PDZ domain 
(black)and PDZ domain with increasing concentrations of compound 54 and 
55 (red, green, blue, yellow and pink, protein:ligands ratios of 1,3,5,7 and 11 
equivalents); e.g. for red, PDZ domain with 1 equivalent of compound 54/55. 
(Bottom) Graph showing the changing of fluorescence anisotropy of TMR- 
labelled Dvl PDZ domain with increasing concentration of compounds 54 and 
55. (Y axis = the fluorescence anisotropy; X axis = compounds 
concentrations).
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interactions were monitored by 1H/15N heteronuclear single-quantum 
coherence nuclear magnetic resonance (1H/15N-HSQC NMR). Unfortunately, 
compound 54b and 55b although soluble in DMSO, were not dissolved in the 
sample buffer which did not allow further testing. The binding of compound 
54 and 55 to Dvl PDZ domain were verified using NMR spectroscopy. Their 
results were compared to a previous reported comprehensive study of 
compound 3289-8625 (Grandy et al. 2009). The chemical shift perturbation 
study of both compounds showed stronger binding affinity towards the Dvl 
PDZ domain compared to compound 3289-8625 or even with the naturally 
occurring membrane bound protein Dapper or Frizzled. This observation 
indicated the possibility of more potent Dvl PDZ inhibitory potential of 
compounds 54 and 55 to the parent compound 3289-8625.
To further confirmed the inhibitory potential of compound 54 and 55, 
fluorescence anisotropy study to calculate the binding affinities of compound
54 and 55 to the Dvl PDZ domain were carried out. The study involved the 
titration of compound 54 and 55 into a solution of fluorescence label 2-((5(6)- 
tetramethylrhodamine)carboxyamino)ethyl methanethiosulfonate (TMR)- 
labelled PDZ domain. The determination of the binding affinity of the 
inhibitors 54 and 55 were done by measuring the anisotropy change due to 
ligand binding to the Dvl PDZ domain. The fluorescence based data showed 
that the measured binding affinity (Kd) of compound 54 was 3.9 pM while 
compound 55 exhibited an equivalent Kd value of 3.2 pM. The data 
generated from the study showed more than 3 folds better binding affinity 
results as compared to the parent compound 3289-8625 (Kd = 10.6+1.7 pM) 
and the naturally occurring Dvl PDZ inhibitor Dapper peptide (Kd= 11.6+1.4 
pM) (Grandy et al. 2009).
The data generated from this study suggested that compound 54 and
55 might have better binding and inhibitory ability to Dvl PDZ domain 
compared to the parent compound 3289-8625 and Dapper peptide. The 
compounds can serve as a useful pharmacophore to study the structure 
activity relationship of this inhibitor series towards the Dvl PDZ domain. A
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more detailed in vivo and in vitro study should also be carried out to further 
validate the anti-Wnt inhibitory activity of these particular compounds.
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CHAPTER 5
TOWARDS THE SYNTHESIS OF 7RAA/S-STILBENE ANALOGUES AS 
POTENTIAL PET RADIOTRACERS
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CHAPTER 5 
TOWARDS THE SYNTHESIS OF 7RANS-STILBENE ANALOGUES AS 
POTENTIAL PET RADIOTRACERS 
5.1 Introduction
5.1.1 Non-invasive techniques in Alzheimer’s disease imaging.
Alzheimer’s disease (AD) is a brain disorder associated with progressive 
memory ioss and decrease of cognitive function (Zhang et al. 2005c). p- 
amyloid (AP) aggregation in brain is the prime suspect as the primary cause 
of AD. Histopathological studies done on post mortem analysis of AD 
sufferers revealed that extensive cortical amyloid-beta depositions were 
detected, although the exact role of amyloid plaques in the onset of dementia 
and AD is still controversial (Kung et al. 2010). To date, the only way to 
accurately diagnose AD is by microscopic detection of beta-amyloid plaques 
and neurofibrillary tangles at brain autopsy during post mortem (Pat et al. 
2010, Wong et al. 2010). In vivo neuroimaging of Ap plaque would be a non- 
invasive method for early diagnosis of AD and development of treatment 
strategies (Qu et al. 2007). Non-invasive techniques such as positron 
emission tomography (PET) and single photon emission computed 
tomography (SPECT) allow the detection of deposited Ap and could enable 
the diagnosis of AD in its presymptomatic stages. Therefore, it is necessary 
to develop probes for PET and/or SPECT with a high affinity for Ap plaques 
(Chen 2006) which may serve as suitable markers for monitoring the amyloid 
formation following the disease progression and for observing the outcomes 
of therapeutic intervention (Zhang et al. 2005c).
5.1.2 Development of 18F-stilbenes as PET imaging agents for 
detecting Ap plaques
During the last few years, there have been a number of stilbene derivatives 
that have been developed as potential tracers for detecting the amyloid
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plaques (Zhang et al. 2005b; Zhang et al. 2005c; Zhang et al. 2007; Qu et al. 
2007; Parhi et al. 2008; Hong et al. 2010). As reviewed by Kung et al. (2010), 
the rigid structure of stilbene, which has a highly conjugated aromatic system 
and is relatively planar, can bind specifically in between the p-sheets of the 
amyloid beta aggregates.
One stilbene-based radiotracer, 18F-BAY94-9172, has shown good 
binding affinity to the Ap plaques in patients and is able to discriminate 
between Alzheimer’s disease and frontotemporal lobar degeneration in 
patients or healthy controls (Rowe et al. 2008). The agent had shown similar 
specificity and characteristics to the most specific and commonly used PET 
Ap ligand, 11C-PIB (Pittsburgh compound B; 2-[4’-(rnethylamino)phenyl]-6- 
hydrobenzothiazole) (Kung et al. 2010) (Figure 5.1). Both are considered as 
small planar molecules with extended aromatic rings and alkyl-amino 
substitution. 18F-BAY94-9172, which is also known as Florbetaben and 
currently being developed by Bayer Healthcare Pharmaceutical Inc., have 
successfully completed phase II clinical trial with the ultimate goal of using 
PET imaging agent to correlate the Ap-plaque burden in living human brain. 
An international Phase III clinical trial is currently underway (Pat et al. 2010). 
Another stilbene-based PET radiotracer, 18F-AV-45 (Flobetapir F 18) (Figure 
5.1) which is developed by Avid Radiopharmaceuticals, Inc. is currently in 
Phase III clinical trial with ultimate goal to image Ap-plaque in living humans 
(Wong et al. 2010). The interim data showed that Flobetapir PET imaging 
results in patients nicely correlated with the levels of Ap-plaque pathology 
later found in their brains at autopsy.
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isF
F-Flobetapir
F-Florbetaben
HO'
C-PIB
Figure 5.1: Chemical structures of 18F-Flobetapir, 18F-Florbetaben and
11C-PIB.
5.1.3 Fluorine-18 as a facile source for the synthesis of PET imaging 
agents
There are a number of compounds that have been developed as PET and 
SPECT ligands targeting Ap plaques, mainly using carbon-11 as their 
labelling precursor (Figure 5.2). Unfortunately, the 20 minutes radioactive 
decay half-life of 11C represents major limitations on the use of 11C-labelled 
compounds. The very short radioactive half-life needs an on-site cyclotron for 
the 11C-labelled compound synthesis and therefore, reliable 11C- 
radiochemists. This will restrict routine clinical use of the 11C-labelled 
compounds and subsequently increase the cost of the studies (Rowe et al. 
2008). Therefore, a tracer for imaging Ap plaques that can be labeled with 
longer-lived isotopes is preferred. Table 5.1 showed the examples of various 
PET isotopes that have been developed for labeling molecules used for 
targeting the Ap-plaques.
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Congo Red 0=^-0 Thioflavine
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Chrysamine G
HO OH
HO'
COOHHOOC C-PIB
HO OH 125|
HOOC COOHX-34 TZDM
HO OH 125|
MeO-X-04 IMPY
B) Molecular scaffolds generated from 
Thioflavine T
A) Molecular scaffolds generated from Congo Red
m-l-stilbene BF-227
CNHO.
CN
NI AD-4FDDNP
C) Miscellaneous molecular scaffolds
Figure 5.2: Examples of different amyloid imaging agents derived from 
various molecular scaffolds (taken from Nilsson 2009).
Table 5.1: PET isotopes for nuclear imaging.
Isotope Half-life
124| 4.17 d a y s
14.74 h
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Cu 12.7 h
“ Ga 9.4 h
18F 110 min
,sBr 96 min
B8Ga 68 min
l1C 20.39 min
iaN 10 min
iSq 2 min
Although metal-based positron isotopes such as 64Cu, 66Ga and 68Ga 
have great potential in PET imaging, their incorporation into a labeled 
molecule can substantially change the pharmacological function (Daniels et 
al. 2010). Therefore, fluorine-18 has become the radioisotope of choice due 
to its various advantages compared to their metal-based counterparts. The 
110 minutes half-life of 18F allows centralized production and regional 
distribution of imaging agent for clinical use. Furthermore, the mode of decay 
of fluorine-18 is attractive for PET imaging (Zhang et al. 2007; Daniels et al. 
2010). 18F has a high percentage (96.7%) and relatively low energy (633 keV) 
of positron (p+), resulting in PET images with best spatial resolution. Using 
18F can strike a balance between enough time to allow synthesis of the 
radiotracers and quality control measurements whilst limiting radioactive 
exposure for no longer than necessary to the patients. Other advantages of 
using 18F are similar to the incorporation of fluorine into other pharmaceutical 
compounds. The fluorine atom is sterically similar to oxygen atom, and has a 
quite similar bond length to carbon, which makes the C-F bond likely to have 
similar binding affinities and ability to hydrogen bond compared to C-0 bond 
(Daniels et al. 2010). Although the C-F bond is considered a strong bond, 
aliphatic C-F is often prone to enzymatic cleavage in vivo. The aryl C-F bond 
is generally stable in vivo but proved to be very challenging for its synthesis 
from 18F-fluoride (Cai et al. 2008).
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As described by Daniels et al. (2010), the traditional way of 
synthesizing 19F-containing molecules often started with starting material that 
already contained fluorine atom that is then carried out through the reaction 
process to yield the final fluorinated compound. Unfortunately, this method is 
not suitable for the synthesis of 18F molecules as the 18F-introduction needs 
to be done in the final or penultimate stage of the synthesis in a fast and 
efficient manner to preserve the positron emitting property. Patient scanning 
needs to be carried out within 4-5 half-lives in order to generate meaningful 
data. Purification steps into injectable GMP standard also need to be done 
efficiently for patient administration. 18F-fluoride is also a nucleophile with low 
reactivity that makes the 18F incorporation into target molecules very 
challenging. All these factors from synthesis and purification highlight the 
challenges that are faced by the radiochemists in order to synthesise 18F- 
containing compounds. At the same time, the incorporation of fluoride ion 
into a radiotracer/drug molecule is always challenging, “particularly when 
direct labeling of large, water soluble, polyfunctional and often temperature 
sensitive macromolecules” were considered (Ting et al. 2008a).
The importance of PET as a non-invasive imaging technique has 
gained much interest over other imaging technologies due to its sensitivity 
and selectivity. It is widely used as a drug development tool and in clinical 
research which has driven the need for increasing 18F-labelled radiotracers. 
To date, 18F-FDG (Figure 5.3) is the most commonly used PET-radiotracer in 
clinical settings as well as for oncology, cardiology and neurology diagnostic 
purposes (Cai et al. 2008; Peterson and Manning 2009). The principle of 18F- 
FDG relies on its ability to detect cells that demonstrate an excess 
consumption of glucose, such as in the detection of hyper metabolic lesions 
or in the cells which are actively proliferating (Pery et al. 2010).
OH
OH
18p
Figure 5.3: Structure of 18F-FDG.
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5.1.4 Aryltrifluoroborates in 18F PET labeling
For decades, aryltrifluoroborates have received considerable attention in 
Suzuki-Miyaura cross-coupling reactions (Molander & Ham 2006). Recently, 
boronic acids derivatives, particularly aryltrifluoroborates have become an 
emerging important approach for 18F-labeling mainly due to their 
“fluorophilicity for anionic [18F]-fluoride to afford trifluoroborates with 
extraordinary chemoselectivity”, which can be used as a captor of aqueous 
[18F]-fluoride (Harwig et al. 2008). The aryltrifluoroborates are increasingly 
preferred due to their facile preparation in inexpensive aqueous potassium 
hydrogen fluoride (KHF2) from their boronate ester or boronic acid 
equivalents, and they are stable to air and moisture. They can be readily 
isolated via precipitation from water and ether-miscible solvents (e.g. 
alcohols, acetone, acetonitrile). Many of these desirable characteristics have 
been attributed to the affirmed stability of the aryltrifluoroborates, which is 
highly dependent on the remarkable strength of the B-F bond (-140 kcal/mol) 
(Molander and Ham 2006; Ting et al. 2008a).
In order to be a reliable 18F-radiolabel, the trifluoroborate needs to 
have an adequate stability and specific activity in vivo. A study carried out by 
Ting et al. (2008a) has provided useful insight on the advantages and 
potential of the trifluoroborates as a future labeling moiety. Their study 
validated their initial hypothesis that an aryl boronic acid/ester can be 
converted into an aryl trifluoroborate anion [ArB (18F)(19F)2] in the presence of 
aqueous (18/19 F)-fluoride, that showed the boronate ester intermediate can 
be an excellent aqueous 18F-fluoride capture. This compound has sufficient 
specific activity that permits the first in vivo PET images of this compound, 
whilst demonstrating great stability and pharmacokinetic clearance in mice. 
Their study showed that the C-B bond and the B-F bond were stable in vivo, 
indicated by no detectable accumulation and leaching of free (18F)-fluoride to 
the bone. In another toxicological and antinociceptive study by Oliveira et al. 
(2009), it has been shown for the first time that potassium thiophene 3- 
trifluoroborate administered orally only induced minimal toxicity and showed 
good antinociceptive effect in mice. Compared with commonly used
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organoboron compounds, organotrifluoroborates have distinguishing features: 
greater nucleophilicity, ready accessibility, and remarkable stability in air and 
moisture (Fang et al. 2004; Molander et al. 2007a).
5.1.5 Incorporation of fluorine-18 into bioactive molecules
It is known the aromatic nucleophilic substitution (SnAr) is the most 
successful approach for introducing fluorine-18 at aryl carbon. However, the 
reaction required the aryl ring to possess a good leaving group and usually at 
least one electron withdrawing group at the ortho or para position (Cai et al. 
2008). Although single step nucleophilic radiofluorination reaction with no 
carrier added (18F)-fluoride is a preferred fluoridation reaction, the reaction is 
not always applicable, especially in the case of electron-rich aromatic 
compounds. Moreover, the typical procedure when utilizing (18F)-fluoride ion 
as the labelling precursor needs harsh reaction condition, usually involving 
reactions in high temperatures and strongly basic conditions. These 
conditions are often not compatible with sensitive functional groups and may 
even lead to decomposition of sensitive compounds (Wuest 2007).
In order to overcome this problem, one of the ways used by the 
radiochemist that has becoming increasingly popular is via indirect labeling, 
that is to incorporate an alkyl group containing 18F (18F-fluoroalkyl reagent) 
that have been previously made, which act as a linker or prosthetic group 
into a drug or biomolecule at their existing sites such as hydroxyl (-OH), 
amine (-NH) or sulfhydryl (-C-SH or R-SH) groups of the parent compound to 
afford PET radiotracers. One of the most commonly used 18F-fluoroalkyl 
reagent is the 2-[18F]fluoroethyltosylate ([18F]FETos) (e.g. Zuhayra et al. 
2009; Lemaire et al. 2010). Nevertheless, this method requires the 18F- 
fluoroalkyl reagent to be synthesised first before being incorporated into the 
molecule of choice which still requires more purification steps to obtain the 
final radiotracer. All these multiple steps can contribute to lowering of the 
overall radiochemical yield. Another better way is by using direct nucleophilic 
substitution, where the parent compound should undergo incorporation with
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an alkyl group containing either sulfonates or halides leaving groups first 
before being subjected to fluoridation steps (e.g Wang et al. 2010).
5.1.6 Aims of study
In light of the above discussion, direct nucleophilic substitution of an alkyl 
chain attached to the parent compound was chosen as the method of choice 
to synthesise cold stilbenes attached to a 19F-linker using a hydroxylated 
stilbene as the parent compound, which later should be amenable to PET 
radiochemistry. Therefore, this study aimed to install an alkylfluoride chain 
(instead of a fluoride ion) and possibly a potassium alkyl trifluoroborate chain 
into hydroxylated stilbenes. This method might be amenable to any 
drug/imaging molecule bearing a hydroxyl and later on amino and sulfhydryl 
groups which have great potential to be developed into a PET radiotracer. 
Many of these compounds were neglected due to the lack of chemical 
synthesis regime which is suitable for their synthesis and which cannot be 
accomplished by any other typical fluoridation method. Stilbenes bearing a 
hydroxyl group on one aromatic ring were chosen as model compounds due 
to their accessibility in our lab and their striking potential as labelling moieties 
for Alzheimers Disease. This chapter will focus on the synthesis of ‘cold’ 
fluorinated trans-stilbene, which later should be applicable for translation to 
PET radiochemistry. To start the synthesis, an attempt to prepare 
tetrabutylammonium tetra(te/t-butyl alcohol)-coordinated fluoride 
[TBAF(fBuOH)4] was made, which has been reported to be a facile fluoride 
source. Next, the synthesis of stilbene containing alkylfluoride chain was 
attempted, from which we studied expansion to the synthesis of stilbene 
containing potassium alkyltyrifluoroborate chain using a novel method. At the 
same time, the synthesis of stilbenes attached directly to potassium 
trifluoroborates from their boronate esters counterparts were also explored.
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5.2 Synthesis of Tetrabutylammonium Tetra(fe/*-Butyl Alcohol- 
coordinated fluoride [TBAF(fBuOH)4] as a facile fluoride source.
Fluoride ion proved to be more favorable for the synthesis of fluorinated 
compounds compared to fluorine because of its higher activity and 
considerable safety issues associated with handling fluorine. For clinical 
purposes, fluorine-18 is mainly produced from a cyclotron through a proton 
irradiation of 180-enriched water. But this method also showed to have many 
limitations as a truly naked fluoride ion is never obtained, as reviewed by Cai 
et al. (2008). Typical methods for the synthesis of fluorinated molecules are 
often based on the use of electrophilic reagents (e.g. xenon difluoride, 
fluorine gas or Selectflour) (Furuya et al. 2008). On the other hand, the field 
of fluorine-18 chemistry is highly focusing on the extension to new synthetic 
modalities achievable with 18F fluoride ion as reagent (Cai et al. 2008).
Therefore, a robust and facile fluoride source is needed to ensure a 
reliable and reproducible nucleophilic fluoridation. In the search to find a 
good fluoride source, Kim et al. (2008) had introduced a new fluoride source, 
TBAF(fl3uOH)4 which was claimed to have good nucleophilicity, good 
solubility in organic solution, in dehydrated state for anhydrous reaction 
condition and low hygroscopicity for easy handling and for reduction of side 
reactions. The synthesis of TBAF(fBuOH)4 (compound 38a) is described 
below:
. fBuOH/Hexane recrystallization
Bu4N F'.xH20   ^  ^  Bu4N+F"(fBuOH)4
90 °C, 30 min 25 °C • 38a
Commercially available TBAF hydrate was heated in fBuOH/hexane 
for 30 min at 90 °C and allowed to precipitate at RT. Compound 38a was 
afforded as white crystalline solid in good yield.
Although the overall reaction was quite straightforward, the resulting 
crystals were not as good and reproducible as expected. The crystals were
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soggy and hygroscopic with high tendency to melt especially when put under 
vacuum for drying or for weighting. The proton and carbon NMR showed the 
exact peak as had been reported. The only difference was at the fBuOH 
peak at around ~1.26-1.27 ppm where the area under the peak only 
represented 18 protons (the right compound should show 36 protons which 
represent four ©uOH atoms surrounding the fluoride ion source). The 
procedure was repeated and after seven attempts, the right compounds were 
obtained only once (during the fourth attempt) but still lacking the criteria of a 
flexible and stable fluoride source (due to its hygroscopic nature). Different 
approaches were tried to improve the resulting crystals, where the reactions 
were done in carefully controlled temperature and condition (the mixture’s 
temperature must reach 25° C when the crystals were collected). Various 
times of drying the crystals under vacuum also gave different results at the 
fBuOH peak (the number of fBuOH protons were different between each 
batch-ranging from 18 to 32 protons). The overall yields also ranged from 66% 
to 100%.
Although the crystals were not consistent and not reproducible, it was 
decided to proceed to the next fluoridation using the afforded crystals, 
following the method described by Kim et al. (2008). So, the next important 
step for testing the fluoride source is to find a model compound (other than 
stilbene) with a good leaving group that is suitable for the fluoridation steps. 
Benzyl bromide was chosen as the first model compound as it is readily 
available. The fluoride sources that showed 36 and 27 protons at the fBuOH 
peak were chosen for fluoridation. The fluoridation steps were also carried 
out in two different solvents, in DMF or acetonitrile at 70 °C for comparison. 
The reaction condition is outlined in Figure 5.4 below:
DMF/CH3CN, TBAF(fBuOH)4
70 °C, 1 h
Figure 5.4: Fluoridation step
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The reaction was carried out for up to five hours, but only the sign of starting 
material can be detected from the TLC. The reaction was further carried out 
overnight with addition of excess fluoride source, but the TLC still showed 
the unreacted starting material. The same results were seen in all different 
reaction conditions and fluoride sources. The observation showed that halide 
(in this case bromide) was not a good leaving group, and a better model 
compound with a better leaving group should be used. Therefore, mesylate 
and tosylate attached to benzyl moiety were chosen as the next model 
compounds to continue with fluoridation reaction.
4-methoxybenzyl mesylate (compound 38b) was first chosen for the 
fluoridation step. The method described by Crossland and Servis (1970) was 
used as outlined below to synthesis the compound:
The reaction involved the synthesis of mesylate from p-methoxy benzyl 
alcohol in the presence of triethylamine as base and dichloromethane as 
solvent under inert atmosphere in ice-cold condition. The reaction was 
allowed to warm slowly to room temperature, followed by standard work-up 
using ether, water and 10% hydrochloric acid solution. Unfortunately, no 
product formation can be detected after the work-up even though the TLC of 
the crude reaction mixture showed the possibility of the product formation. 
The compound was predicted could not survive in the acidic work-up, so a 
modified version of the above procedure was followed which involved the 
work-up procedure in water and sodium bicarbonate, as reported by 
Lebegue et al. (2005) . After 24 h of stirring, the reaction was complete and 
compound 38b was afforded as colourless oil in 78% yield.
O
MsCI, Et3N, ch 2ci2
38b
Figure 5.5: Synthesis of 4-methoxybenzyl mesylate (38b)
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The mesylate was then subjected to fluoridation using the same 
condition as the fluoridation for benzyl bromide. Unfortunately, no product 
formation can be detected even after two attempts; despite the observation 
that only traces of starting material can be detected at the termination of the 
reaction which strongly related to the possible degradation of compound 38b. 
This is in accordance with the report by Bently et al. (1994), which mentioned 
4-methoxybenzyl mesylate as a very reactive mesylate. Therefore, it was 
predicted that the mesylate can be easily decomposed during the fluoridation 
reaction due to its reactivity and unstability, which make it not suitable to test 
the fluoride source.
Therefore, another model compound, 4-methoxybenzyl tosylate 
(compound 38c) was chosen which was predicted to have better stability to 
withstand the fluoridation step. This compound has been reported previously 
and has been successfully synthesized by Velusamy et al. (2004) from 4- 
methoxybenzyl alcohol catalysed by cobalt (II) chloride with p-toluensulfonic 
acid. Nevertheless, the synthesis of this tosylate was also not as easy as 
expected, with no or very small amount of product isolated. Listed below are 
the methods that had been used to synthesize the compound:
a) modification of the mesylate synthesis (Lebegue et al. 2005). The 
methanesulfonyl chloride was substituted with p-toluenesulfonyl 
chloride. No product formation can be detected after the work-up.
b) Using pyridine as base (Cho et al. 2003). The method involved the 
reaction of alcohol with p-toluenesulfonyl chloride in dichloromethane 
and pyridine as base at 0 °C, and then gradually warmed to RT 
(Figure 5.6). The method afforded the product after column 
chromatography in less than 1% yield.
jfY TsCI, pyridine, CH2CI2 rr°-K >
0 °C to RT, 12 h MeO
38c
Figure 5.6: Synthesis of 4-methoxybenzyl tosylate (38c).
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After the unsuccessful attempts to synthesise compound 38c, the 
issue about the stability of the tosylate was once again raised, until later a 
report by Kochi & Hammond (1953) that mentioned the fragility of the 
compound was noticed. The tosylate need very careful exclusion of moisture 
and rapid manipulation, and various attempts to recrystallize the compound 
in a variety of solvents were futile. The 4-methoxybenzyl tosylate was not 
well characterized because it is extremely reactive, as it will polymerizes 
slowly even at -60 °C, and very rapidly at RT. At this stage, the 4- 
methoxybenzyl alcohol was considered as an inappropriate starting material, 
and another alcohol (benzyl alcohol) was considered.
The next synthesis of benzyl tosylate [38c(i)] under a solvent free 
condition was chosen as described by Kazemi et al. (2007). The reaction 
involved the reaction of benzyl alcohol that was vigorously grinded with p- 
toluene sulfonyl chloride in the presence of dry potassium carbonate (Figure 
5.7). After the work-up, traces of benzyl alcohol can still be detected. The 
crude oily compound was subjected to column chromatography (10 hexane: 
1 ethyl acetate) to afford the pure compound 38c(i) in 26% yield as white 
powder. It was believed that prolonging the grinding time of the starting 
materials could increase the yield of the benzyl tosylate significantly.
OH TsCI
38c(i)
o-s
Figure 5.7: Synthesis of benzyl tosylate [38c(i)]
After the successful synthesis of the model compound, compound 
38c(i) was subjected to fluoridation as described in the previous fluoridation 
attempts using the afforded compound 38a (TBAF (ffiuOH)4. After more than 
1 hour, the TLC showed full consumption of the starting material in both 
reactions using DMF or acetonitrile. The TLC spot of the fluoridation 
reactions appeared lower than the starting material spot, which indicated the 
possibility of the desired more polar benzyl fluoride formation. The attempts
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to purify the oily crude mixture using column chromatography in various 
eluents (hexane;ethyl acetate or dichloromethane;methanol) were not very 
successful as the truly pure benzyl fluoride was very hard to isolate. 
Nevertheless, the decoupled fluorine NMR of the purified mixture showed a 
single peak at -152.21 ppm which differs from the decoupled fluorine NMR 
peak of the TBAF(fBuOH)4 (-155.68 ppm) that gave more confidence that the 
targeted benzyl fluoride had been successfully synthesised. But the 
formation of many impurities that were very hard to separate from the pure 
compound suggested that compound 38a that had been synthesised was not 
as facile and as promising as has been claimed. In order to test the reliability 
of this reaction, the same fluoridation reaction was repeated but using the 
commercially available tetrabutylammonium fluoride trihydrate (TBAF). The 
TLC also showed full consumption of the starting material, not surprisingly 
with a quite similar TLC spots pattern as compared to compound 38a and 
problems in purification indicating a relatively comparable reaction condition 
between the synthesised TBAF(fBuOH)4 and commercially available TBAF. 
The decoupled fluorine NMR also showed a single peak at -152.23 ppm.
In conclusion, the commercially available TBAF was found to be a 
good fluoride source, and the synthesis of TBAF(fl3uOH)4 which has been 
claimed to be a better and more stable fluoride source showed no great 
differences in the overall reaction condition as compared to the commercially 
available TBAF for PET chemistry.
5.3 Synthesis of stilbene containing alkyl fluoride chain.
This part of the study focused on the synthesis of stilbenes attached to an 
alkyl fluoride chain. The aim was to synthesise the target compounds in a 
fast and efficient manner to get the fluorinated compounds in good yield. In 
this study, the alkyl chain was derived from 1,4-dibromobutane as it was the 
cheapest alkyl bromide in the market and due to its availability in the lab. The 
chosen method to synthesise the stilbene was based on the HWE reaction 
(chapter 2) that had been previously reported by Lion et al. (2005).
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Previous study done by an Erasmus student (Paola Casule, February- 
July 2010) showed that the attempt to synthesis stilbene 39a {(E)-1-(4- 
bromobutoxy)-4-(4-methoxystyryl)benzene) from 4-methoxybenzyl 
phosphonic acid diethyl ester (compound 1) and 4-(4- 
bromobutoxy)benzaldehyde was unsuccessful (Figure 5.8). It was predicted 
that 1,4-dibromobutane and 4-hydroxybenzaldehyde was cleaved during the 
HWE reaction, leaving the free hydroxyl group to further react and gave 
unwanted side reactions. In order to avoid the same fate, for the next attempt 
two hydroxylated stilbenes which were previously synthesized in the lab were 
chosen for this study (compound 22 and 32) (Figure 5.9).
Br(CH2)4Br, K2C03
acetone, reflux, 24 h
HO'
DMF, NaOMe, 18-crown-6, 
120 °C, 3h
39a
Figure 5.8: Previous study done by Paola Casule (February-July 2010)
I H
I
K J  F>
OMe
Compound 22 Compound 32
Figure 5.9: Compound 22 and 32
The first step of the study involved the incorporation of a 1,4- 
dibromobutane at the hydroxyl group of compound 22 and 32. The method 
involved the reaction of hydroxylated stilbene (1 equiv) with 1,4- 
dibromobutane (1.15 equiv) in acetone and 1.5 equivalent potassium 
carbonate as base, as shown in figure 5.10. The reaction needed purification
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by column chromatography to remove unreacted starting materials and gave 
the desired product in good yield; compound 39a (78%) and 39b (75%).
22: R = 3-OCH3 
32: R = 4-F
0H Br(CH2)4Br, K2C03
acetone, reflux, 24 h
39a: R = 3-OCH3 
39b: R = 4-F
Figure 5.10: Alkylation procedure
The next crucial stage in this study is the fluoridation step. Previous 
study by Paola Casule also revealed that bromide is a less effective leaving 
group for the fluoridation reaction of the stilbene using tetrabutyl ammonium 
fluoride (TBAF) or cesium fluoride (CsF), whether heating in polar protic or 
polar aprotic solvents. Although the product fluoro compound was isolated, 
the reaction was low yielding and even after 24 hours of reaction lots of 
starting material remained unreacted (data not shown) (Figure 5.11). 
Therefore, it is important to find a better leaving group for an efficient 
fluoridation to occur.
(a), (b) or (c) 
reflux, H CQr 
1 h to 24 h 3
a) TBAF, tBuOH, (b) TBAF, DMF (c) CsF, tBuOH
Figure 5.11: Less efficient fluoridation step using bromide as leaving group.
To improve the fluoridation step, mesylates were chosen as the leaving 
group of choice instead of halogens. The synthesis of mesylates was 
straightforward using silver methanesulfonate as the mesylate source in 
acetonitrile with overnight reflux (Figure 5.12). Silver is known to have strong 
affinity to couple with bromide and this helped the reaction to go to 
completion and good yields of mesylates 40a and 40b were obtained (78 and 
75% yield, respectively). It is noteworthy that there is another method that
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can be used in the future for the synthesis of compound attached to alkyl 
tosylates for efficient fluoridation by using commercially available ethylene 
glycol ditosylate derivatives in NaH and DMF with the hydroxylated stilbene 
(Wang etal. 2010).
Rtf
39a: R = 3-OCH- 
39b: R = 4-F
AgOMs, CH3CN
reflux, overnight
40a: R = 3-OCH3 
40b: R = 4-F
Figure 5.12: Synthesis of mesylates
The next crucial step was the fluoridation step of the stilbenes 
attached with alkyl mesylates chain using tetrabutylammonium fluoride 
(TBAF) or cesium fluoride (CsF) in terf-butanol (f-BuOH) or acetonitrile 
(CH3CN). Stilbene 40a was chosen as the model compound. As expected, 
the fluoridation step using TBAF in f-BuOH or CH3CN showed nearly 
complete conversion of the mesylates to the possible product even after 30 
minutes of reaction. After 1 hour, the reaction was terminated. Prior to the 
short column chromatography purification, reaction in f-BuOH gave 90% 
yield of pure compound 41 while reaction using CH3CN afforded pure 
compound 41 in 86% yield. It was noted that the reaction in f-BuOH gave a 
cleaner reaction indicated by less side product formation compared to the 
reaction in CH3CN as indicated by thin layer chromatography (TLC) analysis. 
The fluoridation of stilbene 40b using TBAF in f-BuOH gave the pure 
fluorinated compound 42 in 81% yield. The study also showed that polar 
protic solvent is superior to the polar aprotic solvent for this kind of 
fluoridation reaction which gave less side product formation and better yield, 
as reported previously by Kim et al. (2006). The formation of the fluorinated 
compounds 41 and 42 were evidenced by the disappearance of methyl 
groups of the mesylates in 1H and 13C NMR and the appearance of single 
fluorine peak at 5 -218.52 ppm for compound 41 and the presence of two 
fluorine peaks at 5 -115.27 ppm and 6 -218.57 ppm for compound 42 in 
decoupled 19F-NMR.
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40a: R = 3-OCH3 
40b: R = 4-F
a) TBAF, ffiuOH (b) TBAF, MeCN (c) CsF, ®uOH
(a), (b)or(c) R. 
reflux, 1h
F©
41: R = 3-OCH3 
42: R = 4-F
Figure 5.13: Fluoridation step
This study demonstrated that the synthesis of stilbenes containing 
alkyl fluoride chains can be achieved efficiently by using mesylates as the 
leaving group. TBAF also proved to be a good fluorinating agent in polar 
protic solvent such as f-BuOH. This fluoridation and alkylation method were 
anticipated to be extended to the synthesis of other compounds which may 
not be achievable with the typical fluoridation step for PET imaging especially 
in the case of electron-rich aromatic compounds, where single step 
nucleophilic fluoridation which need harsh reaction condition is preferred, 
provided that the compound should possess either a hydroxyl, amino or 
sulfyhydryl group in any part of the compound.
5.4 Potassium alkyltrifluoroborates as a new approach for labeling
PET radiotracers.
The synthesis of compounds containing potassium trifluoroborate chain for 
PET imaging is still in its infancy. Nevertheless, this area of research have 
attracted much attention due to report by Ting et al. (2008a) which showed 
that 18F-labelled aryltrifluoroborate radiotracers have good stability in vivo 
and are a promising modality for PET imaging. This method however needs 
the intermediate to possess a boronic ester substitution in order to capture 
the free fluoride for trifluoroborate synthesis. The synthesis, application and 
stability of the potassium organotrifluoroborates have been reviewed 
elsewhere (Darses and Genet 2008). To summarise, the synthesis of 
potassium organotrifluoroborates is usually achieved by using four different
C h a p t e r  5 : S t i l b e n e  a n a l o g u e s  a s  P E T  r a d i o t r a c e r s  1143
methods (Figure 5.14): a) from isolated boronic acid (Molander and Biolatto
2003); (b) via transmetallation reaction (Molander and Ham 2006; Cho et al. 
2009); c) via hydroboration (Petasis et al. 1997); and (d) via C-H bond 
activation (Murphy et al. 2007) with potassium hydrogen fluoride (KHF2) as 
the main fluorinating agent. Unfortunately, these methods usually suffer from 
competitive binding with sensitive and existing functionalities in the substrate 
that can limit its usefulness (Molander and Figueroa 2006a; Darses and 
Genet 2008).
,OH MeOH, aqueous KHF2
Sdh
MeO-
1 h, RT
(a) from boronic acid
i) n-BuLi (1.0 equiv) 
B(0'Pr)3 (1.0 equiv)
ii) 1N KHF2 
(b) via transmetallation reaction
i) Catecholborane
ii) 0 2
(c) via hydroboration
Me.
di-ferf-butylbipyridine (dtbpy) THF/H20
B— B 
/  \
[Ir], THF, 80 °C 1N KHF2
Me Me
(d) via C-H bond activation
Figure 5.14: Methods to synthesise organotrifluoroborates
To date, there are no procedures that have been reported to 
synthesise compounds attached to alkyl trifluoroborates directly from its alkyl 
mesylates/triflates/halides (or any other leaving groups) counterparts. The 
existing methods only reported the synthesis of alkyl trifluoroborates 
compounds from alkyl chain that have been previously attached with boronic 
ester or trifluoroborates derivatives (e.g. Molander and Ham 2006; Molander 
et al. 2007b), or by synthesizing the Grignard reagent or organolithium 
intermediate first from alkyl halide which later will be reacted with borate
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esters (e.g. trimethyl borate B(OCH3)3) to produce trifluoroborate upon 
quenching with KHF2 (e.g. Molander and Figueroa 2006b).
Therefore in this study, an attempt was made to present a novel and a 
much simpler method for the synthesis of potassium alkyl trifluoroborates 
using alkyl mesylates as the intermediates and potassium tetrafluoroborates 
(KBF4) as the trifluoroborate source. This approach, if successful was 
anticipated to have a wide applicability to a broad range of compound which 
may have great utility in PET imaging.
For this reaction, stilbene 40a that have been synthesised previously 
was used as the intermediate and model compound. The compound was 
subjected to the synthesis using potassium tetrafluoroborate in different 
solvents (f-BuOH, CH3CN, methanol/tetrahydrofuran or dimethylformamide 
(DMF)) at reflux (Figure 5.15). After 1 hour of heating, the reaction in f-BuOH 
and CH3CN showed no sign of possible product formation. The same 
observation was seen even after 24 hour of prolonged reaction in these two 
particular solvents. However, the reaction in methanol/THF showed a slight 
possible product formation after 1 hour and a few additional side reaction 
spots detected by TLC. Even after prolonged reaction to 24 hours, the same 
observation was seen and the formation of a few other side reaction spots by 
TLC made this reaction look less attractive. Interestingly, the reaction in DMF 
showed a striking observation after 1 hour, indicated by the formation of 
possible product formation as the major constituent in the reaction. 
Prolonged reaction to 24 hours of heating did not give vast changes to the 
observation. Upon quenching with water, precipitate was collected and dried 
in air. Attempts to purify the crude compound by recrystallisation in 
acetone/ether or acetonitrile failed as the compound was found to be soluble 
in those solvents even at room temperature. The next attempt to purify in 
methanol/water managed to produce pure solid. Nevertheless, the NMR 
showed that the desired compound was not isolated. The product still 
retained the stilbene skeleton and the alkyl chain, but was missing the methyl 
peak of mesylate with no detectable fluorine peak from the decoupled
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fluorine NMR. These highlight the failure of the attempted method to produce 
the desired potassium butyl trifluoroborates.
KBF4, ffiuOH
reflux, 1 h to 24 h
reflux, 1 h to 24 h
KBF4, MeOH/THF
40a
reflux, 1 h to 24 h
reflux, 1 h to 24 h
Figure 5.15: Attempts to synthesise potassium alkyl trifluoroborates.
Although this method looked attractive, repeated attempts of simple 
heating at reflux in DMF was not sufficient to synthesise the right compound, 
which emphasise the need to refine the attempted procedure until the correct 
compound is achievable. Other than refinement of the attempted procedure, 
future studies can also be dedicated to the synthesis of stilbenes attached to 
alkyl boronate esters intermediates via Grignard reagent (Molander and 
Figueroa 2006b; Gerbino et al. 2009), or by conversion of arenes to 
arylboronic acid by C-H activation chemistry (Murphy et al. 2007) which later 
will have better possibilities for transformation to trifluoroborate salt.
5.5 Synthesis of potassium (£)-stilbene trifluoroborate
This study was aimed to synthesise stilbene derivatives which are attached 
directly to a potassium trifluoroborate moiety. A few stilbenes that are 
attached directly to trifluoroborates have been prepared previously either 
using HWE or Wittig reactions (Molander and Figueroa 2006; Molander et al. 
2007a). Nevertheless, all the compounds were made using potassium 
trifluoroborates substitution which have been synthesised previously from the
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beginning of the reaction and were carried out through the multistep process 
to afford the potassium stilbene trifluoroborates, which is not compatible with 
future synthesis of 18F derivatives. To date, there a no examples of Wittig or 
HWE reactions that have been reported using suitably functionalized boronic 
acid derivatives, most probably due to the acidic proton in these species. On 
the other hand, the Wittig and HWE reactions using boronate esters with 
stabilized ylides and phosphonates have been reported to a very limited 
extent (e.g. Lautens and Mancuso 2004; Gopalaratnam and Nelson 2006; 
Molander and Figueroa 2006a). The drawback of this method is that the diols 
such as catechol, pinacol and diethanolamine that is used to generate stable 
boronate esters add considerable expense to the overall process and must 
be separated from the final product (Molander and Ham 2006).
The first attempt made to synthesise stilbenes directly attached to 
potassium trifluoroborates was made following previously reported 
procedures (Molander and Ham 2006; Cho et al. 2009). The methods 
involved the formation of organolithium intermediates using triisopropyl 
borates and n-butyllithium in tetrahydrofuran (THF) at -78 °C for at least 1-3 
hours followed by quenching with aqueous KHF2 to afford the potassium 
stilbene trifluoroborates (Figure 5.16).
R = 3-OMe (compound 35) 
= 4-OMe (compound 36)
2 . 1N KHF2, -78 °C to RT
1 ■ [(CH3)2CHO]3B> n-BuLi 
THF, -78 °C
Figure 5.16: First attempt to synthesise potassium stilbene trifluoroborate
A few modifications have been attempted which involved the addition 
of borate ester during or after 1 hour of n-butyllitium addition, or even the 
addition of KHF2 either at -78 °C or after the reaction being warmed to room 
temperature. None of the attempted methods succeeded although freshly 
purchased sources of /7-butyllithium had been used. Attempts to modify the
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method to synthesise boronic acid and boronic ester intermediates upon 
quenching the reaction with water and later on substitution with pinacol also 
failed to give stilbene boronate ester intermediates. It was anticipated that 
the use of new or different kind of borate ester (e.g. trimethyl borate) will 
improve the outcome of the reaction. Nevertheless, further attempt to 
synthesis of the compound via this method was not considered due to 
difficulty in getting the right compound. Therefore, another method was 
sought.
The next attempt was dedicated to the synthesis of stilbene boronate 
esters as intermediates which will later be transformed to potassium 
trifluoroborates upon quenching in aqueous KHF2. The synthesis of stilbenes 
was achieved by using the method described by Lion et al. (2005) utilising 
the HWE coupling reaction. In the previous study done by Paola Casule 
(Erasmus student), 4-formylphenylboronic acid was transformed to 
potassium trifluoro(4-formylphenyl)borate first using KHF2 as the fluorinating 
agent before being coupled to 4-methoxy phosphonic acid diethyl ester 
(compound 1) to synthesise the stilbene attached to potassium 
trifluoroborates. Unfortunately, the reaction failed to give the desired product 
as the trifluoroborate was predicted to be cleaved during the harsh reaction 
condition leaving free boronic acid to further react (Figure 5.17).
MeOH/THF F\© 
F—B
DMF, NaOMe, 18-crown-6, 
120 °C, 3h
^ ^ O C H 3
F -B
Figure 5.17: Previous attempt to synthesise potassium stilbene 
trifluoroborate (Paola Casule).
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Therefore, in the next attempt (Figure 5.18), the boronic acid was 
protected first with pinacol to produce 4-(4,4,5,5,-tetramethyl-1,3,2- 
dioxaborolan-2-yl)benzaldehyde (compound 45a) to make it more stable to 
withstand the harsh reaction conditions of the HWE reaction. The protection 
step was quite straightforward, which involved the reaction of the 4- 
formylphenylboronic acid with a pinacol in diethyl ether for 12h. The next 
step involved the reaction of compound 45a with compound 2 (3- 
methoxybenzyl phosphonic acid diethyl ester) to afford a trans-stilbene 
(cvompound 45b) in only 9% yield after column chromatography. The 
reaction suffered from unreacted starting material and limiting reagent even 
after prolonged heating (48 hours) which contributed to lowering the yield. 
The next crucial step was the fluoridation step with KHF2 in 
methanol/tetrahydrofuran to make the trifluoroborate 45. The reaction was 
achieved within 1 hour of the reaction time, where washing of the crude 
product with hot diethyl ether and water is sufficient to give pure compound 
45 in 63% yield. It is anticipated that during the washing a small amount of 
product may have been washed away which can contribute to lowering the 
overall yield. It is also noted that signal of the carbon atom attached directly 
to boron atom was not observed due to the signal broadening of 11B. The 
formation of compound 45 was proved by the appearance of a single fluorine 
peak at 5 34.68 ppm in decoupled fluorine NMR, together with the 
disappearance of methyl peak of the boronate ester in 1H and 13C-NMR.
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HQ
OH
,0-B
P  (45a)
DMF, NaOMe, 18-crown-6, 
120 °C, 3h
OCH3
KHF2 (aq)
MeOH/THF
(45) (45b)
Figure 5.18: Overall reaction procedures to synthesise compound 45.
The same derivatives containing para-methoxy group was also 
managed to be synthesised, but in a very low yield (less than 1%). The 
problem lies on the synthesis of 4-methoxy stilbene boronate ester which 
suffered from very slow reaction and unreacted starting material which gave 
a very low yield of impure compound (1%). Nevertheless, a single fluorine 
peak was observed after the fluoridation step which indicated that a 
trifluoroborate stilbene with 4-methoxy substitution had likely been 
successfully synthesised.
In conclusion, these results demonstrated that the synthesis of 
stilbene containing direct substitution with potassium trifluoroborate can be 
achieved from stilbene containing boronate ester, but suffered from very slow 
reaction and low yield. This lower reactivity results, in part, from the 
unfavorable hydrolysis of the pinacolboronates to boronic acids (Murphy et al. 
2008). Therefore, a better method should be sought in order to synthesise 
stilbene containg boronate ester with better condition and improved yield, so 
it can be extended to 18F-radiochemistry synthesis for the synthesis of radio 
labeled potassium stilbene trifluoroborates.
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CHAPTER 6
EXPERIMENTAL
6.1 CHEMISTRY
All chemicals obtained from commercial suppliers (e.g. Sigma Aldrich, Fisher 
Scientific) were used as received and were of analytical grade. The 
anhydrous solvents were purchased from Aldrich with subaseal stopper. 
Melting points were recorded on a Griffin Gallenkamp melting point 
apparatus and are uncorrected.
The 1H, 13C and 19F NMR spectra were recorded on a Bruker Avance-500 
spectrometer at 500, 125 and 471 MHz respectively, at 25°C. Chemical shifts 
(5) are reported in parts per million (ppm). J values are reported in Hertz (Hz). 
Thin layer chromatography (TLC) was performed on 60 F254, 0.2 mm 
thickness pre-coated aluminium sheets (Merck) and were visualized under 
both short and long wave ultraviolet light (254 nm and 366 nm) . Flash 
chromatography columns were performed using silica gel 60A (35-70 pm) 
from Fisher. A CEM Discover focused microwave (2450 MHz, 300 W) was 
used for the synthesis of hydroxylated stilbene analogues. High and low 
resolution mass spectroscopy using electron ionisation (El) were run on a 
Waters GCT Premier, and using electrospray (ES) on a Waters LCT Premier 
XE. The mass spectrometries were performed as a service by School of 
Chemistry, Cardiff University. Elemental analysis (CHN) microanalysis was 
performed as a service by MEDAC Ltd, Surrey. Accurate mass (electrospray) 
spectrometry was performed by the EPSRC National Mass Spectrometry 
Service (Swansea, UK).
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6.2 Synthesis of stilbene analogues as potential anticancer agents
Compound Ri r2
4 4-OMe 4-OMe
5 3-OMe 4-OMe
6 3-OMe 3-OMe
7 3-OMe 3,5-diOMe
8 4-OMe 3.5-diOMe
9 4-OMe 3,4-diOMe
10 4-OMe 2,4-diOMe
11 4-OMe 2,5-diOMe
12 3,5-diOMe 3,4-diOMe
13 3,5-diOMe 2,4-diOMe
14 4-OMe 3,4,5-triOMe
16 3,5-diOMe 3,5-diOMe
'17 3,5-diOMe 2,5-diOMe
18 3,5-diOMe 3,4,5-triOMe
19 4-OMe 3-F
20 3-OMe 3-F
28 3-OMe 4-F
29 4-OMe 4-F
34 3-OMe 4-N02
35 4-OMe 4 -NO2
36 3-OMe 4-Br
37 4-OMe 4-Br
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General method for the synthesis of substituted methoxybenzyl 
phosphonic acid diethyl esters
The substituted 4-methoxy, 3-methoxy or 3,5-dimethoxy benzyl bromide (40 
mmol) was heated with excess of triethylphosphite (50 mmol) at 130°C to 
140°C until the completion of the reaction. The remaining triethylphosphite 
was then removed by concentration of the solution in vacuo to afford 
phosphonate esters (as oils).
(4-Methoxybenzyl) phosphonic acid diethyl ester [1] (Lion et al. 2005). 
Colourless oil. Yield = 96%.
1H NMR (CDCkl 6 1.24 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.08 (d, J = 21.0 Hz, 
2H, PCH2), 3.79 (s, 3H, OCH3), 4.00 (m, 4H, OChbCH;,), 6.74 (d, J = 8.5 Hz, 
2H, H3, H5), 7.21 (dd, J = 8.8, 2.5 Hz, 2H, H2, H6)
(3-Methoxybenzyl) phosphonic acid diethyl ester [2] (Murias et al. 2004) 
Colourless oil. Yield = 99%.
1H NMR (CDCIil 8 1.27 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.15 (d, J = 21.5 Hz, 
2H, PCH2), 3.82 (s, 3H, OCH3), 4.04 (m, 4H, OChbCHs), 6.81 (d, J = 8.0 Hz, 
1H, H4), 6.90 (d, J = 7.5 Hz, 2H, H2, H6), 7.24 (t, J = 7.8 Hz, 1H, H5)
(3, 5-dimethoxybenzyl) phosphonic acid diethyl ester [3] (Heynekamp et 
al. 2006).
Colourless oil. Yield = 98%.
1H NMR (CDCU1 6 1.29 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.12 (d, J = 22.0 Hz, 
2H, PCH2), 3.80 (s, 3H, OCH3), 4.05 (m, 4H, OCi^CHs), 6.38 (q, J = 2.5 Hz, 
1H, H4), 6.49 (t, J = 2.3 Hz, 2H, H2, H6)
6.2.1 Synthesis of (£)-methoxylated, fluorinated, brominated and 
nitrated stilbenes via Horner-Wardsworth-Emmons reaction
Substituted phosphonic acid diethyl esters (10 mmol) were dissolved in dry 
DMF (10 mL). Sodium methoxide (20 mmol) and 18-crown-6 (2 mmol) were 
added and the mixture were stirred at room temperature for 5 min. The
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substituted methoxybenzaldehyde or fluorobenzaldehyde (15 mmol) 
dissolved in dry DMF (5 mL) was added dropwise at 0 °C. The mixture was 
stirred at room temperature for 1 h and then subsequently heated to 100 °C 
for 3-5 h, or until the completion of the reaction. The reaction was quenched 
by pouring into water (30 mL) with stirring. Reactions that gave solids were 
filtered and recrystallised from diluted ethanol. Reactions that gave oils were 
extracted with diethyl ether (3 x 20 mL). The ether was evaporated in vacuo, 
and the residues redissolved in dichloromethane (15 mL). Girard’s reagent T 
(6 mmol) and acetic acid (60 mmol) were added, and the reaction stirred at 
room temperature for 2 h. After quenching with water (15 mL), the organic 
layers were collected, washed with brine (3x 15  mL) and aqueous saturated 
sodium carbonate (3 x 15 mL), dried over magnesium sulfate and 
evaporated in vacuo. The residue which gave solids were purified by 
recrystallisation from ethanol/water, while the oily residues were purified by 
column chromatography (hexane/ethyl acetate) to afford pure substituted 
methoxylated or fluorinated stilbenes.
(E) - 4, 4’ dimethoxystilbene [4]
White solid. Yield = 91%. mp = 214-215 °C (lit: 214-215 °C [Zhang & Go 
2007])
1H NMR (CDCU1 5 3.85 (s, 6H, 2 x OCH3), 6.92 (d, J = 9.0 Hz, 4H, H3, H5, 
H3\ H5’)> 6.96 (s, 2H, Ha, Ha’), 7.45 (d, J = 9.0 Hz, 4H, H2, H6, H2’, H6’)
(E) - 3, 4’ dimethoxystilbene [5]
White solid. Yield = 84%. 106-108 °C (lit: 106-109 °C [Zhang & Go 2007])
1H NMR tCDCUl 5 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 6.82 (dd, J = 8.3,
2.5 Hz, 1H, H4), 6.93 (d, J =  5.0 Hz, 2H, H3’, H5’), 6.98 (d, J =  16.5, 1H, Ha),
7.06 (s, 1H, H2), 7.09 (d, J = 16.5 Hz, 1H, Ha’), 7.12 (d, J = 8.0 Hz, 1H, H6), 
7.29 (t, J = 7.5 Hz, 1H, H5), 7.48 (d, J = 9.0 Hz, 2H, H2’, H6’)
(E) - 3, 3’ dimethoxystilbene [6]
White crystals. Yield = 57%. mp = 92-93 °C (lit: 99-100 °C [Chen & Chen 
2007]). Recystallised (EtOH/water).
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1H NMR (CDCh) 5 3.88 (s, 6H, 2 x OCH3), 6.85 (dd, J = 8.0, 2.5 Hz, 2H, H4, 
H4’), 7.08 (s, 2H, H2, H2’), 7.10 (s, 2H, Ha, Ha’), 7.14 (d, J =  7.5 Hz, 2H, H6, 
H6’), 7.31 (d, J = 8.0 Hz, 2H, H5, H5’)
(E) -  3, 3’, 5 trimethoxystilbene [7]
White solid. Yield = 16%. mp = 67-68 °C (lit: oil [Velder et al. 2006]). Column 
chromatography (hexane:ethyl acetate = 9:1).
1H NMR (CDCkl 5 3.86 (s, 6H, OCH3x 2), 3.88 (s, 3H, OCH3), 6.44 (t, J =
2.2 Hz, 1H, H4), 6.70 (d, J = 2.5 Hz, 2H, H2, H6), 6.86 (dd, J = 8.0, 2.5 Hz, 
1H, H4'), 7.05 (d, J = 16.5 Hz, 1H, Ha), 7.09 (d, J = 16.5 Hz, 1H, H a’), 7.08 
(m, 1H, H2’), 7.17 (d, J=  7.5 Hz, 1H, H6’), 7.30 (t, J = 8.0 Hz, 1H, H5’)
(E) -  3 ,4 ’, 5 trimethoxystilbene [8]
Tan-coloured crystals. Yield = 18%. mp = 54-55 °C (lit: 55-57 °C [Murias et al. 
2004]). Column chromatography (hexane:ethyl acetate = 6:1).
1H NMR (CDCU) 5 3.86 (s, 9H, 3 x OCH3), 6.41 (t, J = 2.3 Hz, 1H, H4), 6.68 
(d, J = 2.0 Hz, 2H, H2, H6), 6.926 (d, J = 9.0 Hz, 2H, H3\ H5’), 6.93 (d, J =
16.0 Hz, 1H, Ha), 7.07 (d, J = 16.0 Hz, 1H, H a’), 7.47 (d, J = 8.5 Hz, 2H, 
H2\ H6’)
(E) -  3, 4, 4’ trimethoxystilbene [9]
White solid. Yield = 68%. mp = 132 °C (lit: 135 °C [Zhang & Go 2007]). 
Recrystallise (EtOH/water).
1H NMR (CDCIsl 6 3.86 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.95 (s, 3H, 
OCH3), 6.88 (d, J = 8.0 Hz, 1H, H5), 6.92 (d, J = 9.0 Hz, 2H, H3’, H5’), 6.96 
(d, J =  16.5 Hz, 1H, Ha), 7.00 (d, J =  16.5 Hz, 1H, Ha’), 7.05 (dd, J = 8.5, 2 
Hz, 1H, H6), 7.08 (d, J = 5.0 Hz, 1H, H2), 7.46 (d, J = 9.0 Hz, 2H, H2', H6’)
(E) -  2 ,4 ,4 ’ trimethoxystilbene [10]
Pale yellow solid. Yield = 57%. mp = 86-88 °C (lit: 86-88 °C [Zhang & Go 
2007]). Recrystallise (EtOH/water).
1H NMR (CDCy 5 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.89 (s, 3H, 
OCH3), 6.50 (d, J = 2.5 Hz, 1H, H3), 6.54 (dd, J = 8.5, 2.5 Hz, 1H, H5), 6.91
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(d, J = 9.0 Hz, 2H, H3\ H5’) 6.98 (d, J = 16.0 Hz, 1H, Ha), 6.28 (d, J = 16.0 
Hz, 1H, Ha’), 6.47 (d, J = 9.0 Hz, 2H, H2\ H6 ’), 6.51 (d, J = 9.0 Hz, 1H, H6 )
(E) -  2 ,4’, 5 trimethoxystilbene [11]
Yellowish crystals. Yield = 45%. mp = 67-68 °C (lit: 67-68 °C [Heynekamp et 
al. 2006]). Recrystallise (EtOH/water).
1H NMR (CDCy 6 3.84 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.71 (s, 3H, 
OCH3), 6.80 (dd, J = 8.5, 3 Hz, 1H, H4), 6.86  (d, J=  9.0 Hz, 1H, H5), 6.92 (d, 
J = 8.5 Hz, 2H, H3’, H5'), 7.08 (d, J = 16.5 Hz, 1H, Ha), 7.17 (d, J = 3.0 Hz, 
1H, H2), 7.35 (d, J=  16.5 Hz, 1H, Ha’), 7.51 (d, J = 9.0Hz, 2H, H2’, H6 ’)
(E) -  3, 3’, 4, 5’ tetramethoxystilbene [12]
White crystals. Yield = 40%. mp = 68=69 °C (lit: 67 °C [Murias et al. 2004]). 
Column chromatography (hexane:ethyl acetate = 6:1).
1H NMR (CDCh) 5 3.86 (s, 6 H, 2 x OCH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, 
OCH3), 6.41 (t, J = 2.3 Hz, 1H, H4’), 6.69 (d, J = 2.5 Hz, 2H, H2’, H6 '), 6.89 
(d, J = 8.0 Hz, 1H, H5), 6.93 (d, J = 16.0 Hz, 1H, Ha), 7.06 (d, J = 16.0 Hz, 
1H, Ha’), 7.08 (m, 2H, H2, H6 )
(E) -  2, 3 \ 4, 5’ tetramethoxystilbene [13]
Colourless crystals. Yield = 19%. mp = 81-82 °C (lit: 81-82 °C [Li et al.2006]). 
Column chromatography (hexane: ethyl acetate = 6 :1).
1H NMR (CDCkl 5 3.86 (s, 6 H, 2 x OGH3), 3.86 (s, 3H, OCH3), 3.90 (s, 3H, 
OCH3), 6.40 (t, J = 2.0 Hz, 1H, H4’), 6.50 (d, J = 2.5 Hz, 1H, H3), 6.54 (dd, J 
= 8.5, 2.5 Hz, 1H, H5), 6.70 (d, J = 2.0 Hz, 2H, H2’, H6 ’), 6.97 (d, J = 16.0 Hz, 
1H, Ha), 7.39 (d, J = 16.0 Hz, 1H, Ha’), 7.52 (d, J = 8.5 Hz, 1H, H6 )
(E) -  3 ,4 ,4 ’, 5 tetramethoxystilbene [14]
White crystals. Yield = 21%. mp = 157-158 °C (lit: 157-159 °C [Murias et al. 
2004]). Column chromatography (hexane: ethyl acetate = 6:1).
1H NMR (CDCk) 8  3.86 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.94 (s, 6 H, 2 x 
OCH3), 6.75 (s, 2H, H2, H6 ), 6.93 (d, J = 16.5 Hz, 1H, Ha), 6.93 (d, J = 2.0 
Hz, 2H, H3’, H5’), 7.00 (d, J = 16.5 Hz, 1H, Ha’), 7.47 (d, J = 9.0 Hz, 2H, H2’, 
H6’)
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(E) -  3, 3’, 5, 5’ tetramethoxystilbene [16]
White crystals. Yield = 18%. mp = 129-130 °C (lit: 129-135 °C [Murias et al. 
2004]). Column chromatography (hexane: ethyl acetate = 5:1).
1H NMR (CDCh) 5 3.86 (s, 12H, 4 x OCH3), 6.43 (t, J = 2.3 Hz, 2H, H4, H4’), 
6.70 (d, J = 2.0 Hz, 4H, H2, H6, H2’, H6'), 7.04 (s, 2H, Ha, Ha’)
(E) -  2, 3’, 5, 5’ tetramethoxystilbene [17]
Milk white amorphous solid. Yield = 22%. mp = 54-55 °C (lit: 54-55 °C [Li et 
al. 2006]). Column chromatography (hexane: ethyl acetate = 6:1).
1H NMR (CDChl 6 3.85 (s, 3H, OCH3), 3.86 (s, 6H, 2 x OCH3), 3.87 (s, 3H, 
OCH3), 6.42 (s, 1H, H4’), 6.73 (d, J = 2.0 Hz, 2H, H2’, H6’), 6.83 (dd, J = 6.8,
1.6 Hz, 1H, H4), 6.87 (d, J = 9.0 Hz, 1H, H3), 7.06 (d, J = 16.5 Hz, 1H, Ha), 
7.17 (d, J = 2.0 Hz, 1H, H6), 7.46 (d, J =  16.5 Hz, 1H, Ha’)
(E) -  3, 3’, 4, 5, 5’ pentamethoxystilbene [18]
White crystals. Yield = 74%. mp = 132 °C (lit: 136-138 °C [Murias et al. 2004]) 
Recrystallise (EtOH/water).
1H NMR (CDCU1 5 3.86 (s, 6H, 2 x OCH3), 3.90 (s, 3H, OCH3), 3.94 (s, 6H, 2 
x OCH3), 6.42 (t, J = 2.5 Hz, 1H, H4’), 6.69 (d, J = 2.0 Hz, 2H, H2, H6), 6.76 
(s, 2H, H2’, H6’), 6.96 (d, J=  16.0 Hz, 1H, Ha), 7.04 (d, J =  16.0 Hz, 1H, Ha’)
(E) — 3-fluoro-4’-methoxy stilbene [19]
Colourless crystals. Yield = 1%. Mp = 108-110 °C (lit: 108-110 °C [Ager et al. 
1972]). Recrystallise (EtOH/water).
1H NMR (CDCIV1 5 3.86 (s, 3H, OCH3), 6.93 (d, J = 8.5 Hz, 1H, H6), 6.94 (d, 
J=  10.0 Hz, 1H, H4), 6.95 (d, J=  16.5 Hz, 1H, Ha), 7.07 (d, J =  16.5 Hz, 1H, 
Ha’), 7.21 (dt, J=  10.5, 2 Hz, 1H, H5), 7.26 (d, J=  8.0 Hz, 2H, H2,’ H6’), 7.32 
(m, 1H, H2), 7.48 (d, J = 8.5 Hz, 2H, H3’, H5’)
(E) -  3’-methoxy 3-fluoro stilbene [20]
Colourless oil. Yield = 48%. (lit: Mitchell and Phillips 1975). Column 
chromatography (hexane: ethyl acetate = 9:1).
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1H NMR (CPCI3) 6 3.89 (s, 3H, OCH3), 6.88 (dd, J=  2.5, 8.5 Hz, 1H, H4'),
7.00 (t, J= 9.0 Hz, 1H, H5), 7.10 (m, 3H, Ha', H2’, H6’), 7.15 (d, J = 16.0 Hz, 
1H, Ha), 7.25 (d, J=  10.0 Hz, 1H, H4), 7.33 (m, 3H, H2, H6, H5’).
(E) -  3’-methoxy 4-fluoro stilbene [28]
White crystals. Yield = 7%. Mp = 45-46 °C (lit: 43-44 °C [Ager et al. 1972]). 
Column chromatography (hexane: ethyl acetate = 9:1).
1H NMR iCDChi 6 3.88 (s, 3H, OCH3), 6.86 (dd, J= 2.5, 8.5 Hz, 1H, H4’),
7.03 (t, J = 16.0 Hz, 2H, Ha, Ha’), 7.10 (m, 4H, H2, H6, H2’, H6’), 7.31 (t, J =
8.0 Hz, 1H, H5’), 7.50 (q, J = 5.0 Hz, 2H, H3,H5)
(E) -  4-fluoro 4’-methoxy stilbene [29]
White solids. Yield = 79%. Mp = 146-147 °C (lit: 147-149 °C [Pews and Ojha 
1969]). Recrystallise (EtOH/water).
1H NMR /CDCkl 6 3.86 (s, 3H, OCH3), 6.92 (d, J = 8.5 Hz, 2H, H3’, H5’),
6.98 (d, J = 8.5 Hz, 2H, H2’, H6’), 7.06 (t, J = 16.0 Hz, 2H, Ha, Ha’), 7.47 (m, 
4H, H3, H5, H2, H6)
(E) -  4-nitro 3’-methoxy stilbene [33]
Light orange solid. Yield = 52%. Mp = 78-79 °C (lit: 87-88 °C [Guesten & 
Salzwedel 1967]). Recrystallise (EtOH/water).
1H NMR (CDChl 5 3.89 (s, 3H, OCH3), 6.92 (dd, J = 2.5, 8.5 Hz, 1H, H4’), 
7.10 (t, J = 2.0 Hz, 1H, H2’), 7.16 (d, J =  16.5 Hz, 1H, Ha ’), 7.17 (d, J = 8.0 
Hz, 1H, H6’), 7.26 (d, 1H, J = 16.0 Hz, 1H, Ha), 7.34 (t, J = 8.0 Hz, 1H, H5’), 
7.62 (d, J = 8.5 Hz, 2H, H2, H6), 8.24 (d, J = 9.0 Hz, 2H, H3, H5)
(E) -  4-nitro 4’-methoxy stilbene [34]
Orange solid. Yield = 41%. Mp = 126-127 °C (lit: 133 °C [Guesten and 
Salzwedel 1967]). Recrystallise (EtOH/water).
1H NMR (CDCkt 5 3.88 (s, 3H, OCH3), 6.96 (d, J = 9.0 Hz, 2H, H3’, H5’),
7.03 (d, J=  16.0 Hz, 1H, Ha’), 7.25 (d, J =  16.0 Hz, 1H, Ha), 7.52 (d, J = 9.0 
Hz, 2H, H2’, H6’), 7.62 (d, J = 9.0 Hz, H2, H6) 8.23 (d, J = 9.0 Hz, 2H, H3, 
H5).
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(E) -  4-bromo 3’-methoxy stilbene [35]
Yellow crystals. Yield = 30%. Mp = 80-81 °C [lit: Alowi et al. 2006]
Recrystallise (EtOH/water).
1H NMR (CDCIa) 5 3.88 (s, 3H, OCH3), 6.86 (dd. J = 2, 8.5 Hz, 1H, H4’), 7.04 
(d, J =  16.5 Hz, 1H, Ha), 7.06 (d, J = 3.0 Hz, 1H, H2’), 7.10 (d, J =  16.0 Hz,
1H, Ha’), 7.13 (d, J = 8.0 Hz, 1H, H6’), 7.31 (d, J = 8.0 Hz, 1H, H5’) , 7.40 (d, 
J = 8.5 Hz, 2H, H2, H6), 7.50 (d, J = 8.5 Hz, 2H, H3, H5).
(E) -  4-bromo 4’-methoxy stilbene [36]
Pale yellow solid. Yield = 69%. Mp = 181-182 °C (lit: 177-179 °C [Diana et al.
1978]). Recrystallise (EtOH/water).
1H NMR (CDCU15 3.86 (s. 3H. OCH3), 6.92 (d,J= 16.0 Hz, 1H, Ha), 6.93 (d, 
J = 8.0 Hz, 2H, H3’, H5’), 7.07 (d, J = 16.0 Hz, 1H, Ha’), 7.37 (d, J = 8.0 Hz, 
2H, H2’, H6’), 7.48 (t, J = 8.0 Hz, 4H, H3.H5, H2, H6).
Synthesis of protected acetyl vanillin
A solution of acetic anhydride (10.9 mmol) in ether (7.6 mL) was added to a 
well stirred mixture of 3-methoxy 4-hydroxy benzaldehyde (vanillin) (10 mmol) 
and NaOH (10 mmol) in water (7.6 mL) in ice-cold condition. After the 
addition was complete the reaction mixture was stirred at RT for 30 min. The 
organic layer was separated and the aqueous layer was extracted with ether 
( 2 x 1 0  mL). The combined organic extracts were washed with water, dried 
and evaporated to give the acetyl vanillin as white solid.
o
H
OMe
4-formyl-2-methoxyphenyl acetate [15a]
White powder. Yield = 92%. Mp = 75-76° C (lit: 75-76° C [Banerjee et al. 
2006])
1H NMR (CDCh) 5 2.37 (s, 3H, CH3), 3.94 (s, 3H, OCH3), 7.25 (d, J = 8.0 Hz, 
1H, H5), 7.50 (d, J = 8.0 Hz, 1H, H6), 7.53 (s, H-3), 9.98 (s, CHO)
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6.2.2 General method for the synthesis of 4-hydroxy 3’-methoxy (£)- 
stilbene.
A mixture of 4-hydroxy benzaldehydes (6.5 mmol), 3-methoxy phenylacetic 
acid (7.2 mmol), methylimidazole (9.8 mmol), piperidine (9.8 mmol) and 
polyethylene glycol (PEG - average molecular weight: 200) (4-5 mL) were 
added in a 50 mL round bottom flask. The flask was shaken well and 
irradiated under focused monomode microwave system (50 W, 160 °C) fitted 
with reflux condenser for 10 min. After the completion of the reaction, the 
reaction mixture was cooled and acidified with diluted 1M HCI (pH 5). Then 
the aqueous layer was extracted with ethyl acetate (2 x 20mL) and the 
organic layer was dried over magnesium sulphate to obtain crude product. It 
was further purified by column chromatography with a 1:5 mixture of ethyl 
acetate and hexane to give the pure hydroxylated stilbene analogues.
(E) -  3’-methoxy 4-hydroxy stilbene [22]
White solid. Yield = 25%. mp = 120-122 °C (lit: 132-134 °C [Sinha et al. 
2007 ])
1H NMR (CDCh) 5 3.88 (s, 3H, OCH3), 6.83 (d, J = 2.5 Hz, 1H, H2’), 6.86 (d, 
J = 8.5 Hz, 2H, H3, H5), 6.97 (d, J = 16.5 Hz, 1H, Ha), 7.07 (d, J = 16.5 Hz, 
1H, Ha’), 7.12 (d, J=  7.5 Hz, 2H, H4\H6’), 7.30 (t, J=  8 Hz, 1H, H5’), 7.43 (d, 
J = 8.5 Hz, 2H, H2, H6).
6.2.3 Synthesis of fluorinated stilbenes via Heck reaction:
Synthesis of palladium-oxazoline complex.
To a methanol solution of Li2PdCl4 (0.28M; 2.0 mL, 0.56 mmol) was added 
MeOH (7 mL) and 2-ethyl-2-oxazoline (1.0 mL; 9.9 mmol) at room 
temperature in air. The mixture was stirred for 3 h during which time an 
orange precipitate formed. This solid was then isolated by filtration and 
washed with MeOH ( 3 x 7  mL), petroleum ether (3 x 7mL) and diethyl ether 
( 3 x 7  mL) and dried in air. The palladium-oxazoline complex was obtained 
as an orange solid.
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Palladium oxazoline complex (Pd-Ox) [29a]
Orange solid. Yield = 70%. Mp = 173-174 °C (lit: 178-179 °C [Gossage et al.
2004])
1H NMR (CDCy 5 1.42 (t, J = 8.0 Hz, 3H, CH3,), 3.02 (q, J = 8.0 Hz, J = 16.0 
Hz, 2H, CH2CH3), 3.99 (t, J = 10.0 Hz, 2 H, CH2N), 4.45 (t, J = 10.0 Hz, 2 H, 
CH20).
General procedure for the synthesis o f substituted stilbenes via Heck 
reaction
Substituted iodobenzene (5 mmol), palladium-oxazoline complex (5 mol%), 
substituted styrene (5 mmol) and sodium acetate (6 mmol) were dissolved in 
DMF (5 mL). The mixture was heated between 140-150 °C until the 
completion of the reaction (5-48 h) monitored by TLC. The reaction mixture 
was cooled to RT, quenched with water and the precipitate was collected 
and allowed to dry. The precipitate was then purified by column 
chromatography (hexane: ethyl acetate = 5:1) to afford the pure compound in 
moderate yield.
Compound no. R Ri
29 4-F 4-OMe
31 4-F 4-F
32 (unprotected) 4-OH 4-F
32 (protected) 4-OAc 4-F
F:t
b
C h a p t e r  6 : E x p e r i m e n t a l  1162
(E) -  4-fluoro 4’-methoxy stilbene [29]
White solids. Yield = 79%. Mp = 146-147°C (lit: 147-149°C [Pews and Ojha 
1969])
1H NMR (CPChl 6 3.86 (s, 3H, OCH3), 6.92 (d, J = 8.5 Hz, 2H, H3\ H5’),
6.98 (d, J = 8.5 Hz, 2H, H2\ H6’), 7.06 (d, J = 16.0 Hz, 1H, Ha), 7.09 (d, J =
16.0 Hz, 1H, Ha’), 7.47 (m, 4H, H3, H5, H2, H6)
(E) -  4, 4’-difluoro stilbene [31]
Light yellow crystals. Yield = 55%. Mp = 132-134°C (lit: 130°C [Ager et al. 
1972])
1H NMR (CDCh) 6 7.03 (s, 2H, Ha, Ha’), 7.08 (t, J = 9.0 Hz, 4H, H3, H5, H3’, 
H5’), 7.49 (dd, J = 2.5, 9.0 Hz, 4H, H2, H6, H2’, H6’).
(E) -  4-fluoro 4’-hydroxy stilbene [32]
Yellowish solid. Yield = 87%. Mp = 179-180 °C (lit: 179-180 °C [Lion et al.
2005])
1H NMR (CDChl 5 6.77 (d, 2H, H2’, H6’, J = 9.0 Hz), 7.01 (d, J = 16.5 Hz, 1H, 
Ha’), 7.09 (d, J =  16.5 Hz, 1H, Ha), 7.18 (t, J=  9.0 Hz, 2H, H2, H6), 7.41 (d, 
J = 9.0 Hz, 2H, H3’, H5’), 7.58 (m, 2H, H3, H5), 9.56 (s, 1H, OH)
Synthesis of protected iodophenol (acetic acid 4-iodophenoi ester)
Acetic anhydride (4.3 mL, 45.47 mmol) was added to a solution of 4- 
iodophenol (1.0 g, 4.55 mmol) in pyridine (5 mL). After stirring for 24 h, the 
reaction was concentrated in vacuo and purified by flash chromatography (10 
hexane: 1 ethyl acetate) to yield the protected iodophenol as a white solid.
Acetic-acid 4-iodophenol ester [32a]
White crystals. Yield = 88%. Mp = 46-47 °C (lit: 45-46 °C [Adamski-Werner et 
al. 2004])
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1H NMR (CDCy 6 2.3 (s, 3H, CH3), 6.89 (d, J = 9 Hz, 2H, H-2, H6), 7.71 (d, 
J = 9 Hz, 2H, H3, H5)
Method for synthesis of substituted stilbenes via Heck reaction in PTS
(dtbpf) PdCb (0.01 mmol) and 4-fluoroiodobenzene (0.5 mmol) were added 
under inert atmosphere to a flask equipped with a large stir bar and a septum. 
Commercially available PTS solution (1.0 mL), triethylamine (1.5 mmol) and
4-methoxy styrene (1.0 mmol) were added via syringe. The heterogenous 
mixture was stirred vigorously at RT, becoming pseudo-homogenous after 
20-40 minutes. After the completion of the reaction, the mixture was diluted 
with ethyl acetate (~1.5 mL) and filtered through a pad of silica gel using 
ethyl acetate as the eluent. The volatiles were removed in vacuo. The crude 
product was purified by recrystallisation in ethanol to afford compound 29 in 
moderate yield (35%) (NMR as previously described).
6.3 Synthesis of indole-containing 3,5-diarylisoxazoles as potential 
anticancer agents
6.3.1 Synthesis of 3-(1H-indol-2-yl)-5-phenylisoxazoles and 3-(1- 
methyl-1H-indol-2-yl)-5-phenylisoxazoles via condensation or 
cyclisation of alkynyl ketones and hydroxylamine
General procedure for the synthesis of acid chlorides
o^ ^  (61a); R = OMe; R1 = H
N Cl (63a) ; R = H; R1 = CH3i
Ri
To a stirred suspension of indole-2-carboxylic acid (20 mmol) in dry 
dichloromethane (30 mL), oxalyl chloride (25 mmol) was added followed by a 
catalytic amount of DMF (1-2 drops). The mixture was stirred at room 
temperature for 24 hours. The resulting solution was dried in vacuo to afford 
the acid chlorides in excellent yield which were used straight away in the 
next reaction.
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5-Methoxy-1tf-indole-2-carbonyl chloride [61a]
Prepared according to the general procedure for the synthesis of acid 
chlorides, using 5-methoxy-1/-/-indole-2-carboxylic acid as the starting 
material.
Dark green solid. Yield: 97%; m.p: 186-188 °C [ref: Wahlstroem et al. 2004]. 
1H NMR (CDCIa) 5 3.76 (s. 3H, OCH3), 6.89 (dd, J = 2.5, 9.0 Hz, 1H, H5),
6.99 (d, J=  1.5 Hz, 1H, H3), 7.10 (d, J=  1.0 Hz, 1H, H4), 7.32 (d, J=  9.0 Hz, 
1H, H6), 11.95 (s, 1H, NH).
1-Methyl-1 tf-indole-2-carbonyl chloride [63a]
Prepared according to the general procedure for the synthesis of acid 
chlorides, using 1-methyl-1 H-indole-2-carboxylic acid as the starting material. 
Brown solid. Yield: 98%; m.p.: 123 °C [ref: Eggers et al. 2007].
1H NMR (CDCM 5 4.00 (s, 3H, CH3), 7.11 (t, J =8.0 Hz, 1H, H5), 7.22 (s, 1H, 
H3), 7.32 (td, J =  1.0, 8.0 Hz, 1H, H6), 7.56 (d, J = 9.0 Hz, 1H, H4), 7.68 (d, J 
= 9.0 Hz, 1H, H7).
General procedure for preparation of 1-(1H-indol-2-yl)-3-(phenyl)-prop-
2-yn-1-one and 1-(1 -methyl-1 H-indol-2-yl)-3-(phenyl)-prop-2-yn-1 -one
3'
Compound no: R1 R2 R3
61c o c h 3 H 3-OCH3
62c o c h 3 H 3-F
63c H c h 3 4-OCH3
64c H c h 3 3-F
65c H c h 3 3-OCH3
To a solution of indole-2-carbonylchloride (1.55 mmol) and terminal alkyne 
(1.1 mmol) in dry THF was added triethylamine (1.1 mmol), Cul (3 mol%) 
and PdCI2(PPh3)2 (0.9 mol%). The mixture was stirred at room temperature 
under nitrogen atmosphere. The reaction was completed in 30 minutes to 1 
hour by TLC analysis. The mixture was washed with water (5 mL) and 
extracted with ethyl acetate (5 mL x 3) to remove the amine hydrochloric acid 
salt. The organic layer was dried over MgS04  and evaporated in vacuo. The
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resulting crude compound was purified by column chromatography (hexane: 
ethyl acetate = 4:1).
1 -(5-methoxy-1 tf-indol-2-yl)-3-(3-methoxyphenyl)-prop-2-yn-1 -one [61 c]
Prepared according to general procedure starting with 5-methoxyindol-2- 
carbonylchloride and 3-ethynylanisole.
Green solid. Yield: 23%, m.p.: 147°C.
1H NMR (CDCIO 6 3.88 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 7.06 (d, J = 2.0 
Hz, 1H, H2’), 7.08 (d, J = 2.5 Hz, 1H, H3), 7.11 (dd, J = 2.0, 8.0 Hz, 1H, H4’),
7.15 (d, J = 2.5 Hz, 1H, H4), 7.23 (d, J = 9.0 Hz, 1H, H5’), 7.39 (d, .7=8.0 Hz, 
1H, H5), 7.41 (d, J = 8.0 Hz, 1H, H6), 7.45 (dd, J = 2.0, 8.0 Hz, 1H, H6’),
8.97 (s, 1H, NH).
13C NMR (CDCkt 5 55.45, 55.67 (OCH3 x 2), 86.52, 91.61 (C2”, C3”), 102.82, 
113.03, 113.26, 117.51 (C3, C4, C6, C7), 118.96, 119.35, 127.57, 129.81 
(C2’, C4’, C5’, C6’), 121.15, 127.89, 133.73 (C2, C3a, C7a), 137.12 (C1’),
155.04 (C3’), 159.50 (C5), 168.50 (C1”).
1-(5-methoxy-1//-indol-2-yl)-3-(3-fluorophenyl)-prop-2-yn-1-one [62c]
Prepared according to general procedure starting with 5-methoxy indol-2- 
carbonyl chloride and 3-fluorophenyl acetylene.
Light green solid. Yield: 33%, m.p.: 142 °C.
1H NMR (CDCIO 5 3.89 (s, 3H, OCH3), 7.11 (dd, J =2.5, 9.0 Hz, 1H, H6’), 
7.14 (d, J = 2.5 Hz, 1H, H3), 7.23 (td, J =2.5, 9.0 Hz, 1H, H5’), 7.36 (d, J =
9.0 Hz, 1H, H5), 7.37-7.44 (m, 2H, H 2', H4’), 7.46 (d, J = 2.0 Hz, 1H, H4),
7.51 (d, J = 7.5 Hz, 1H, H6), 9.17 (s, 1H, NH)
13C NMR (CDCIO 5 55.67 (OCH3), 87.07, 89.63 (C2”, C3”), 102.83, 113.20, 
113.32, 130.40 (C3, C4, C6, C7), 118.08 (d, J = 21.4 Hz, C2’), 119.56 (d, J =
22.7 Hz, C4’), 122.0 (d, J = 10.0 Hz, C1'), 127.89 (C7a), 128.89 (d, J = 2.5 
Hz, C5’), 130.46 (C6’), 133.75 (C3a), 136.96 (C2), 155.11 (C5), 161.35 (d, J 
= 249.5 Hz, C3’), 168.18 (C1”).
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1 -(1 -methyl-1 H- indol-2-yl)-3-(4-methoxyphenyl)-prop-2-yn-1 -one [63c]
Prepared according to general procedure starting with 1-methylindol-2- 
carbonyl chloride and 4-ethynylanisole.
White solid. Yield: 64%, m.p.: 112 °C.
1H NMR (CDCtO 6 3.88 (s, 3H, OCH3), 4.15 (s. 3H, CH3), 7.97 (d, J = 9.0 Hz, 
2H, H3’, H5’), 7.20 (td, J = 2.0, 8.0 Hz, 1H, H5), 7.40 (td, J = 2.5, 8.0 Hz, 1H, 
H6), 7.46 (d, J = 9.0 Hz, 1H, H4), 7.66 (s, 1H, H3), 7.67 (d, J = 9.0 Hz, 2H, 
H2’, H6’), 7.77 (d, J = 7.5 Hz, 1H, H7)
13C NMR (CDChl 5 32.08 (CH3), 55.45 (OCH3), 87.81, 90.75 (C2”, C3”), 
110.41 (C3\ C5’), 114.40, 115.97, 120.97, 123.29, 126.67 (C3, C4, C5, C6, 
C7), 112.23, 126.01 (C3a, C7a), 134.90 (C2’, C6’), 136.28 (C1’), 140.93 (C2), 
161.52 (C4), 169.87 (C1”).
1 -(1 -methyl-1 H-indol-2-yl)-3-(3-fluorophenyl)-prop-2-yn-1 -one [64c]
Prepared according to general procedure starting with 1-methylindol-2- 
carbonylchloride and 3-fluorophenyl acetylene.
Yellow solid. Yield: 64%, m.p.: 94 °C
1H NMR (CDCht 6 4.12 (s, 3H, CH3), 7.19-7.23 (m, 2H, H2’, H6’), 7.37 (dd, J 
= 2.5, 9.5 Hz, 1H, H4’), 7.39 (m, 1H, H5'), 7.42 (t, J = 8.0 Hz, 1H, H5), 7.45 (t, 
J = 8.0 Hz, 1H, H6), 7.50 (dd, J = 2.0, 8.0 Hz, 1H, H4), 7.65 (s, 1H, H3), 7.76 
(dd, J = 2.0, 8.0 Hz, 1H, H7)
13C NMR (CDCM 8 31.62 (CH3), 87.72, 88.28 (C2”, C3”), 110.60, 116.68,
121.16, 123.20, 127.08 (C3, C4, C5, C6, C7), 117.85 (d, J = 20.2 Hz, C2’), 
119.45 (d, J = 22.7 Hz, C4’), 128.82 (C6’), 130.41 (d, J = 8.8 Hz, C5’), 
122.30, 125.99 (C3a, C7a), 135.93 (C1’), 141.13 (C2), 161.35 (d, J = 246.5 
Hz, C3’), 169.20 (C1”).
1 -(1 -methyl-1 H-indol-2-yl)-3-(3-methoxyphenyl)-prop-2-yn-1 -one [65c]
Prepared according to general procedure starting with 1 -methylindol-2- 
carbonyl chloride and 3-ethynylanisole.
Yellow solid. Yield: 95%, m.p.: 75 °C
1H NMR fCDCIO 5 3.87 (s, 3H, OCH3), 4.13 (s, 3H, CH3), 7.06 (dq, J = 1.5,
8.0 Hz, 1H, H4’), 7.21 (td, J = 2.0, 8.0 Hz, 1H, H5’), 7.23 (s, 1H, H2’), 7.33 (td, 
J = 2.0, 8.0 Hz, 1H, H5), 7.36 (d, J = 8.0 Hz, 1H, H4), 7.40 (dd, J = 2.0, 8.0
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Hz, 1H, H6’), 7.46 (td, J = 2.0, 8.0 Hz, 1H, H6), 7.68 (s, 1H, H3), 7.76 (d, J =
8.0 Hz, 1H, H7)
13C NMR (CDCM 8 32.07 (CH3), 55.44 (OCH3), 87.71, 89.59 (C2”, C3”),
110.45, 117.27, 117.51, 117.59, 121.20 (C3, C4, C5, C6, C7), 123.39,
125.46, 126.49, 127.73 (C2’, C4’, C5’ C6’), 121.36, 126.01 (C3a, C7a), 
136.11 (C1'), 141.05 (C2), 159.50 (C3'), 169.59 (C1”).
General procedure for the synthesis of 3,5-diaryl isoxazoles (via 
condensation/cyclisation of alkynyl ketones and hydroxylamine)
To a stirred solution of 1-(1/-/-indol-2-yl)-3-(phenyl)-prop-2-yn-1-one and 1-(1- 
methyl-2-indol-2-yl)-3-(phenyl)-prop-2-yn-1-one (61c to 65c) in ethanol (15 
ml) and pyridine (5 ml) was added hydroxylamine hydrochloride (2.8 mmol). 
The mixture was heated under reflux for 5 hours and monitored by TLC. The 
reaction mixture was cooled and the solvent was evaporated to dryness. 
Water (10 mL) was added to the residue and extracted with ethyl acetate (10 
mL x 3). The organic layer was dried and evaporated. The crude compound 
was further purified by column chromatography (hexane: ethyl acetate = 6:1) 
as eluent.
3-(5-Methoxy-1 A/-indol-2-yl)-5-(3-methoxyphenyl)isoxazole (61):
MeO.
OMe
5'
Prepared according to the general procedure starting with 1 -(5-methoxy-1 H-
2-indol-2-yl)-3-(3-methoxyphenyl)-prop-2-yn-1 -one [61 c].
Orange solid. Yield: 25%; m.p.: 202 °C
1H NMR (CDCIs) 5 3.90 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 6.80 (s, 1H, H4”),
6.97 (d, J = 2.0 Hz, 1H, H2’), 6.99 (d, J = 2.5 Hz, 1H, H3), 7.05 (dd, J = 2.0,
8.0 Hz, 1H, H4’), 7.12 (d, J = 2.5 Hz, 1H, H4), 7.35 (d, J = 9.0 Hz, 1H, H5’), 
7.40 (d, J = 8.0 Hz, 1H, H6), 7.42 (d, J = 8.0 Hz, 1H, H7), 7.46 (dd, J = 2.0,
8.0 Hz, 1H, H6’), 8.76 (s, 1H, NH).
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13C NMR (CDCIO 5 55.43, 55.78 (OCH3 X 2), 97.32 (C4”), 102.35, 103.31,
111.87, 112.32 (C3, C4, C6, C7), 115.18, 116.29, 119.41, 130.04 (C2', C4’, 
C5’, C6’), 125.57, 128.62 (C3a, C7a), 131.88 (C2), 132.11 (C1’), 154.90 
(C3’), 160.03 (C5), 162.97 (C5”), 163.80 (C3”).
MS (El positive ion) m/z 320.12 (M+)
HRMS (ES) m/z = 321.1236 [M+Hf; calcd: 320.1161.
3-(5-Methoxy-1tf-indol-2-yl)-5-(3-fluorophenyl)isoxazole (62) and 5-(5- 
Methoxy-1 H-indol-2-yl)-3-(3-fluorophenyl)isoxazole (62b):
Prepared according to the general procedure starting with 1-(5-methoxy-1H-
2-indol-2-yl)-3-(3-fluorophenyl)-prop-2-yn-1-one [62c]. The first isomer (62) 
was eluted first followed by the second isomer (62b), while a few fractions 
remain inseparable as a mixture of both isomers.
3-(5-Methoxy-1 H-indol-2-yl)-5-(3-fluorophenyl)isoxazole (62)
MeO.
5'
Light yellow crystals. Yield: 2%; m.p.: 214 °C
1H NMR (CDChl S 3.90 (s, 3H, OCH3), 6.88 (s, 1H, H4-isoxazole), 6.91 (d, J 
=2.5 Hz, 1H, H4), 6.99 (dd, J=2.5, 9.5 Hz, 1H, H4’), 7.14 (d, J = 2.0 Hz, 1H, 
H3), 7.20 (m, 1H, H2’), 7.38 (d, J = 9.0 Hz, 1H, H6), 7.51 (dd, J = 5.0, 9.5 Hz, 
1H, H5’), 7.59 (d, J = 9.5 Hz, 1H, H6’), 7.67 (d, J = 8.0 Hz, 1H, H7), 8.94 (s, 
1H, NH)
13C NMR (CDChl 8 55.82 (OCH3), 98.19 (C4”), 102.44, 104.12, 112.19, 
114.83 (C3, C4, C6, C7), 113.05 (d, J = 23.4 Hz, C2’), 117.30 (d, J = 21.8 Hz, 
C4’), 121.64 (C6’), 131.80 (d, J = 7.8 Hz, C5'), 126.77, 129.84 (C3a, C7a),
131.23 (C1’), 134.77 (C2), 151.32 (C5”), 155.17 (C5), 164.23 (d, J = 246.2 
Hz, C3’) 166.13 (C3”).
MS (El positive ion) m/z 308.10 (M+)
HRMS (ES) m/z = 309.1034 [M+H]+; calcd: 308.0961.
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5-(5-Methoxy-1 tf-indol-2-yl)-3-(3-fluorophenyl)isoxazole (62b)
MeO.
5'
Yellow solid. Yield: 5%; m.p.: 117-118 °C
1H NMR (CPCI3) 8 3.90 (s, 3H, OCH3), 6.79 (s, 1H, H4”), 6.99 (d, J = 2.0 Hz, 
1H, H4), 7.00 (dd, J = 2.5, 9.0 Hz, 1H, H4’), 7.13 (d, J = 2.0 Hz, 1H, H3),
7.20 (m, 1H, H2’), 7.36 (d, J = 9.0 Hz, 1H, H6), 7.49 (dd, J = 5.0, 9.0 Hz, 1H, 
H5’), 7.60 (d, J = 9.5 Hz, 1H, H6'), 7.67 (d, J = 8.0 Hz, 1H, H7), 8.67 (s, 1H, 
NH)
13C NMR (CDCI-0 8 55.77 (OCH3), 97.07 (C4"), 102.37, 103.51, 112.19, 
115.37 (C3, C4, C6, C7), 114.01 (d, J = 23.9 Hz, C2'), 117.21 (d, J = 21.4 Hz, 
C4’), 122.61 (C6’), 130.60 (d, J = 8.8 Hz, C5’), 125.34, 128.60 (C3a, C7a),
130.67 (C1’), 132.12 (C2), 150.90 (C5”), 154.96 (C5), 162.08 (d, J = 245.7 
Hz, C3’), 164.13 (C3”).
MS (El positive ion) m/z 308.10 (M+)
HRMS (ES) m/z = 309.1031 [M+Hf; calcd: 308.0961.
3-(1-methyl-1 H-indol-2-yl)-5-(4-methoxyphenyl)isoxazole (63)
OMe
5'
Prepared according to general procedure starting with 1 -(1 -methyl-1H- indol-
2-yl)-3-(4-methoxyphenyl)-prop-2-yn-1 -one [63c]
Yield: 56%; m.p.: 168 °C
1H NMR ICDCU1 5 3.90 (s, 3H, OCH3), 4.07 (s, 3H, CH3), 6.79 (s, 1H, H4”),
7.03 (d, J = 9.0 Hz, 2H, H3’, H5’), 7.05 (s, 1H, H3), 7.20 (t, J = 8.0 Hz, 1H, 
H5), 7.36 (t, J = 8.0 Hz, 1H, H6), 7.43 (d, J = 9.0 Hz, 1H, H4), 7.69 (d, J = 7.5 
Hz, 1H, H7) , 7.86 (d, J =  9.0 Hz, 2H, H2’, H6’)
13C NMR (CDCkl 5 31.83 (CH3), 55.39 (OCH3), 99.55 (C4”), 109.82 (C3’, 
C5’), 104.69, 114.41, 120.51, 121.52, 123.65 (C3, C4, C5, C6, C7), 121.18,
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127.25 (C3a, C7a), 128.28 (C2\ C6 ’), 127.30 (C1’), 138.88 (C2), 161.16 
(C4’), 162.27, 164.05 (C3”, C5”).
MS (El positive ion) m/z 304.13 (M+)
Anal, calcd for C19H16N2O2; C, 74.98; H, 5.30; N, 9.20; found C, 74.84; H, 
5.29; N, 9.20.
3-(1 -Methyl-1 H-indol-2-yl)-5-(3-fluorophenyl)isoxazole (64)
5'
Prepared according to general procedure starting with 1-(1-methyl-1H- indol-
2-yl)-3-(3-fluorophenyl)-prop-2-yn-1 -one [64c]
Yield: 18%; m.p.: 124 °C
1H NMR (CDCy 6 4.07 (s, 3H, CH3), 6.83 (s, 1H, H4”), 7.08 (d, J = 2.0 Hz, 
1H, H3), 7.19-7.23 (m, 2H, H2’, H6 ’), 7.37 (td J = 2.5, 9.5 Hz, 1H, H5), 7.43 
(d, J = 8.0 Hz, 1H, H7), 7.49 (q, J = 5.0, 9.5 Hz, 1H, H5'), 7.64 (dd, J = 2.5,
9.5 Hz, 1H, H4’), 7.68 (d, J = 8.0 Hz, 1H, H4), 7.72 (t, J = 8.0 Hz, 1H, H6 )
13C NMR (CDCkl fi 31.82 (CH3), 99.54 (C4”), 105.01, 109.87, 120.62, 121.60, 
122.61 (C3, C4, C5, C6 , C7), 113.80 (d, J = 22.7 Hz, C2’), 117.02 (d, J =
21.4 Hz, C4’), 123.86 (C6 ’), 130.62 (d, J = 8.8  Hz, C5'), 127.20, 130.89 (C3a, 
C7a), 138.95 (C2), 161.73 (C5”), 162.08 (d, J = 248.2 Hz, C3’), 164.66 (C3”). 
MS (El positive ion) m/z 292.11 (M+)
Anal, calcd for Ci8Hi3N2OF; C, 73.96; H, 4.48; N, 9.58; found C, 73.93; H, 
4.40; N, 9.58.
3-(1-Methyl-1 H-indol-2-yl)-5-(3-methoxyphenyl)isoxazole (65) and 5-(1- 
Methyl-1 A/-indol-2-yl)-3-(3-methoxyphenyl)isoxazole (65b):
Prepared according to the general procedure starting with 1 -(1 -methyl-1 H-2- 
indol-2-yl)-3-(3-methoxyphenyl)-prop-2-yn-1-one [65c]. The first isomer (65b) 
was eluted first followed by the second isomer (65), while a few fractions 
remain inseparable as a mixture of both isomers.
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3-(1-Methyl-1 H-indol-2-yl)-5-(3-methoxyphenyl)isoxazole (65)
OMe
CH
5'
Yellow solid. Yield: 20%; m.p.: 73-74 °C
1H NMR (CDCh) S 3.92 (s, 3H, OCH3), 4.04 (s, 3H, CH3), 6.81 (s, 1H, H4 ”),
7.05 (dq, J = 1.5, 8.0 Hz, 1H, H4’), 7.07 (s, 1H, H2’), 7.21 (td, J = 2.0, 8.0 Hz, 
1H, H5’), 7.35 (td, J = 2.0, 8.0 Hz, 1H, H5), 7.42 (d, J = 8.0 Hz, 1H, H4), 
7.43 (dd, J = 2.0, 8.0 Hz, 1H, H6 ’), 7.45 (td, J = 2.0, 8.0 Hz, 1H, H6 ), 7.49 (s, 
1H, H3), 7.72 (d, J = 8.0 Hz, 1H, H7)
13C NMR (CDCIV) 5 31.82 (CH3), 55.44 (OCH3), 99.81 (C4”), 104.83, 109.85,
111.88, 120.56, 121.55 (C3, C4, C5, C6 , C7), 116.26, 119.14, 123.74,
130.05 (C2\ C4’, C5’ C6 ’), 127.15, 127.24 (C3a, C7a), 130.06 (C1’), 138.91 
(C2), 160.06 (C3'), 162.60, 164.30 (C3", C5”).
MS (El positive ion) m/z 304.12 (M+)
Anal, calcd for C19H16N2O2; C, 74.98; H, 5.30; N, 9.20; found C, 74.91; H, 
5.22; N, 9.23.
3-(1 -Methyl-1 tf-indol-2-yl)-5-(3-methoxyphenyl)isoxazole (65b)
5
OMe6
5'
Light yellow solid. Yield: 4%; m.p.: 125 °C
1H NMR (CDCU1 5 3.92 (s, 3H, OCH3), 4.18 (s, 3H, CH3), 6.86  (s, 1H, H4”),
6.98 (s, 1H, H2’), 7.04 (dq, J = 1.5, 8.0 Hz, 1H, H4’), 7.19 (td, J = 2.0, 8.0 Hz, 
1H, H5’), 7.34 (td, J = 2.0, 8.0 Hz, 1H, H5), 7.42 (d, J = 8.0 Hz, 1H, H4), 7.43 
(dd, J = 2.0, 8.0 Hz, 1H, H6 ’), 7.46 (s, 1H, H3), 7.47 (td, J = 2.0, 8.0 Hz, 1H, 
H6 ), 7.71 (d, J = 8.0 Hz, 1H, H7)
13C NMR (CDCht S 32.44 (CH3), 55.45 (OCH3), 99.70 (C4”), 104.94, 109.93,
111.16, 120.19, 121.22 (C3, C4, C5, C6 , C7), 116.34, 118.42, 123.29, 
130.19 (C2\ C4’, C5’ C6 ’), 127.32, 128.33 (C3a, C7a), 128.73 (C1’), 139.21 
(C2), 157.42 (C3’>, 160.05, 169.18 (C3”, C5”).
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MS (El positive ion) m/z 304.13 (M+)
HRMS (ES) m/z = 305.1281 [M+H]+; calcd: 304.1212.
6.3.2 Synthesis of 5-(1-methyl-indol-2-yl)-3-substituted
phenylisoxazoles via 1,3-dipolar cycloaddition 
Synthesis of 2-ethynyl-1-methyl-indole
c h 3
(66b)
p-Toluenesulfonylazide: A stirring solution of sodium azide (0.11 mol) in 20  
mL water was diluted with ethanol (40 mL) and a warm solution of p- 
toluenesulfonylchloride (190.65 mol) in 100 ml ethanol was added causing a 
separation of NaCI and a light brown mixture. After stirring for 3.5 hours, 
most of the solvent was evaporated and 20 mL water was added to the 
residue where 2 layers are formed. The oily layer is separated, dried 
(MgS04 ) and filtered to afford p-toluenesulfonylazide as colourless oil which 
solidifies at low temperatures (-20 °C) (yield: 89%).
Dimethyl-2-oxopropylphosphonate (1.2 mmol) was added to a suspension of 
K2CO3 (3 mmol) and p-toluenesulfonylazide (1.2 mmol) in acetonitrile (15 
mL) and the mixture was stirred at room temperature. After 2 hours, 1-methyl 
indole-2-carboxaldehyde (1 mmol) dissolved in 2 mL methanol was added 
and the stirring was continued for 24 hours. The solvents were removed in 
vacuo and the resultant residue was extracted with ethyl acetate, dried using 
magnesium sulfate and concentrated in vacuo. Purification with column 
chromatography (dichloromethane: methanol = 9:1) afforded the pure 
compound in moderate yield.
Orange solid. Yield: 44%; m.p.: 55 °C [lit: Banzies et al. 1986].
1H NMR (CDCh) 8 3.54 (s, 1H, H-acetylene), 3.87 (s, 3H, CH3), 6.92 (s, 1H, 
H3), 7.21 (qd, J = 2.0, 8.0 Hz, 1H, H5), 7.37 (d, J = 8.0 Hz, 1H, H4), 7.36 (qd, 
J=  1.0, 8 Hz, 1H, H6 ), 7.67 (d, J = 8.0 Hz, 1H, H7).
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General procedure for synthesis ofaldoximes
To a solution of hydroxylamine hydrochloride (7.4 mmol) in water (15 mL) 
was added sodium bicarbonate (11.2 mmol) portion wise at 0 °C and the 
mixtures were stirred for 30 min at room temperature. The aldehyde (6.2 
mmol) dissolved in methanol (20 mL) was then added to the reaction mixture 
and the mixture was stirred for additional hour. Water was added to the 
reaction mixture and the precipitate was collected by filtration to give a pure 
product of aldoxime.
4-Methoxybenzaldoxime (68b)
N -O H
Prepared according to the general procedure for synthesis of aldoxime using
4-methoxybenzaldehyde as the starting material.
Light brown solid. Yield: 78%; m.p.: 55-57 °C [lit: m.p.: 63-66 °C (Owston et 
al. 2007)].
1H NMR (CDCKI8 3.86 (s, 3H, OCH3), 6.94 (dd, J = 2.0, 9.0 Hz, 2H, H3, H5), 
7.55 (dd, J = 2.5, 8.5 Hz, 2H, H2, H6), 8.13 (s, 1H, CH=N-OH).
4-Fluorobenzaldoxime (69b)
F
Prepared according the general procedure for synthesis of aldoxime using 4- 
fluorobenzaldehyde as the starting material.
Brown solid. Yield: 86%; m.p.: 88-90°C [lit: m.p.: 115-116 °C (ref: Jain et al.
2005).
1H NMR (CDCk) 5 2.0 (bs, 1H, CH=N-OH), 7.11 (t, J = 8.0 Hz, 2H, H2, H6),
7.59 (dd, J = 2.5, 8.5 Hz, 2H, H3, H5), 8.15 (s, 1H, CH=N-OH)
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General procedure for the preparation of 3,5-diarylisoxazoles (via 1,3- 
dipolar cycloaddition)
To a solution of terminal alkyne (1.4 mmol) and triethylamine (0.14 mmol) in 
anhydrous dichloromethane was added under inert atmosphere a 13% 
aqueous solution of sodium hypochlorite NaOCI (2.6 mmol), and at 0 °C, a 
solution of oxime (1.4 mmol) in anhydrous dichloromethane was added 
dropwise over a period of 1 hour. The reaction was stirred at room 
temperature for 24 hours. After reaction completion as indicated by TLC, 
water was added and the mixture was extracted with dichloromethane. The 
organic layer was dried over MgS0 4 , evaporated under reduced pressure 
and the residue was purified by column chromatography using hexane/ethyl 
acetate (5:1) as eluent.
5-(1 -Methyl-1 tf-indol-2-yl)-3-(4-methoxyphenyl)isoxazole (66)
5
6
OMe
5'
Light brown crystals. Yield: 23%; m.p.: 169 °C
1H NMR (CDCkl 8 3.91 (s, 3H, OCH3), 4.06 (s, 3H, CH3), 6.79 (s, 1H, H4"),
7.03 (dd, J = 1.5, 8.5 Hz, 2H, H3', H5’), 7.20 (t, J = 8.0 Hz, 1H, H5), 7.35 (t, J 
= 0.5, 8.0 Hz, 1H, H6), 7.42 (d, J = 8.5 Hz, 1H, H4), 7.70 (d, J=  8.0 Hz, 1H, 
H7), 7.86 (dd, J = 2.0, 8.0 Hz, 2H, H2’, H6’)
13C NMR fCDChl 8 31.84 (CH3), 55.39 (OCH3), 99.56 (C4”), 104.96, 109.82, 
114.41, 120.51, 121.52 (C3, C4, C5, C6, C7), 121.33, 124.30 (C3a, C7a), 
123.65, 128.28 (C27C6’, C37C5’), 127.30 (C1’), 138.88 (C2), 161.16 (C4’), 
162.27, 164.05 (C3”, C5”).
MS (El positive ion) m/z 304.13 (M+)
Anal, calcd for C19H16N2O2; C, 74.98; H, 5.30; N, 9.20; found C, 74.55; H, 
5.27; N, 9.19.
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5-(1-Methyl-1 tf-indol-2-yl)-3-(4-fluorophenyl)isoxazole (67)
5
6
5'
Brown crystals. Yield: 29%; m.p.: 145 °C
1H NMR (CDCI.il 6 4.06 (s, 3H, CH3), 6.80 (s, 1H, H4”), 7.07 (s, 1H, H3),
7.21 (t, J = 8.0 Hz, 1H, H5), 7.22 (q, J = 2.0, 9.0 Hz, 2H, H2’, H6 ’), 7.36 (t, J 
= 1.0, 8.0 Hz, 1H, H6 ), 7.44 (d, J = 8.5 Hz, 1H, H4), 7.72 (d, J =  8.0 Hz, 1H, 
H7), 7.90 (q, J = 2.0, 9.0 Hz, 2H, H3’, H5’)
13C NMR (CDCkl 5 31.84 (CH*1. 99.52 (C4”), 104.92, 109.85, 120.60, 121 .57 , 
123.81 (C3, C4, C5, C6 , C7), 116.22 (d, J = 22.7 Hz, C3’, C5'), 125.08,
127.03 (C3a, C7a), 128.85 (d, J = 8.0  Hz, C2 ’, C6 ’), 127.21 (C1’), 138.93 
(C2), 161.75 (C5”), 162.94 (d, J = 250.7 Hz, C4’), 164.50 (C3”).
MS (El positive ion) m/z 292.11 (M+)
Anal, calcd for C18H13FN2O; C, 73.96; H, 4.48; N, 9.58; found C, 73.93; H, 
4.50; N, 9.59.
6.3.3 Synthesis of 5-(1H-indol-5-yl)-3-phenylisoxazoles via 1,3-dipolar 
cycloaddition
Synthesis o f 5-ethynylindole (68a)
A mixture of 5-iodoindole (0.82 mmol), triethylsilylacetylene (1.28 mmol), 
Pd(PPh3)4 (0.024 mmol), Cul (0.042 mmol) and triethylamine (0.23 mmoL) in 
acetonitrile (10 mL) was refluxed for 4 hours. After completion of reaction as 
indicated by TLC, water was added and the mixture was extracted with ethyl 
acetate, the organic layer was dried over magnesium sulfate and evaporated 
in vacuo. The residue containing 5-(2-triethylsilylethynyl)-indole (68a-i) was 
used in the next step without further purification.
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The residue was dissolved in THF, 1 mmol of 1 M TBAF was added, and the 
mixture was stirred at room temperature for 24 hours. Water was added and 
the mixture was extracted with ethyl acetate. The organic layer was dried 
over magnesium sulfate and evaporated under reduced pressure. The 
residue was purified by column chromatography using petroleum etherethyl 
acetate (2:1) as eluent to afford compound 5-ethynyl-1/-/-indole (68a) in good 
purity.
Brown solid. Yield: 61%; m.p.: 59-60 °C
1H NMR (CDCU) 8 2.95 (s, 1H, H-acetylene), 6.48 (d, J = 8.0 Hz, 1H, H7),
7.16 (dd, J = 2.0, 8.0 Hz, 1H, H6), 7.29 (s, 2H, H 2, H3), 7.87 (s, 1H, H4),
8.23 (bs, 1H, NH).
13C NMR (CDCh) 8 74.02 (CH of acetylene), 85.26 (C of acetylene), 101.25,
110.98, 122.93, 124.77, 126.90 (C2, C3, C4, C6, C7), 111.98, 126.87, 
137.01 (C3a, C5, C7a).
Synthesis of substituted benzaldoxime
3,4,5-trimethoxybenzaldoxime (70b)
MeO.
MeO'
OMe
Prepared according the general procedure for synthesis of aldoxime using
3,4,5-trimethoxybenzaldehyde as the starting material.
White solid. Yield: 90%; m.p.: 88-90 °C [lit: m.p.: 95-97 °C (Simoni et al.
2006).
1H NMR (CDCIV) 5 3.90 (s, 9H, OCH3), 6.84 (s, 2H, H2. H6), 8.08 (s, 1H, 
CH=N-OH).
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Synthesis of 5-(1H-indol-5-yl)-3-phenylisoxazoles 
5-(1 H-indol-5-yl)-3-(4-meyhoxyphenyl)isoxazole (68)
OMe
2
Prepared according to the general procedure for synthesis of 3 ,5-diaryl 
isoxazoles (via 1,3-dipolar cycloaddition) using 5-ethynylindole (68a) and 4- 
methoxybenzaldoxime (68b) as the starting materials.
Brown solid. Yield: 7%; m.p.: 151-152 °C
1H NMR (CDCy 8 3.90 (s, 3H, OCH3), 6.67 (s, 1H, H2), 6.76 (s, 1H, H4”),
7.02 (d, J = 8.0 Hz, 2H, H3’, H5’), 7.32 (s, 1H, H4), 7.50 (d, J = 8.0 Hz, 1H, 
H6 ), 7.70 (d, J = 8.0 Hz, 1H, H7), 7.85 (d, J = 8.0 Hz, 2H, H2', H6 '), 8.19 (s, 
1H, H3), 8.33 (s, 1H, NH).
13C NMR (CDCIV) 8 55.74 (OCH3), 96.13 (C4"), 103.64, 112.06, 119.01,
120.05, 126.19 (C2 , C3, C4, C6 , C7), 114.68 (C3’,C5’), 120.32 (C1’), 121.37, 
129.70 (C3a, C7a), 128.47 (C2’, C6 ’), 137.13 (C2), 161.43 (C4’), 162.86, 
163.09 (C3”, C5”).
MS (El positive ion) m/z 290.11 (M+)
HRMS (ES) m/z = 291.1122 [M+H]+; calcd: 290.1055.
5-(1 H-indol-5-yl)-3-(4-fluoroyphenyl)isoxazole (69)
2
Prepared according to the general procedure for synthesis of 3,5-diaryl 
isoxazoles (via 1,3-dipolar cycloaddition) using 5-ethynylindole (68a) and 4- 
fluorobenzaldoxime (69b) as the starting materials.
Brown crystals. Yield: 36%; m.p.: 162-163 °C
1H NMR (CDCI3) 5 6.69 (s, 1H, H2), 6.77 (s, 1H, H4”), 7.09 (dd, J = 2.5, 9.5 
Hz, 2H, H3\ H5’), 7.32 (s, 1H, H4), 7.51 (d, J = 8.0 Hz, 1H, H7), 7.70 (d, J =
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8.0 Hz, 1H, H6 ), 7.90 (dd, J = 2.5, 8.5 Hz, 2H, H2\ H6 ’), 8.19 (s, 1H, H3), 
8.34 (s, 1H, NH).
13C NMR CCDCIO 5 95.86 (C4”), 103.63, 111.63, 119.00, 120.16, 125.59 (C2, 
C3, C4, C6 , C7), 115.89 (d, J = 25.1 Hz, C3’, C5’), 120.28 (C1 ’), 125.08,
128.06 (C3a, C7a), 128.72 (d, J = 10.2 Hz, C2', C6 ’), 136.75 (C2), 162.00 
(C5”), 162.90 (d, J = 248.5 Hz, C4’), 169.03 (C3”).
MS (El positive ion) m/z 278.09 (M+)
HRMS (ES) m/z = 279.0932 [M+H]+; calcd: 278.0855.
5-(1 H-indol-5-yl)-3-(3,4,5-trimethoxyphenyl)isoxazole (70)
OMe
OMe
2 OMe
Prepared according to the general procedure for synthesis of 3,5-diaryl 
isoxazoles (via 1,3-dipolar cycloaddition) using 5-ethynylindole (68a) and
3,4,5-trimethoxybenzaldoxime (70b) as the starting materials.
White solid. Yield: 29%; m.p.: 57-58 °C
1H NMR (CDCM 5 3.94 (s, 3H, OCH3), 3.95 (s, 6 H, OCH3X 2), 6.66  (s, 1H, 
H2), 6.78 (S, 1H, H4”), 7.14 (s, 2H, H2’, H6 ’), 7.30 (s, 1H, H4), 7.50 (d, J =
8.0 Hz, 1H, H6 ), 7.70 (d, J = 8.0 Hz, 1H, H7), 8.19 (s, 1H, H3), 8.77 (s, 1H, 
NH)
13C NMR (CDCIO 8 56.31 (OCH3 x 2 ), 60.93 (OCH3), 96.01 (C4”), 103.47,
104.16, 111.67, 118.94, 120.07 (C2, C3, C4, C6 , C7), 119.53 (C1 ’), 124.98,
128.07 (C3a, C7a), 125.71 (C2', C6 ’), 136.80 (C2), 139.54 (C3’, C5’), 153.61 
(C4’), 162.85, 172.17 (C3”, C5”).
MS (El positive ion) m/z 350.13 (M+)
HRMS (ES) m/z = 351.1343 [M+Hf ; calcd: 350.1267.
Synthesis of(E)-1H-indole-3-carbaldehyde oxime
OH
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Prepared according the general procedure for synthesis of aldoxime using 
indole-3-carboxaldehyde as the starting material.
Yield: 73%, m.p.: 178-179 °C
CH=N-OH).
13C NMR (DMSO-dfi) 8 106.31 (C3), 111.73, 118.15, 119.86, 121.84, 130.43
6.4 Synthesis of specific inhibitors targeting the Dvl PDZ domain of 
Wnt signaling pathway: analogues of 3289-8625
Synthesis of methyl 3-nitro-4-methyl-benzoate (50a)
A mixture of 3-nitro-4 -methyl-benzoic acid (0.1 mmol) and 
chlorotrimethylsilane (0.35 mmol) in methanol (0.5 mmol) was heated at 
reflux for 5 hours until the evolution of hydrogen chloride was no longer 
observed. Volatile product was removed under atmospheric pressure. The 
resulting brown solid were further purified by using acid base extraction, 
where the solid were diluted in ethyl acetate, and excess benzoic acid were 
washed away be extracting three times with sodium bicarbonate solution, 
washed with brine, dried over magnesium sulphate and evaporated to give 
the pure compound.
Light yellow solid. Yield: 71%; m.p.: 42-44 °C [lit: 49-50 °C (Noyce and Dolby 
1961)].
1H NMR (CDCIs) 8 2.69 (s, 3 H, CH3), 3.98 (s, 3H, OCH3), 7.45 (d, J = 8.0 Hz,
NMR (DMSO-dfi) 6 7.12 (t, J = 8.0 Hz, 1H, H5), 7.18 (t, J = 8.0 Hz, 1H, 
H6 ), 7.45 (d, J = 8.0 Hz, 1H, H4), 7.80 (s, 1H, NH), 7.86 (d, J = 8.0 Hz, 1H, 
H7), 8.25 (d, J = 1.5 Hz, 1H, H2), 11.19 (s, 1H, CH=N-OH), 11.57 (s, 1H,
(C2, C4, C5, C6 , C7), 126.19, 134.90 (C3a, C7a), 138.35(-CH=N-OH).
O
1H, H5), 8.16 (d, J = 8.0 Hz, 1H, H6 ), 8.63 (d, J=  1.5 Hz, 1H, H2).
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Methyl 3-amino-4-methyl-benzoate (50b)
o
h2n o c h 3
h3c
Pd(C) (10%) was added to a solution of compound 50a (11 mmol) in ethanol 
(200 mL) at room temperature. The reaction mixture was stirred vigorously 
under an atmosphere of H2 (balloon) for 23 h before being filtered through a 
plug of Celite and washed with ethanol (2x10  mL). The resulting filtrate was 
concentrated under vacuum before being purified by column chromatography 
(hexane: diethyl ether = 4:1).
Yellow crystals. Yield: 86%; m.p.: 113-115 °C [lit: 114-115 °C (Noyce and 
Dolby 1961)].
1H NMR (CDCU1 8 2.25 (s, 3H, CH3), 3.90 (s, 3H, OCH3), 4.19 (bs, 2 H, NH2),
7.13 (d, J = 8.0 Hz, 1H, H5), 7.40 (s, 1H, H2), 7.43 (d, J = 8.0 Hz, 1H, H6 )
GeneraI procedure for the synthesis of Methyl 5-amino-2-chloro-4- 
methyIbenzoate (51) and Methyl 3-amino-2-chlorO‘4-methylbenzoate
A mixture of compound 50b (16.9 mmol) and A/-chlorosuccinimide (NCS) 
(1.15 equivalents) in acetonitrile (50 mL) was refluxed for 18 h, then poured 
into a mixture of 1g Na2S03  dissolved in 200 mL water. The mixture was 
extracted twice with 50 mL portions of diethyl ether. The organic phases 
were collected, washed with water (50 mL) and brine (50 mL), dried over 
magnesium sulfate and evaporated in vacuo. Further purification need to be 
carried out to separate the formed isomers by column chromatography using 
hexane: ethyl acetate (6:1) as eluent, to afford compound 51 and 52 in low to 
moderate yield respectively.
Methyl 5-amino-2-chloro-4-methylbenzoate (51)
o
(52).
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Prepared according to the general procedure to synthesis compound 51 and 
52. Compound 51 was eluted second in low yield.
Dark brown oil. Yield: 20%; [lit: Berger et al. 2010].
7.14 (s, 1H, H 6 ), 7.18 (s, 1H, H3).
13c  NMR (CDCh) 5 17.20 (CH3), 52.18 (OCH3), 117.24 (C6), 122.40, 127.70, 
127.79 (C2, C4, C5), 132.52 (C3), 143.18 (C1), 166.26 (C=0).
MS (El positive ion) m/z 199.03 (M+)
Methyl 3-amino-2-chloro-4-methylbenzoate (52)
Cl o
Prepared according to the general procedure to synthesise compound 51 
and 52. Compound 52 was eluted first in moderate yield.
Orange oil. Yield: 43%; [ref: Mitani et al. 2006]
1H NMR (CDCkl 8 2.27 (s, 3H, CH3), 3.92 (s, 3H, OCH3), 4.3 (bs, 2H, NH2),
7.02 (d, J = 8.0 Hz, 1H, H5), 7.18 (d, J = 8.0 Hz, 1H, H6 )
13C NMR (CDCkl 6 18.33 (CH3), 52.20 (OCH3), 111.3, 126.94, 128.35 (C2 , 
C3, C4), 120.08, 127.94 (C5, C6 ), 142.21 (C1), 166.71 (C=0).
MS (El positive ion) m/z 199.03 (M+)
3-nitro-4-methyl-benzoyl chloride (50c)
o
To a stirred suspension of 3-nitro-4 -methyl-benzoic acid (20 mmol) in dry 
dichloromethane (30 mL), oxalyl chloride (25 mmol) was added followed by a 
catalytic amount of DMF (1-2 drops). The mixture was stirred at room 
temperature for 24 hours. The resulting solution was dried in vacuo to afford 
the acid chlorides in excellent yield which was used straight away in the next 
reaction.
Yield: 93%; pale green oil [ref: Desrousseaux et al. 2000]
H NMR (CDCIg) 5 2.18 (s, 3H, CH3), 3.75 (bs, 2H, NH2), 3.91 (s, 3H, OCH3),
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1H NMR (CDCy 5 2.69 (s, 3H, CH3), 7.55 (d. J = 8.0 Hz, 1H, H5), 8.23 (d, J 
= 8.0 Hz, 1H, H6 ), 8.72 (d, J=  1.5 Hz, 1H, H2).
General procedure for the synthesis of chloro-substituted-4-methyl-5- 
(2-phenylacetamido)benzoic acid methyl ester (51a and 52a)
A solution of phenyl acetyl chloride (2 mmol) in anhydrous tetrahydrofuran (4 
mL) was cooled to 0 °C under nitrogen atmosphere. Potassium phosphate 
(2.5 mmol) was added in one portion followed by the addition of compound 
51 or 52 (2 mmol). The mixture was allowed to react for 18h at room 
temperature. The reaction was quenched with water (6 mL) and ethyl acetate 
(2 mL). The organic layer was evaporated in vacuo to obtained crude 
compound which can be further purified by recrystallisation in hot ethanol.
Methyl 2-chloro-4-methyl-5-(2-phenylacetamido)benzoate (51a)
Prepared according to the general procedure for the synthesis of amide bond 
starting with compound 51 and phenyl acetyl chloride.
Me'
Light yellow solid. Yield: 78%; m.p.: 152-153 °C
1H NMR (CDCh) 6 1.93 (s, 3H, CH3), 3.80 (s, 2 H, CH2), 3.91 (s, 3H, OCH3),
6.97 (s, 1H, H3), 7.20 (s, 1H, H6 ), 7.32-7.47 (m, 5H, phenyl), 8.41 (s, 1H, 
NH).
13C NMR (CDCU) 8 17.00 (CH3), 44.71 (CH2), 52.37 (OCH3), 117.24, 124.94,
128.02, 129.64, 132.55 (Ar-CH), 127.89, 129.31, 134.19, 134.25, 138.64 (Ar- 
CH), 165.53, 169.10 (C=0 x2).
MS (El positive ion) m/z 317.08 (M+)
Methyl 2-chloro-4-methyl-3-(2-phenylacetamido)benzoate (52a)
Prepared according to general procedure for the synthesis of amide bond 
starting with compound 52 and phenyl acetyl chloride.
I.
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3’ 5
Light yellow solid. Yield: 88%; m.p.: 122-123 °C
1H NMR (CDCI?) 5 2.25 (s, 3H, CH3), 3.82 (s, 2H, CH2), 3.90 (s, 3H, OCH3),
7.02 (s, 1H, NH), 7.17 (d, J = 8.0 Hz, 1H, H5), 7.29-7.46 (m, 5H, phenyl), 
7.65 (d, J = 8.0 Hz, 1H, H6)
13C NMR (CPCI3) S 19.03 (CH3), 44.02 (CH2), 52.43 (OCH3), 127.79, 128.64, 
129.26, 129.53, 129.79 (Ar-CH), 128.35, 130.94, 133.91, 134.43, 141.99 (Ar- 
CH), 165.80, 169.44 (C=0 x2).
MS (El positive ion) m/z 317.08 (M+)
General procedure for the synthesis o f chloro-substituted-4-methyl-5- 
(2-phenylacetamido)benzoic acid (51b and 52b).
Either of the methyl esters 51a or 52a (0.6 mmol) and lithium hydroxide (1 
mmol) in methanol (10 mL) and water (6 mL) was allowed to stand at 50- 
60°C for 3 hours. The solution was concentrated to remove methanol and the 
aqueous layer was extracted with dichloromethane to remove unreacted 
esters. The aqueous layer was carefully acidified with 1N hydrochloric acid to 
pH 2-3 and extracted with dichloromethane. The organic layer was collected, 
dried over magnesium sulfate and evaporated to dryness to give the pure 
compound in good yield.
2-chloro-4-methyl-5-(2-phenylacetamido)benzoic acid (51b)
Prepared according to general procedure for the synthesis of benzoic acid 
from the corresponding 51 a.
White solid. Yield: 71%; m.p.: 228 °C
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1H NMR (DMSO-d^5 2.22 (s, 3H, CH3), 3.75 (s, 2H, CH2), 7.23-7.36 (m, 5H, 
phenyl), 7.42 (s, 1H, H3), 7.93 (s, 1H, H6), 9.64 (s, 1H, NH), 12.8-13.3 (bs, 
1H, COOH).
13C NMR (DMSO-d«1 8 17.47 (CH3), 42.58 (CH2), 52.37 (OCH3), 126.40,
127.02, 128.31, 129.08, 132.20 (Ar-CH), 127.89, 129.31, 134.19, 134.25,
138.64 (Ar-CH), 165.53, 169.10(0=0 x2).
2-chloro-4-methyl-3-(2-phenylacetamido)benzoic acid (52b)
Prepared according to general procedure for the synthesis of benzoic acid 
from the corresponding 52a.
Light yellow solid. Yield: 69%; m.p.: 222 °C
1H NMR (DMSO-dfil 8 2.13 (s, 3H, CH3), 3.70 (s, 2H, CH2), 7.26-7.36 (m, 5H, 
phenyl), 7.38 (d, J = 8.0 Hz, 1H, H5), 7.57 (d, J = 8.0 Hz, 1H, H6), 9.83 (s, 
1H, NH), 13.11 -13.39 (bs, 1H, COOH).
13C NMR (DMSO-cU) 8 18.37 (CH3), 42.71 (CH2), 117.22, 126.50, 127.83,
128.23, 129.11 (Ar-CH), 125.90, 130.34, 134.92, 135.88, 141.15 (Ar-CH), 
166.72, 169.04 (C=Ox2).
General procedure for the synthesis of Methyl 2-(chloro-substituted-4- 
methyl-5-(2-phenylacetamido)benzamido)benzoate
To a benzoic acid (compound 51b or 52b) (1.26 mmol) was added 
anhydrous THF (6 mL) under inert atmosphere, treated with triethylamine (3 
equivalents) and then methanesulfonyl chloride (3 equivalents). To the 
reaction mixture was then added methyl anthranilate (1.26 mmol). The 
reaction was stirred at room temperature for 72 hours or until the completion 
of reaction as monitored by TLC. The reaction mixture was evaporated to 
remove THF, then redissolved in dichloromethane and partitioned between 
saturated NaHCOa. The organic layer was collected, dried (MgS0 4 ) and 
evaporated in vacuo to give the crude compound. Further purification using
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column chromatography (dichloromethane.methanol = 98:2) afforded the 
pure compound in moderate to good yield.
Methyl 2-(2-chloro-4-methyl-5-(2-phenylacetamido)benzamido)benzoate 
(54b)
Prepared according to the general procedure for the synthesis of amide bond 
formation starting with compound 51b and methyl anthranilate.
4"
Me' OMe
Yellowish solid. Yield: 73%; m.p.: 110-112 °C
1H NMR (CDCy 8 1.94 (s, 3H, CH3), 3.78 (s. 2H. CH2), 3.90 (s, 3H, OCH3), 
7.142 (td, J = 1.0, 8.0 Hz, 1H, H4”), 7.16 (s, 1H, NH), 7.32-7.42 (m, 5H, H 2’- 
H5’), 7.45 (s, 1H, H3), 7.59, (td, J = 1.0, 8.0 Hz, 1H, H5”), 8.06 (dd, J = 1.5,
8.0 Hz, 1H, H6”), 8.11 (s, 1H, H6), 7.61 (d, J = 8.0 Hz, 1H, H3”), 11.84(s, 1H, 
NH’).
13C NMR (CDCkl 8 17.07 (CH3), 44.52 (CH2), 52.46 (OCH3), 120.60, 123.11, 
123.15, 127.73, 129.24, 129.56, 130.95, 131.91, 134.80 (Ar-CH), 115.68, 
126.49, 133.02, 134.11, 134.54, 134.63, 114.00 (Ar-CH), 165.33, 168.41, 
169.35 (C=Ox3).
MS (El positive ion) m/z 436.12 (M+)
HRMS(ES) m/z = 454.1528 [M+NH4]+; calcd: 436.1190.
Methyl 2-(2-chloro-4-methyl-3-(2-phenylacetamido)benzamido)benzoate 
(55b)
Prepared according to the general procedure for the synthesis of amide bond 
formation starting with compound 52b and methyl anthranilate.
4'
O
5'
6 OMe4' Me'
Light yellow solid. Yield: 73%; m.p.: 150-152 °C
t
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1H NMR (CDCIn) 6 2.16 (s, 3H, CH3), 3.72 (s, 2H, CH2), 3.83 (s, 3H, OCH3), 
7.26 (td, J = 1.0, 8.0 Hz, 1H, H4”), 7.28 (d, J = 8.0 Hz, 1H, H5), 7.33-7.41 (m, 
5H, phenyl), 7.50 (d, J = 8.0 Hz, 1H, H6), 7.69 (td, J = 1.0, 8.0 Hz, 1H, H5”),
7.98 (dd, J=  1.5, 8.0 Hz, 1H, H6”), 8.36 (d, J =  8.0 Hz, 1H, H3”), 9.90 (s, 1H, 
NH), 11.08 (s, 1H, NH’).
13CNMR (CPCI3) S 19.18 (CH3), 44.08 (CH2), 52.45 (OCH3), 120.61, 123.10,
126.99, 127.74, 129.23, 129.29, 129.64, 133.68, 134.71 (Ar-CH), 115.53, 
128.60, 130.92, 134.51, 134.59, 140.42, 141.12 (Ar-CH), 165.16, 168.49, 
169.30(0=0x3).
MS (El positive ion) m/z 436.12 (M+)
Anal, calcd for C24H21CIN2O4; C, 65.98; H, 4.84; N, 6.41; found C, 65.77; H, 
4.83; N, 6.54.
2-(2-chloro-4-methyl-5-(2-phenylacetamido)benzamido)benzoic acid
(54)
Prepared according to general procedure for the synthesis of benzoic acid
(chloro-substituted-4-methyl-5-(2-phenylacetamido)benzoic acid -  compound
51b or 52b) from the corresponding compound 54b and lithium hydroxide.
4"
O
OHClMe'
White solid. Yield: 72%; m.p.: 242 °C
1H NMR (DMSO-dfil 5 2.25 (s, 3H, CH3), 3.73 (s, 2H, CH2), 7.22 (td, J = 1.0,
8.0 Hz, 1H, H4”), 7.27-7.38 (m, 5H, phenyl), 7.48 (s, 1H, H3), 7.67, (td, J =
1.0, 8.0 Hz, 1H, H5”), 7.81 (s, 1H, H6), 8.04 (dd, J = 1.5, 8.0 Hz, 1H, H6”),
8.60 (d, J = 8.0 Hz, 1H, H3”), 9.68 (s, 1H, NH), 11.64 (s, 1H, NH’), 13.61-
13.84 (bs, 1H, COOH).
13C NMR (DMSO-dfi) 8 17.47 (CH3), 42.59 (CH2), 120.04, 123.40, 124.88, 
125.36, 128.30, 129.09, 131.19, 131.64, 134.21 (Ar-CH), 116.95, 126.53, 
133.43, 135.70, 135.89, 135.93, 140.29 (Ar-CH), 164.13, 169.45, 169.46 
(C=0 x3).
MS (ES positive ion) m/z 423.11 (M+H)
i
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Anal, calcd for C23H19CIN2O4; C, 65.33; H, 4.53; N, 6.62; found C, 65.26; H, 
4.53; N, 6.69.
2-(2-chloro-4-methyl~3-(2-phenylacetamido)benzamido)benzoic acid
(55)
Prepared according to general procedure for the synthesis of benzoic acid 
(chloro-substituted-4-methyl-5-(2-phenylacetamido)benzoic acid -  compound 
51b or 52b) from the corresponding compound 55b and lithium hydroxide.
4"
3' 5
Light yellow solid. Yield: 74%; m.p.: 208 °C
1H NMR fDMSO-dfil 8 2.17 (s, 3H, CH3), 3.72 (s, 2H, CH2), 7.23 (td, J = 1.0,
8.0 Hz, 1H, H4”), 7.28 (d, J = 8.0 Hz, 1H, H5), 7.33-7.41 (m, 5H, phenyl),
7.53 (d, J=  8.0 Hz, 1H, H6), 7.68 (td, J =  1.0, 8.0 Hz, 1H, H5”), 8.03 (dd, J =
1.5, 8.0 Hz, 1H, H6”), 8.61 (d, J = 8.0 Hz, 1H, H3”), 9.89 (s, 1H, NH), 11.60 
(s, 1H, NH’), 13.6-13.9 (bs, 1H, COOH).
13C NMR (DMSO-dfil 8 18.31 (CH3), 42.17 (CH2), 120.05, 123.40, 126.51,
128.24, 128.99, 129.12, 129.37, 131.19, 134.79 (Ar-CH), 117.05, 128.76, 
131.19, 134.13, 134.19, 140.35, 141.07 (Ar-CH), 164.47, 169.07, 169.45 
(C=0 x3).
MS (ES positive ion) m/z 445.09 (M+Na)
Anal, calcd for C 2 3 H 1 9 C IN 2 O 4 ;  C, 65.33; H, 4.53; N, 6.62; found C, 65.18; H, 
4.48; N, 6.69.
6.5 Towards the synthesis of fra/is-stilbene analogues as potential 
PET radiotracers
Synthesis of Tetrabutylammonium tetra (ferf-butyl alcohol)-coordinated 
fluoride (TBAF(fBuOH)4 (38a).
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Commercially available TBAF hydrate (1.0 g, 3.17 mmol) was added to tert- 
butanol (88 mL) and n-hexane (22 mL). The mixture was stirred for 30 
minutes at 90 °C. During this time TBAF dissolved completely. The solution 
was cooled to room temperature, and a white crystalline solid precipitated. 
The crystalline solid was filtered and washed rapidly with 40 mL of 70% 
fBuOH/hexane. The filtrate was kept in vacuum for 15-20 minutes to remove 
residual solvent and TBAF(fBuOH)4 was afforded as white crystalline solid.
OH HO
White crystalline solid. Yield = 88%. (Kim et al. 2008)
1H NMR (CDCM 5 1.01 (t, J = 7.5 Hz, 12H, CH3x4), 1.27 (s, 36H), 1.46 (m, 
CH2x4), 1.67 (m, CH2x4), 3.36 (m, CH2x4).
Synthesis of 4-methoxy benzyl mesylate (38b)
4-Methoxy benzyl alcohol (6 mmol, 1 equiv) was dissolved under inert 
atmosphere in dry dichloromethane (7 mL), followed by addition of 
triethylamine (12 mml, 2 equiv). The reaction mixture was cooled to 0 °C. 
Methanesulfonyl chloride (MsCI) (12 mmol, 2 equiv) in dry dichloromethane 
(3 mL) was added dropwise. After complete addition, the reaction mixture 
was allowed to slowly warm to RT. The reaction mixture was washed with 
water and saturated sodium carbonate. The organic layer was dried and 
concentrated in vacuo to afford yellowish oil which was used for fluoridation 
reaction without further purification.
Yellowish oil. Yield = 78%. (Bentley et al. 1994)
1H NMR (CDCh) 6 3.69 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 4.60 (s, 2H, CH2), 
6.91 (d, J = 8.5 Hz, 2H, H-3, H-5), 7.34 (d, J = 8.5 Hz, 2H, H-2, H-6)
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Synthesis of benzyl tosylate [38c(i)]
A mortar was charged with dry potassium carbonate (5 g), benzyl alcohol (10 
mmol), p-toluenesulfonyl chloride (TsCI) (15 mmol) and grinded vigorously 
for 5 minutes. After the completion of tosylation, the remaining tosyl chloride 
was removed by addition of powdered potassium hydroxide (50 mmol) and 
vigorously grinded (2 minutes). Addition of a few drops of f-BuOH accelerate 
the disappearance of TsCI. The product was extracted by addition of ether 
(50 ml_), filtered and finally by the evaporation of organic solvent. The 
purification of the oily crude product by column chromatography (10 hexane: 
1 Et2 0 ) afforded the pure benzyl tosylate.
White powder. Yield = 26%. Mp = 56-57 °C (lit: 58.5-58.9 °C [Kochi and 
Hammond 1953)].
1H NMR (CDCIi) 5 5.08 (s, 2H, CH2), 7.27 (m, 2H), 7.34 (m, 3H), 7.35-7.39 
(m, 5H)
General procedure for the synthesis of (E)-1-(4-bromobutoxy)-4- 
(substituted-styryl)‘benzene
To a solution of hydroxylated compound 22 or 32 (1 mmol) in acetone (30 
mL), anhydrous K2C 0 3 (4 mmol) and 1,4-dibromobutane (1.15 mmol) were 
added and the mixture refluxed for 12 h. After the completion of the reaction, 
K2C 03 was removed by filtration and the solvent was evaporated under 
reduced pressure to give the crude product. This was further purified by 
column chromatography (hexane:ethyl acetate = 20:1) to afford the pure 
compound in good yield.
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(E)-1 -(4-bromobutoxy)-4-(3-methoxystyryl)benzene (39a)
5
4
OMe
Light yellow solid. Yield: 78%; m.p.: 61-62 °C
1H NMR(CDCI3) 5 1.97-2.01 (m, 2H, CH2), 2.09-2.14 (m, 2H, CH2), 3.53 (t, J 
= 6.5 Hz, 2H, CH2), 3.89 (s, 3H, OCH3), 4.03 (t, J = 6.0 Hz, 2H, CH2), 6.87 
(dd, J = 2.0, 8.5 Hz, 1H, H4), 6.93 (d, J = 9.0 Hz, 2H, H3’, H5'), 7.03 (d, J =
16.5 Hz, 1H, Ha), 7.11 (s, 1H, H2), 7.14 (d, J=  16.5 Hz, 1H, Ha’), 7.17 (d, J 
= 7.5 Hz, 1H, H6), 7.33 (t, J = 8.0 Hz, 1H, H5), 7.49 (d, J = 8.5 Hz, 2H, H2’, 
H6’).
13C NMR fCDCM S 27.99, 29.87, 33.89, 67.28 (CH2 x 4), 55.61 (OCH3),
111.97 (Ar-CH/Ca), 113.28 (Ar-CH/Ca), 114.96 (C2\ C6’), 119.28 (Ar- 
CH/Ca), 126.90 (Ar-CH/Ca), 127.86 (C3’, C5’), 128.19 (Ar-CH/Ca), 128.90 
(Ar-CH/Ca), 130.14 (C1), 139.19 (C1’), 158.72 (C4'), 159.99 (C3).
(£)-1-(4-bromobutoxy)-4-(4-fluorostyryI)benzene (39b)
F
3
White powder. Yield: 75%; m.p.: 109-110 °C
1H NMR (CPCI3) 5 1.97-2.01 (m, 2H, CH2), 2.08-2.14 (m, 2H, CH2), 3.52 (t, J 
= 6.5 Hz, 2H, CH2), 4.04 (t, J = 6.5 Hz, 2H, CH2), 6.91 (dd, J = 2.0, 8.5 Hz, 
2H, H3’, H5’), 6.97 (d, J = 16.5 Hz, 1H, Ha), 6.98 (d, J = 16.5 Hz, 1H, Ha’),
7.06 (td, J = 2.0, 8.5 Hz, 2H, H2, H6), 7.45 (dd, J = 2.0, 8.5 Hz, 2H, H2’, H6’), 
7.48 (t, J = 9.5 Hz, 2H, H3, H5).
13C NMR (CDCh) 8 27.92, 29.49, 33.43, 66.93 (CH2 x 4), 114.73 (C3’, C5’),
115.05 (Ca’), 115.65 (d, J = 21.4 Hz, C3, C5), 125.47 (Ca), 127.66 (d, J =
7.6 Hz, C2, C6), 128.02 (C2\ C6’), 130.08 (C1’), 133.86 (d, J = 2.5 Hz, C1),
158.64 (C4’), 161.15 (d, J = 246.9 Hz, C4).
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General procedure for the synthesis of (E)-4-(4-(substituted 
styryl)phenoxy)butyl methanesulfonate
A solution of (£)-1-(4-bromobutoxy)-4-(substituted-styryl)-benzene (0.5 mmol) 
and silver methanesulfonate (AgOMs) (5 mmol) in anhydrous acetonitrile (10 
ml_) was refluxed overnight under argon. Upon completion of the reaction by 
TLC, the solvent was evaporated to dryness. The residue was redissolved in 
ethyl acetate and was filtered to remove the silver bromide side product. The 
resulting filtrate was evaporated in vacuo to afford the pure compound of 
substituted methanesulfonate 40a or 40b in good yield without the need for 
further purification.
(£)-4-(4-(3-methoxystyryl)phenoxy)butyl methanesulfonate (40a)
5
4
OMe
Light yellow solid. Yield: 98%; m.p.: 77-78 °C
1H NMR (CDCh) 5 1.94-2.02 (m, 4H, CH2x 2), 3.04 (s, 3H, S 02CHa), 3.87 (s, 
3H, OCH3), 4.06 (t, J = 6.0 Hz, 2H, CH2), 4.35 (t, J = 6.0 Hz, 2H, CH2), 6.82 
(dd, J = 2.0, 8.5 Hz, 1H, H4), 6.89 (d, J = 9.0 Hz, 2H, H3’, H5’), 6.96 (d, J =
16.5 Hz, 1H, Ha), 7.05 (s, 1H, H2), 7.06 (d, J=  16.5 Hz, 1H, Ha’), 7.15 (d, J 
= 7.5 Hz, 1H, H6), 7.29 (t, J = 8.0 Hz, 1H, H5), 7.46 (d, J = 8.5 Hz, 2H, H2’, 
H6’).
13C NMR (CDCIs) 5 25.40, 26.14 (CH2 x 2), 37.46 (SO^Hs), 55.25 (OCH3),
67.00, 69.59 (CH2 x 2), 111.54 (Ar-CH/Ca), 112.94 (Ar-CH/Ca), 114.69 (C2\ 
C6’), 119.02 (Ar-CH/Ca), 126.63 (Ar-CH/Ca), 127.80 (C3\ C5’), 128.48 (Ar- 
CH/Ca), 126.90 (Ar-CH/Ca), 130.23 (C1), 139.10 (CV), 158.54 (C41), 159.91 
(C3).
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(E)-4-(4-(4-fluorostyryl)phenoxy)butyl methanesulfonate (40b)
O -S -C H
F
3
White powder. Yield: 96%; m.p.: 106 °C
1H NMR (CDCI*) 5 1.94-2.02 (m, 4H, CH2 x 2), 3.04 (s, 3H, SC^CH^), 4.06 (t, 
J = 6.5 Hz, 2H, CH2), 4.35 (t, J = 6.5 Hz, 2H, CH2), 6.91 (dd, J = 2.0, 8.5 Hz, 
2H, H3’, H5’), 6.97 (d, J = 16.5 Hz, 1H, Ha), 6.98 (d, J = 16.5 Hz, 1H, Ha’),
7.06 (t, J = 8.5 Hz, 2H, H2, H6), 7.44 (dd, J = 2.0, 8.5 Hz, 2H, H2', H6’), 7.48 
(t, J = 9.5 Hz, 2H, H3, H5).
13C NMR (CDCU1 6 25.40, 26.14 (CH2 x 2), 37.43 (SO^Hs), 67.02, 69.65 
(CH2 x 2), 114.72 (C3\ C5’), 115.04 (Ca’), 115.65 (d, J = 21.4 Hz, C3, C5),
125.51 (Ca), 127.70 (d, J = 7.6 Hz, C2, C6), 127.98 (C2’, C6’), 130.15 (C1 ’),
133.84 (d, J = 2.5 Hz, C1), 158.54 (C4’)_ 161.14 (d, 7=246.9 Hz, C4).
General procedure for the synthesis of (E)-1-(4-(4-fluorobutoxy)styryl)- 
substituted benzene
TBAF (tetrabutylammonium fluoride) or CsF (cesium fluoride ) (2 mmol) was 
added to a solution of a substrate ((E)-4-(4-(substituted styryl)phenoxy)butyl 
methanesulfonate) (40a or 40b) (1 mmol) in acetonitrile or tert-butanol (4 ml_). 
The mixture was stirred for 1h at 70 °C. The residue was dissolved in water 
(6 mL) and extracted from the aqueous phase with diethyl ether (6 mL x 3). 
The organic layer was dried and evaporated under reduced pressure. The 
residue was purified by short column chromatography (hexane:ethyl acetate 
= 6:1) to afford the desired compound 41 or 42 in good yield.
(E)-1 -(4-(4-fluorobutoxy)styryl)-3-methoxybenzene (41)
5'
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Light yellow powder. Yield: 90%; m.p.: 56 °C
1H NMR (CPCI3) 8 1.92-2.00 (m, 4H, CH2 x 2), 3.88 (s, 3H, OCH3), 4.06 (t, J 
= 5.5 Hz, 2H, CH2), 4.53 (t, J = 6.0 Hz, 2H, CH2), 6.83 (dd, J = 2.0, 8.5 Hz, 
1H, H4), 6.91 (d, J = 9.0 Hz, 2H, H3’, H5’), 6.97 (d, J = 16.5 Hz, 1H, Ha),
7.06 (s, 1H, H2), 7.07 (d, J =  16.5 Hz, 1H, Ha’), 7.12 (d, J =  7.5 Hz, 1H, H6), 
7.29 (t, J = 8.0 Hz, 1H, H5), 7.47 (d, J = 8.5 Hz, 2H, H2’, H6').
13C NMR (CDCIsl 8 25.32, 29.74 (CH2 x 2), 55.26 (OCH3), 67.31, 83.18 (CH2 
x 2), 111.48 (Ar-CH/Ca), 112.90 (Ar-CH/Ca), 114.68 (C2\ C6’), 119.01 (Ar- 
CH/Ca), 126.48 (Ar-CH/Ca), 127.80 (C3\ C5'), 128.54 (Ar-CH/Ca), 129.63 
Ar-CH/Ca), 130.03 (C1), 139.13 (C1’), 158.70 (C4’), 159.89 (C3).
19F NMR (CDCkl 8 -218.52.
MS (El positive ion) m/z 300.13 (M+)
Anal, calcd for C i 9H2i F0 2; C, 75.98; H, 7.05; found C, 75.91; H, 7.27.
(£)-1 -fluoro-4-(4-(4-fluorobutoxy)styryl)benzene (42)
F
3
White powder. Yield: 81%; m.p.: 110-112 °C
1H NMR fCPCI3) 8 1.90-2.00 (m, 4H, CH2 x 2), 4.06 (t, J = 5.5 Hz, 2H, CH2),
4.53 (t, J = 5.5 Hz, 2H, CH2), 6.93 (dd, J = 2.0, 8.5 Hz, 2H, H3’, H5’), 6.97 (d, 
J =  16.5 Hz, 1H, Ha), 6.99 (d, J =  16.5 Hz, 1H, Ha’), 7.06 (t, J = 2.0, 8.5 Hz, 
2H, H2’, H6’), 7.45-7.50 (m, 4H, H2, H3, H5, H6).
13C NMR /CDCIol 8 25.31, 27.60, 67.31, 84.48 (CH2 x 4), 114.70 (C3’, C5’), 
115.49 (Ca’), 115.66 (d, J = 21.4 Hz, C3, C5), 125.39 (Ca), 127.65 (d, J =
7.6 Hz, C2, C6), 128.01 (C2\ C6’), 130.93 (C1’), 133.84 (d, J = 2.5 Hz, C1),
158.67 (C4’)> 161.12 (d, J = 246.9 Hz, C4).
19F NMR (CPCI3) 8 -115.27, -218.57.
MS (El positive ion) m/z 288.14 (M+)
Anal, calcd for CisHi8F20; C, 74.98; H, 6.29; found C, 75.43; H, 6.66.
Synthesis o f potassium (E)-stilbene trifluoroborate
Synthesis of
yl)benzaldehyde (45a)
4-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-
4-formylbenzeneboronic acid (33.35 mmol) and pinacol (33.35 mmol) were 
added to anhydrous diethyl ether (200 mL) and the mixture was stirred for 9 
h at room temperature whereby the remaining solid dissolves. The solution 
was washed with water (3 x 30 mL) and dried over MgSC>4. Evaporation of 
the solvent under reduced pressure leads to a pure white to yellowish solid of 
45a which does not need further purification.
White solid. Yield: 90%; m.p.: 50 °C [lit: 51 °C (Oehlke et al. 2007)].
1H NMR (CDCI-0 8 1.39 (s, 12H, CH3 x 4), 7.88 (d, J = 8.0 Hz, 2H, H3, H5), 
7.98 (d, J = 8.0 Hz, 2H, H2, H6), 10.07 (s, 1H, CHO).
Synthesis of (E)-2-(4-(3-methoxyxtyryl)phenmyl-4,4,5,5,-tetramethyl- 
1,3,2-dioxaborolane (45b)
Synthesis of 45b was achieved following the previous method for the 
synthesis of stilbenes via HWE method (6.2.2) where compound 45a and 
compound 2 were used as the starting materials.
White solid. Yield: 9%; m.p.: 78 °C
1H NMR (CDCIs) 5 1.40 (s, 12H, CH3 x 4), 3.88 (s, 3H, OCH3), 6.86 (dd, J =
OMe
2.0, 8.5 Hz, 1H, H4), 7.10 (s, 1H, H2), 7.13 (d, J=  16.5 Hz, 1H, Ha), 7.17 (d
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J = 7.5 Hz, 1H, H6), 7.18 (d, J = 16.5 Hz, 1H, Ha'), 7.31 (t, J = 8.0 Hz, 1H, 
H5), 7.57 (d, J = 8.0 Hz, 2H, H3’, H5’), 7.85 (d, J = 8.0 Hz, 2H, H2’, H6’)
13C NMR (CDCIO 5 24.91 (CH3 x 4), 55.26 (OCH3), 83.81 (B(0 )2-C2-(CH3)4), 
111.81, 113.62 (Ca, Ca’), 119.36 (C2’_ C6’), 126.19 (C3', C5’), 128.96 (Ar- 
CH), 129.59 (Ar-CH), 129.68 (Ar-CH), 135.52 (Ar-CH), 138.68 (C1’), 139.59 
(C1), 159,95 (C3).
C4’ attach to B could not be detected from the NMR spectra.
Synthesis of potassium (£)-trifluoro(4-(3-methoxystyryl)phenyl)borate 
(45)
OMe
Compound 45b (2.32 mmol) was dissolved in a mixture of methanol (15 mL) 
and THF (10 mL) with stirring before addition of 4.5 M KHF2 (aqueous) (20.7 
mmol). The resulting mixture was stirred for 1 h before concentrating to 
dryness. The residue, a white solid was collected by filtration, washed 
several times with hot diethyl ether (total ~100 mL) followed by water (~50 
mL) and dried to afford the pure trifluoroborate salt.
White solid. Yield: 63%; m.p.: >250 °C [lit: reported as a mixed of cis and 
trans isomers, m.p. (E + Z) = 236-243 °C (Molander et al. 2007)].
1H NMR (Acetone-dfi) 5 3.85 (s, 3H, OCH3), 6.81 (dd, J = 2.0, 8.5 Hz, 1H, 
H4), 7.09 (d, J = 16.5 Hz, 1H, Ha), 7.15 (d, J = 7.5 Hz, 1H, H6), 7.16 (s, 1H, 
H2), 7.19 (d, J = 16.5 Hz, 1H, Ha'), 7.26 (t, J = 8.0 Hz, 1H, H5), 7.34 (d, J =
8.0 Hz, 2H, H3\ H5’), 7.51 (d, J = 8.0 Hz, 2H, H2’, H6’).
13C NMR (Acetone-dfi) 5 55.46 (OCH3), 112.09, 113.65 (Ca, Ca5), 119.63 
(C2\ C6’), 125.63 (C3\ C5*), 126.65 (Ar-CH), 130.35 (Ar-CH), 131.30 (Ar-CH), 
132.93 (Ar-CH), 134.84 (C1’), 140.54 (C1), 161.06 (C3).
19F NMR (Acetone-dfi) 5 34.68.
C4’ attached to B could not be detected from the NMR spectra.
MS (ES negative ion) m/z 277.10 (M-K+)" ,calcd for Ci5H13BF30  (M-K+)' 
277.1012
CHAPTER 7
GENERAL CONCLUSION AND FUTURE STUDIES
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CHAPTER 7 
GENERAL CONCLUSION AND FUTURE STUDIES
7.1 General discussion
Cancer is becoming an exceedingly common disease. The area of targeted 
cancer drug discovery is becoming more complex, involving multi-disciplinary 
areas. The need to find potent anticancer agents which can counteract the 
current problem of resistance, efficacy and selectivity of the classical 
anticancer agents has long been desperately awaited. Unfortunately, the 
number of compounds able to pass the clinical trials and gain regulatory 
approval is still very low, due to the complexity of the disease itself which 
makes the cancer drug discovery processes very challenging. Many scientist 
and pharmaceutical companies have shifted their approach to the more 
targeted personalised therapies. Nevertheless, the area of high throughput 
screening to identify lead compounds for cancer therapy has yet still makes a 
significant contribution in cancer drug development.
Due to the increasing potential of natural products to be developed as 
new anticancer agents, the second chapter of this thesis is dedicated to the 
development of resveratrol-based stilbene analogues as new anticancer 
agents. Although most of the stilbenes synthesized in this chapter have been 
previously reported, the compounds are aimed to show novel therapeutic 
potential especially as new anti cancer agents. The simplicity of the stilbene 
scaffold makes it amenable to various modifications and substitutions in 
order to enhance its bioavailability, but still retaining the small size which is 
an important feature for good drug-like properties, making it potentially a 
better drug candidate compared to the parent compound resveratrol. 
Synthesis of methoxylated, fluorinated, brominated and nitrated stilbenes 
were conveniently achieved using HWE reaction, giving the compounds in 
variable yields and good purity. The synthesis was further expanded in order 
to compare various synthetic procedures for stilbene formation, using 
microwave activation via modified Perkin reaction and Heck coupling
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reaction. By using microwave activation, synthesis of hydroxylated 
compound 22 was achieved without the need to protect the free hydroxyl 
group in low yield. Nevertheless, the procedure was lacking applicability to 
various substitution patterns, as indicated by the failure of all other attempts 
to synthesise different hydroxylated stilbenes. At the same time, Heck 
reaction via palladium -oxazoline complex proved to be a reliable method 
giving methoxylated, fluorinated and hydroxylated stilbenes in moderate to 
good yield. Synthesis of compound 29 via both HWE and Heck reaction 
methods showed that the HWE reaction is superior to the Heck reaction for 
stilbene synthesis in terms of overall product yield and cost effectiveness. 
The stilbenes were then subjected to screening on a panel of cancer cell 
lines, namely prostate (PC3), non-small lung (A549), colon (Lovo) and breast 
cancer (MCF-7), where some of them demonstrated inhibitory activity in the 
micromolar range. The best result is showed by compound 14 which can 
inhibit the MCF-7 breast cancer cell line at less than 0.1 uM, and compound 
17 which can inhibit the A549 cell line at 1 uM. Unfortunately, no structure 
activity relationship can be generated from these results. But one common 
feature from the compounds which showed promising antiproliferative activity 
is the existence of methoxyl group on stilbene skeleton, which is in 
accordance to the previous study showing the importance of the methoxyl 
group on stilbene backbone to induce cancer cell death in cancer cell lines. 
These findings highlighted the potential of a few tested stilbene analogues to 
inhibit certain cancer cell types, although a more detailed and 
comprehensive study should be carried out to further validate their 
anticancer property. At the same time, the stilbene analogues were tested for 
their ability to inhibit the Wnt signaling pathway, which is one of a prominent 
signaling pathway which becomes aberrant in cancer. Unfortunately, none of 
the stilbene analogues were able to reduce the intensity of the GFP (green 
fluorescence protein) or to reduce the number of colon cancer stem cells 
(CSC) after treatment of the compounds in different concentrations, which 
suggested the inability of the compounds to inhibit the Wnt signaling pathway 
especially at the downstream level. Nevertheless, a more specific assay 
which could determine the ability of the stilbene analogues to inhibit the Wnt
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signaling at different level is anticipated to give better insights of the ability of 
the synthesised stilbenes to act as novel Wnt inhibitors.
The next chapter was dedicated to the synthesis of indole-based 3,5- 
diaryl isoxazoles as novel anticancer agents. The study was carried out to 
extend the previous work on the synthesis of indole-based 3,5-diaryl 
oxadiazoles and isoxazoles, which posses low micromolar antiproliferative 
activity and apoptosis induction activity through caspase activation. The 
syntheses were achieved using two different pathways: either via cyclization 
of alkynyl ketones with hydroxylamine which suffered from unselective 
regioisomer formation, or via dipolar cycloaddition between nitrile oxides and 
terminal alkynes which gave selective regioisomers, to afford title 
compounds with different substitution patterns on the phenyl ring and indole 
ring in low to moderate yields. The compounds will later be tested on human 
cancer cell lines for their antiproliferative and anticancer properties in order 
to generate structure-activity relationship data for further development of this 
series of compounds.
The next study was aimed at the synthesis of 3289-8625 derivatives, 
especially the one which will combine structural features of both derivatives 
6569188 and 7359885. All these derivatives had been previously reported to 
be potent inhibitors of Dishevelled (Dvl)-PDZ domain of the Wnt signalling 
pathway, and further synthesis of their analogues is anticipated to show 
better binding affinity towards the protein-protein interaction domain. The 
syntheses were achieved using various methods, which gave rise to two 
major analogues; compound 54 and 55. The testing of the two analogues 
using NMR-based chemical shift perturbation assay and fluorescence- 
binding affinity study confirmed the ability of the analogues to bind more 
tightly towards the Dvl-PDZ domain, with more than three fold affinity 
compared to the parent compound and even to the naturally occurring 
membrane bound peptide Dapper. The findings highlighted the potency of 
compound 54 and 55 to be developed as potential Wnt signaling antagonists, 
where the expansion of 3289-8625 scaffolds through structu re-activity
studies can open the possibilities for the development of more potent Wnt 
inhibitors.
On the other hand, the development of non-invasive imaging 
modalities especially PET for disease monitoring, staging or even in drug 
development is of increasing interest owing to the sensitivity and good 
resolution achieved by the imaging technique. This highlights the need to 
have reliable imaging probes specifically designed to the targeted site. The 
case of interest is the imaging of amyloid plaques which is a prominent 
feature in Alzheimer’s disease. Stilbene-based compounds not only show 
promising potential as good anticancer agents, but also as novel PET 
imaging probes, as indicated by two stilbene-based compounds, Florbetaben 
and Flobetapir F 18, which are currently in the late phase clinical trial for non- 
invasive imaging of Alzheimer’s disease. Therefore, this study is dedicated to 
the synthesis of ‘cold’ (19F) trans-stWbenes, which later is anticipated to be 
applicable for translation to PET radiochemistry. Stilbenes attached to 
alkylfluoride chain has been successfully synthesised in good yields, purity 
and within a time-frame which is applicable to PET radiochemistry. Although 
the next attempt to synthesise stilbenes attached to potassium 
alkyltrifluoroborate chain failed, the synthesis of stilbene attached directly to 
potassium trifluoroborate moiety via HWE reaction managed to give the 
desired compound in moderate yield. Nevertheless, the compound suffered 
from low susceptibility to different substitution on the stilbene ring which 
limits its applicability for PET imaging.
7.2 Future studies
The works presented here can generate various opportunities for further 
studies. Further modification and more diverse substitution patterns of 
stilbene-based analogues, compound 3289-8625 derivatives and possibly 
indole-based 3,5-diaryl isoxazoles will generate more reliable structure 
activity relationship studies, which upon detailed biological evaluations are 
anticipated to generate potent lead compounds for anticancer drug 
development. On the other hand, the synthesis of stilbene attached to
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alkylfluoride chain is amenable to expansion to radiochemistry synthesis 
using different substitution pattern and different length of alkyl chain which 
upon in vivo testing can predict its applicability for imaging of p-amyloid 
plaques. Nevertheless, the synthesis of stilbenes whether attached directly 
or indirectly via alkyl chain to potassium trifluoroborate should be refined 
before any attempt to forward the reaction to radiochemistry synthesis.
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